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Thesis Summary 
 
The noradrenaline system is extensively innervated throughout the brain, 
implicated in the aetiology of a wide range of psychiatric conditions, and the 
pharmacological modulation of the noradrenaline system has had a positive 
influence upon the alleviation of symptoms for those suffering psychiatric or 
neurological disease.  Clinical imaging of the brain with technologies such as 
Single Photon Emission Computed Tomography (SPECT) can provide clinicians 
and researchers with valuable information for elucidating disease aetiology, 
monitoring patient condition, and also confirming the mechanism of action for drug 
development through occupancy studies.  However, to date, there is no SPECT 
brain imaging tracer for the noradrenaline transporter in regular clinical use. 
 
This thesis is a body of work to develop a novel SPECT brain imaging tracer for 
the noradrenaline transporter with compounds that are iodinated forms of 
reboxetine, the selective noradrenergic reuptake inhibitor and clinically used 
antidepressant.  From the compounds synthesised and tested, the one which 
demonstrated the best pharmacological affinity and selectivity for the 
noradrenaline transporter was NKJ-64.  This same compound also displayed 
many of the HPLC-derived properties predicting in vivo molecular behaviour that 
are associated with successful brain imaging tracers.  Therefore, NKJ-64 was 
recommended for radiolabelling and further study. 
 
PCP Model of the Metabolic Hypofrontality Observed in 
Schizophrenia 
 
The metabolic hypofunction observed in the prefrontal cortex of schizophrenic 
patients is mimicked in a rat model via repeated, low-dose phencyclidine 
administration.  The neural mechanisms underlying this hypofrontality are unclear.  
Whilst dopaminergic transmission is classically associated with aberrant activity in 
schizophrenia, modulation of noradrenergic neurotransmission is correlated with 
the alleviation of negative symptoms.  Furthermore, the noradrenaline transporter 
rather than the dopamine transporter functions as the dominant dopaminergic 
reuptake mechanism in the prefrontal cortex.  It was hypothesised that repeated 
phencyclidine administration in the rat would induce a down-regulation of the NAT. 
 xviii 
 
Ligands labelled with [3H] were used for autoradiographic imaging of the 
noradrenaline, dopamine, and serotonin transporters in phencyclidine-treated and 
control groups, and [35S]-labelled oligonucleotide probes specific for the mRNA of 
each transporter were used for in situ hybridisation.  The binding densities of the 
noradrenaline and dopamine transporters were unaltered in the model, however 
significant selective reductions of serotonin transporter binding sites were 
measured.  The densities of mRNA for all three monoamine transporters were 
unaltered, so the unaltered densities of noradrenaline and dopamine transporter 
binding sites and the changes in serotonin transporter binding densities were not 
the result of altered gene expression. 
 
Although the noradrenaline transporter was not directly affected in this model of 
one particular aspect of schizophrenia and the model is not ideal for demonstrating 
the capability of a SPECT tracer for the NAT, this does not imply that the 
noradrenaline transporter is uninvolved in the disease aetiology of schizophrenia 
or of diminished importance to future schizophrenia studies.  The aforementioned 
correlation of noradrenaline transporter modulation to the alleviation of negative 
symptoms emphasises the importance of acquiring the clinical ability to assess the 
density and/or occupancy of the noradrenaline transporter by developing a useful 
SPECT brain imaging tracer for this site. 
 
Pharmacological Characterisation of Potential SPECT 
Brain Imaging Tracers for the Noradrenaline Transporter 
 
In vivo imaging of the noradrenaline transporter was previously limited to 
peripheral tracers such as metaiodobenzylguanidine (MIBG), which does not cross 
the blood-brain barrier, and neuroligands such as radiolabelled desiprimine, which 
demonstrated problematically high nonspecific binding.  Recent efforts in the 
literature have focused upon modified reboxetine analogues, and some progress 
was made with the S,S-isomer of iodophenoxy-ring reboxetine, referred to as both 
INER and IPBM in publication (Tamagnan et al. 2007; Kanegawa et al. 2006). 
 
Synthesised iodophenyl-ring compounds in S,S-, R,R-, S,R-, and R,S-isomers 
were evaluated for their affinity for the NAT.  The R,S-isomer demonstrated a very 
similar level of binding to the S,S-isomer and so this was explored in an 
 xix 
iodophenoxy isomer to determine if improvement upon the characteristics of lead 
iodinated reboxetine compounds in the literature was possible. 
 
The R,S-isomer iodophenoxy reboxetine analogues were synthesised with the 
iodine in the ortho, meta, and para positions of the phenoxy ring and assigned the 
designations NKJ-64, NKJ-67, and NKJ-68, respectively.  NKJ-64 has strong 
affinity and selectivity for the noradrenaline transporter, with a KD of 8.4 ± 1.7 nM, 
a 6-fold selectivity for the noradrenaline transporter over the serotonin transporter, 
and a 63-fold selectivity for the noradrenaline transporter over the dopamine 
transporter.  From the compounds synthesised and tested, NKJ-64 has the most 
suitable pharmacology to be developed further as a SPECT brain imaging tracer 
for the noradrenaline transporter and has an affinity in the same order of 
magnitude as iodinated compounds in the literature, such as the aforementioned 
INER/IPBM. 
 
Using High-Performance Liquid Chromatography (HPLC) to 
Predict in vivo Characteristics of Tracer Candidates 
 
The development of any candidate tracer compound must include an evaluation of 
its in vivo properties.  To streamline this process and select only the most viable 
compounds for further testing, predictors of in vivo molecular characteristics are 
used to conserve research effort.  Measures such as lipophilicity, 
phospholipophilicity, and plasma protein binding, used to estimate the potential for 
blood-brain barrier penetration, nonspecific binding, and the likelihood of serum 
availability would be very time-intensive to determine via traditional bench-top 
methodologies. 
 
High-performance liquid chromatography (HPLC) is a quick, precise, and reliable 
technique that is a rapid and high-throughput automatable process with 
exceptional precision that does not rely on the bench-top proficiency of an 
individual experimenter.  The optimisation of gradient elution protocols and 
formulae to interpret sample retention times on commercially available columns 
into reproducible standardised units has allowed for the efficient evaluation of 
tracer candidate compounds. 
 
 xx 
The iodinated reboxetine compounds were compared to examples of both 
successful and failed neuroimaging tracers.  Generally, the evaluations of the 
successful and failed neuroimaging tracers validated the combined methodologies 
of the HPLC-derived predictors of in vivo molecular behaviour.  In applying these 
methodologies to the synthesised iodoreboxetine compounds, NKJ-64 displayed 
many of the HPLC-determined properties that are consistent with successful 
tracers. 
 xxi 
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Chapter 1 
General Introduction 
 
1. Introduction 
 
Monoamine transmission plays an important role in a variety of CNS functions 
ranging from mood, sleep regulation, the initiation of movement, and modulation of 
pathways tasked with executive function (Bear et al. 2001; Moore & Bloom 1979).  
The extensive projections of monoamine systems can also become implicated in 
the aetiology of a similarly wide range of diseases such as clinical depression, 
severe anxiety, Parkinson’s disease, learning and memory disorders, aberrant 
sleep and schizophrenia (De Sarro et al. 1987; Yamamoto & Hornykiewicz 2004; 
Hipolide et al. 2005). 
 
Currently, a SPECT brain imaging tracer for the noradrenaline transporter (NAT) is 
not available for clinical use and, until one is developed, imaging studies in vivo 
will remain limited to probing with radiolabelled substrates (Eisenhofer 2001).  It is 
expected that the production of successful SPECT and/or PET ligands for imaging 
of the NAT in the CNS will be derived from compounds structurally related to 
nisoxetine (Hadrich et al. 1999a) and indeed, early efforts have focused upon 
iodinated forms of reboxetine, the clinically used selective noradrenergic reuptake 
inhibitor and antidepressant.  Nisoxetine itself cannot be used because 
compounds radiolabelled with [123/125I] for SPECT imaging have lacked selectivity 
for the NAT (Kiyono et al. 2004; Kung et al. 2004) and nisoxetine-like compounds 
radiolabelled with [11C] for PET imaging have demonstrated poor in vivo kinetics 
such as slow brain uptake and rapid metabolism (Tamagnan et al. 2007; Ding et 
al. 2005).  
 
1.1. Monoamine systems 
 
1.1.1. Noradrenaline system 
 
The noradrenergic system projects from the locus coeruleus to many anatomical 
structures including – but not limited to – the neocortical mantle (prefrontal cortex 
included), thalamus, hippocampus, amygdala, hypothalamus, nucleus accumbens, 
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the cingulum (cingulate anterior), cerebellar cortex, reticular core of the lower brain 
stem, and spinal cord (Yamamoto & Hornykiewicz 2004; Moore & Bloom 1979).   
 
Noradrenergic innervation is received by more widespread areas of the cerebrum 
than is dopaminergic innervation and, furthermore, noradrenaline is the 
predominant monoamine in many of the aforementioned brain regions – the 
nucleus accumbens being one of the noteworthy exceptions (Hipolide et al. 2005; 
Andersen et al. 2005). 
 
The effect of noradrenaline, like many neurotransmitters, depends upon the 
receptors through which it exerts its action (see Figure 1-01).  Action upon 
postsynaptic ß-adrenoceptors stimulates adenylate cyclase, which catalyses the 
reaction to convert ATP to cAMP.  Rising intracellular levels of cAMP opens Ca2+ 
channels and allows a Ca2+ influx that will facilitate vesicle fusion with the 
presynaptic membrane to exocytose stored neurotransmitter into the synaptic cleft.  
Auto-inhibition is achieved through presynaptic α2-adrenoceptors, which inhibit 
adenylate cyclise – thus inhibiting the conversion of ATP to cAMP and thereby 
preventing the opening of the Ca2+ channels that promote quantal release of 
noradrenaline.  Pharmacological modulation of the noradrenergic system can also 
be achieved directly through α2-adrenoceptors (Table 1-01).  
 
Activity of the noradrenergic locus coeruleus neurons is correlated with states of 
vigilance (Yamamoto & Hornykiewicz 2004): highest activity is apparent in an alert 
waking state, with activity declining through drowsy wakefulness, slow-wave sleep 
states, and finally silent during rapid eye movement sleep. Observations in non-
human primates, felines, and rats that were exposed to arousing stimuli have 
provided evidence to support the theory that noradrenergic locus coeruleus 
neurons are essential to sustain vigilance.  Furthermore, noradrenaline has been 
shown to increase in the brain during times of stress or in anticipation of stress 
(Tanaka 1999; Tanaka et al. 2000), and is implicated in depression and the 
treatment of depression (Brunello et al. 2002).  Indeed, pharmacological 
modulation of the noradrenergic system can result in disturbances of sleep, 
attention, stress sensitivity, and social interaction (Yamamoto & Hornykiewicz 
2004).  Noradrenaline is also important in the periphery and is integrated into the 
sympathetic nervous system, and noradrenaline increases are also correlated with 
 3 
peripheral stress responses such as an increased heart rate and elevated blood 
pressure.   
 
 
 4 
 
 
Figure 1-01: The noradrenergic nerve terminal (adapted from: 
Rang et al. 2003).  Following an action potential, increases in 
cAMP stimulate calcium influxes that cause excitation of 
noradrenaline into the synaptic cleft where they simultaneously 
stimulate postsynaptic adrenergic receptors as well as pre-
synaptic α2 autoreceptors that regulate the termination of the 
noradrenergic release.  Free noradrenaline (NA) in the synapse is 
transported back into the presynaptic neuron by the noradrenaline 
transporter (NAT) or metabolised by monoamine oxidase (MAO) 
and catechol-O-methyltranferase (COMT). 
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Table 1-01: Noradrenergic System Modulation 
Pharmacological 
modulation Injection site Effect 
α2-adrenoceptor 
agonist 
(e.g. clonidine) 
Third ventricle 
• Inhibition of synaptic noradrenaline 
release 
• Induction of behavioural sedation 
• Induction of sleep 
• Induction of EEG synchronization. 
α2-adrenoceptor 
antagonist 
(e.g. yohimbine) 
Intraventricularly, 
or into the locus 
coeruleus 
• Stimulation of synaptic 
noradrenaline release 
• Induction of behavioural arousal 
• Stimulation of locomotion 
• Stimulation of exploratory behaviour 
• Induction of EEG desynchronization. 
Table 1-01: Effects of pharmacological modulation of the noradrenergic system 
(adapted from De Sarro et al. 1987). 
 6 
1.1.2. Serotonin system 
 
The serotonergic system projects from the extensively innervated raphe nuclei to 
diverse regions throughout the brain (Adell et al. 2002). Significant densities of the 
serotonin transporter have been localised to the raphe nuclei themselves as well 
as other structures such as the amygdala, hippocampus, hypothalamus, locus 
coeruleus, striatum, substantia nigra, thalamus, and superior colliculi (D'Amato et 
al. 1987). 
 
The effects of released serotonin (5-hydroxytryptamine or 5-HT) are varied and 
depend greatly upon the receptor class and subtype it is activating (Rang et al. 
2003; Barnes & Sharp 1999).  The serotonin receptors 5-HT1A, 5-HT1B, 5-HT1D, 5-
HT4, and 5-HT7 all mediate their effects through the down-regulation of cAMP.  
Serotonin receptors 5-HT2A, and 5-HT2C both mediate their effects through the up-
regulation of IP3/DAG and 5-HT3 is a ligand-gated potassium channel. 
 
The serotonin system has been implicated in psychiatric diseases such as 
depression, schizophrenia (Abi-Dargham 2007; Frankle et al. 2005a; Ohuoha et al. 
1993), and the modulation of it with selective serotonin reuptake inhibitors such as 
fluoxetine, paroxetine, and citalopram have been used in treatment programmes 
for clinical depression (Whittington et al. 2004). 
 
 
1.1.3. Dopamine system 
 
The dopaminergic system can be subdivided into two major systems; the 
nigrostriatal system and the mesocorticolimbic system (Adell & Artigas 2004; 
Table 1-02).  The nigrostriatal system projects from the substantia nigra to the 
striatum and has great relevance to Parkinson’s disease, where the onset of 
symptoms is correlated to the death of dopaminergic neurons in the substantia 
nigra (Przuntek et al. 2004).  The mesocorticolimbic system projects from the 
ventral tegmental area (VTA) and can be further subdivided into the paranigral and 
parabrachial pathways (Adell & Artigas 2004).  The paranigral pathway is part of 
the mesolimbic system and projects from the VTA to the nucleus accumbens, 
while the parabrachial pathway is part of the mesocortical system and projects 
from the VTA to the cortical structures.  The paranigral pathways are associated 
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with reward and locomotor activity while the parabrachial pathways are associated 
with the modulation of cognitive function. 
 
Other systems – notably serotonergic, cholinergic, and noradrenergic – have 
modulatory effects upon dopaminergic neurotransmission.  Dopaminergic neurons 
of the VTA (Figure 1-02) receive stimulatory modulation from noradrenergic 
neurons of the locus coeruleus and cholinergic neurons of the brainstem, while 
serotonergic neurons of the raphe nuclei offer both stimulatory and inhibitory 
modulation through the differing 5-HT receptor subtypes.  One interesting point is 
that dopaminergic neurons have D2 autoreceptors in the VTA that provide a tonic 
inhibition of further action potentials from a dopaminergic neuron.  For example, 
noradrenergic innervations of the VTA cannot increase the rate of dopaminergic 
cell firing unless this tonic inhibition is pharmacologically blocked by D2 receptor 
antagonists. 
 
The effects of dopamine are mediated by dopamine receptors, of which there are 
two main categories (Neal 2002): the D1 (and D1-like) receptors and the D2 (and 
D2-like) receptors.  There are five types of dopamine receptors, all of which are 7-
transmembrane G-protein-coupled receptors: with D1 and D5 belong to the D1 
category, while D2, D3, and D4 belong to the D2 category.  The D2-like dopamine 
receptors are involved in presynaptic, postsynaptic, and extrasynaptic inhibition.  
The D2 receptor is the dominant dopamine receptor subtype in the human brain by 
both number and influence, with the majority of these occurring in the 
mesocorticolimbic system.  The mass activation of D2-like receptors (or 
autoreceptors) leads to an increase in potassium conductance which 
hyperpolarizes the membrane of dopaminergic neurons and prevents the 
generation or propagation of an action potential.  Therefore, D2-like receptor 
agonists diminish the rate of dopaminergic neuronal firing and D2-like receptor 
antagonists such as classical neuroleptics enhance (or enable modulatory 
systems to enhance) the rate of dopaminergic neuronal firing (Adell & Artigas 
2004).  The D1-like dopamine receptors are involved mainly in postsynaptic 
inhibition and it has been found that most classical neuroleptic drugs also block 
D1-like receptors as well as D2-like receptors (Abi-Dargham et al. 2002).   
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Table 1-02: Dopaminergic Projections 
Nigrostriatal system Substantia 
nigra  Striatum 
Paranigral 
pathways VTA  
Nucleus 
accumbens Mesocorticolimbic 
system Mesocortical 
pathways VTA  
Cortical 
structures 
Table 1-02: Subdivisions of dopaminergic system projections (adapted from: 
Adell & Artigas 2004). 
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1.1.4. Monoamine neurotransmitters, receptors, and transporters 
 
The monoamine transmitters noradrenaline (also known as norepinephrine) and 
dopamine share a synthesis path, whilst that of serotonin (also known as 5-
hydroxytryptamine or 5-HT) is separate (Figure 1-03).  Tyrosine hydroxylase is the 
rate-limiter in the synthesis of noradrenaline and dopamine, and tryptophan 5-
hydroxylase (tryptophan 5-monooxygenase) limits the rate of synthesis for 
serotonin (Haavik et al. 2008).  Monoamine transmitters are modulatory and can 
either cause neuronal excitation or inhibition depending upon which receptor they 
activate (Table 1-04).  In the cases of noradrenaline and dopamine, their effects 
are usually mediated by the upregulation or downregulation of cAMP, while 
serotonin has receptors linked to cAMP, IP3/DAG, and ligand-gated K+ channels 
(Barnes & Sharp 1999).   
 
Monoamine transporters are known to be relatively non-selective and will transport 
other monoamines in addition to that which binds most strongly or is most 
commonly transported (Graefe & Bönisch 1988).  Given this, it is not surprising to 
see that the dopamine transporter has greater affinity for dopamine than for 
noradrenaline – although it is interesting to find that the noradrenaline transporter 
also shares this order of affinity for these monoamines (Table 1-03).  Furthermore, 
the noradrenaline transporter has been shown to be the dominant mechanism of 
dopaminergic reuptake in the prefrontal cortex (Moron et al. 2002) and that 
blockers of the noradrenaline transporter increase levels of dopamine specifically 
in the prefrontal cortex region of the neocortical mantle (Valentini et al. 2004).  
This data can be used to explain the reasons behind reduced reliance of the 
dopaminergic mesocorticolimbic system upon the dopamine transporter for 
neurotransmitter clearance in comparison to the dopaminergic nigrostriatal system 
while maintaining comparable levels of dopaminergic innervation. 
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Figure 1-03: The synthesis and metabolism of monoamine neurotransmitters 
(adapted from Haavik et al. 2008).  MAO-A and COMT are important mechanisms 
for reducing extracellular concentrations of monoamine neurotransmitters that are 
not recovered by presynaptic monoamine transporters following quantal release. 
Abbreviations for enzymes: 
TH: tyrosine 3-hydroxylase or tyrosine 3-monooxygenase 
TPH1: tryptophan 5-hydroxylase isoform1 / tryptophan 5-monooxygenase isoform1 
TPH2: tryptophan 5-hydroxylase isoform2 / tryptophan 5-monooxygenase isoform2 
AADC: aromatic L-amino acid decarboxylase 
DβH: dopamine β-hydroxylase 
PNMT: phenylethanolamine N-mehtyltransferase 
MAO-A: monoamine oxidase A 
ALDH: aldehyde / aldose dehydrogenase/oxidoreductase 
AR: aldehyde / aldose reductase 
ADH: alcohol dehydrogenase 
COMT: catechol O-methyltransferase 
SUNLT1A3: sulfotransferase type 1A3 
Abbreviations for metabolites: 
DHPG: 3,4-dihydrophenylglycol 
DOPAC: dihydroxyphenylacetic acid 
5HTP: 5-hydroxytryptophan 
5HIAA: 5-hydroxyindoleacetic acid 
HVA: homovanillic acid 
L-DOPA: 3,4-dihydroxyphenylalanine 
MET: metanephrine 
MHPG: 3-methoxy-4-hydroxyphenylglycol 
3MT: 3-methoxytryptamine 
3OMD: 3-O-methyldopa 
NMET: normetanephrine 
SO4: sulphate 
VMA: vanillylmandelic acid 
VLA: vanillactic acid 
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Table 1-03: Noradrenaline and Dopamine Transporter Specificities 
Substrate Specificity 
(Km value as µmol/L) 
 
Transporter 
 
Dopamine Noradrenaline Serotonin 
Noradrenaline 
Transporter 0.1 0.4 8.6 
Dopamine 
Transporter 0.3 1.9 8.5 
Table 1-03: The substrate specificity of noradrenaline and dopamine transporters 
(adapted from Graefe & Bönisch 1988). 
 
 
 
Table 1-04: Monoamine Neurotransmitters, Receptors, and Effects 
Monoamine CNS Receptor Main effects 
Second 
Messenger 
(if applicable) 
α2 Neuronal inhibition ↓cAMP Noradrenaline 
β2 Neuronal excitation ↑cAMP 
D1 
(D1-type) Neuronal excitation ↑cAMP 
D5 
(D1-type) Neuronal excitation ↑cAMP 
D2 
(D2-type) Neuronal inhibition ↓cAMP 
D3 
(D2-type) Neuronal inhibition ↓cAMP 
Dopamine 
D4 
(D2-type) Neuronal inhibition ↓cAMP 
5-HT1A Neuronal inhibition ↓cAMP 
5-HT1B Presynaptic inhibition ↓cAMP 
5-HT1D Cerebral vasoconstriction ↓cAMP 
5-HT2A Neuronal excitation ↑IP3/DAG 
5-HT2C Neuronal excitation CSF secretion ↑IP3/DAG 
5-HT3 Neuronal excitation 
N/A 
(ligand-gated K+ 
channel) 
5-HT4 Neuronal excitation ↑cAMP 
5-HT5   
5-HT6   
Serotonin 
(5-hydroxytryptamine) 
5-HT7  ↑cAMP 
Table 1-04: Monoamine receptors, their function and mechanism of action 
(adapted from Rang et al. 2003; Barnes & Sharp 1999). 
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The transporters – presynaptic reuptake mechanisms – of monoamine 
neurotransmitters have also been demonstrated as the sites of action for a variety 
of psychostimulants such as cocaine in various forms, amphetamine, and 
methamphetamine (Elliott & Beveridge 2005; Sora et al. 2009).  Drugs binding to 
these systems can and do cause widespread modulation or disruption of brain 
function.  There is a potential for using drugs based on the pharmacologies of 
such psychostimulants to modulate the rate of monoamine transporters uptake, 
and thus adjust synaptic concentrations of neurotransmitter.  However, the ability 
to do so without causing unwanted side effects requires that various structural 
modifications of the compounds are explored.  The effects of any drug given as 
treatment over time must also be evaluated and monitored, so therefore the 
modulation (Table 1-05), evaluation, and monitoring of monoamine systems is 
very important for the investigation, diagnosis, treatment, and follow-up of many 
neuropsychiatric disorders – as well as being useful for drug development itself 
(Tatsumi et al. 1997; Tatsumi et al. 1999; Brunello et al. 2002). 
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Table 1-05: Drugs Modulating Monoamine Systems 
Monoamine 
System Target Site Drug Condition 
NAT Reboxetine (SNRI) Clinical depression 
α2-receptor partial 
agonist Clonidine 
Hypertension and 
migraine Noradrenaline 
NAT > SERT >> 
DAT Zotepine Schizophrenia 
SERT Citalopram (SSRI)  Clinical depression Serotonin 
(5-HT) SERT Paroxetine (SSRI) Clinical depression 
D2-receptor 
antagonist Haloperidol Schizophrenia Dopamine 
D2-receptor agonist Bromocriptine Parkinson’s disease 
Table 1-05: Examples of drugs used to modulate monoamine systems (Tatsumi et 
al. 1997; Tatsumi et al. 1999; Bear et al. 2001; Rang et al. 2003). 
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1.2. Schizophrenia 
 
Schizophrenia is a serious mental illness that afflicts 7.2 per 1,000 individuals 
during their lifetime, and there are 15.2 per 100,000 new cases reported each year 
(Saha et al. 2005).  The Saha meta-analysis also highlights that the prevalence of 
schizophrenia in richer countries is higher than that of the prevalence in poorer 
ones, that the sexes are equally at risk to developing schizophrenia in their 
lifetime, and that migrants are at greater risk than native-born individuals in a given 
country.  In the modern world, increasing numbers of people are living and working 
abroad – thus exposing them to this migrant risk factor. 
 
As of 2006, the global human population reached 6.5 billion inhabitants, with that 
figure set to surpass 7 billion by 2012 (United Nations Population Division 2006) – 
using the prevalence calculations of the Saha meta-analysis, this equates to an 
existing global population of 46.8 million schizophrenia sufferers and a 2012 
projection exceeding 50 million.  Apart from the human factor, there is also an 
economic factor encouraging the furtherance of research into mental disease such 
as schizophrenia.  An economic evaluation of the impact of schizophrenia put 
United States expenditure on  schizophrenia alone at $65 billion  in 1991 (Wyatt et 
al. 1995) – this equates to approximately $92-96 billion in today’s money after 
adjustment for inflation (Cyr 2005; Friedman 2000). 
 
1.2.1. Symptoms 
 
The onset of symptoms in schizophrenic patients usually occurs during late 
adolescence to early adulthood (Morris et al. 2005; Saha et al. 2005).  The exact 
cause of schizophrenia has not yet been discovered, although risk factors such as 
genes that give a biological predisposition have been identified – such as 
Disrupted In Schizophrenia 1 (DISC1), a gene that contributes to schizophrenia 
predisposition as well as other mental illnesses (Hennah et al. 2006; Porteous et 
al. 2006) – and it is thought that the environmental conditions (i.e. ambience or 
social setting) a person is exposed to during childhood years of neural 
development, as well as acute environmental conditions in later life, can influence 
(for better or worse) the risk of developing schizophrenia (Hollister et al. 2006). 
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Clinical presentation is characterised by both ‘positive’ / ‘type I’ and ‘negative’ / 
‘type II’ symptoms (Hollister et al. 2006; Abi-Dargham & Guillin 2007; Morris et al. 
2005; Yamamoto & Hornykiewicz 2004).  ‘Positive’ symptoms are described as 
being additive to normal experiences, for example: hallucinations (e.g. auditory, 
visual, tactile, olfactory, etc…), delusions (e.g. intense paranoia), thought 
broadcasting (the belief that others are listening or stealing one’s thoughts), 
thought insertion (the belief that others are inserting their thoughts into one’s 
mind), and deranged logic in thought.  ‘Negative’ symptoms are described as 
being subtractive from normal experiences, for example: depression, affective 
flattening (the reduction in range and intensity of emotional experiences), 
anhedonia (incapacity for pleasure), self-neglect, reduced motivation, social 
withdrawal, alogia (poverty of speech) and cognitive deficits in working memory, 
selective attention, and mental flexibility (i.e. planning and strategizing) (Javitt 
1987; Montgomery 1979).  
 
1.2.2. Imaging in schizophrenia 
 
There are no specific biomarkers per se that will confirm that a patient has 
schizophrenia, so diagnosis remains limited to performance testing and psychiatric 
evaluation using such criteria as the Brief Psychiatric Rating Scale (BPRS) and the 
Comprehensive Psychopathological Rating Scale (CPRS) (Montgomery 1979; 
Yamamoto & Hornykiewicz 2004).  However, while not used as diagnostic tools, 
there are several biomarker trends that can be indentified in the schizophrenia 
sufferer. 
 
Following reports that schizophrenia patients may exhibit enlarged cerebral 
ventricles, a neuroimaging study of monozygotic twins discordant for 
schizophrenia used magnetic resonance imaging (MRI) to reveal significant 
reductions of hippocampal volume and significant increases in lateral and third 
ventricle volume (Suddath et al. 1990; Figure 1-04).  The increases in ventricular 
volume are regarded to be secondary to the atrophy of hippocampal and grey 
matter tissue rather than a primary process of dilation. It is uncertain whether the 
initial loss of tissue itself is primary or secondary to the pathogenesis of 
schizophrenia, although it appears not to be secondary to the treatment regimes of 
schizophrenic patients due to the extent and duration of neuroleptic exposure 
exhibiting poor correlation to the findings. 
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Researchers also discovered as early as the 1980’s that noradrenaline levels in 
the cerebrospinal fluid of schizophrenic patients are elevated (Sternberg et al. 
1981; Gomes et al. 1980; Lake et al. 1980), with paranoid schizophrenics 
demonstrating the most striking differences compared to those of normal healthy 
individuals (Kemali et al. 1985; Kemali et al. 1982).  Furthermore, noradrenaline 
concentrations have been show to be elevated in the blood plasma of 
schizophrenics – correlated to CPRS diagnoses, emergence of positive 
symptoms, and exhibition of paranoid phenotypes (Bondy et al. 1984; Dajas et al. 
1983). 
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Figure 1-04: Coronal MRI sections from two sets of monozygotic twins (paired by 
purple arrows) discordant for schizophrenia (Adapted from Suddath et al. 1990).  
The lateral ventricles in the affected twins (B and D, red circles) are visibly 
enlarged in comparison to those of the healthy twins (A and C, blue circles). 
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1.2.3. Treatment and prognosis 
 
The clearance of monoamines from the synapses of monoamine nerve terminals, 
thereby terminating stimulation of synaptic receptors, is primarily achieved through 
reuptake through monoamine transporters.  Many examples of effective 
antipsychotics have been shown to exert at least part of their action through the 
blockade of the monoamine transporters: the noradrenaline transporter, the 
dopamine transporter, and the serotonin transporter (Tatsumi et al. 1999). 
 
Neuroleptic drugs – antagonists for dopaminergic neurotransmission, particularly 
D2 receptors – control many of the symptoms of schizophrenia, although the 
negative symptoms such as social withdrawal are less responsive to treatment 
(Abi-Dargham & Laruelle 2005).  Typical neuroleptics, such as haloperidol (Morita 
et al. 2000; Carlsson & Lindqvist 1963), were among the first drugs used to treat 
schizophrenic patients, but many carry adverse side effects, ranging from 
sensitivity reactions, haemolytic anaemias, rashes, cholestatic jaundice, 
photosensitisation, retinal degeneration, to severe movement disorders.  Atypical 
neuroleptics are characterised by having lower incidences of movement disorders 
and are also better tolerated by patients than other anti-psychotics.  Clozapine is 
considered to be one of the few ‘true’ atypical neuroleptics because it is 
sometimes effective in patients whose conditions were non-responsive to typical 
neuroleptics (Morita et al. 2000; Neal 2002). 
 
It is noteworthy that in the cited examples of haloperidol (typical) and clozapine 
(atypical), while the typical neuroleptic instigates a near-total blockade of D2 
receptors, the atypical neuroleptic causes only a partial D2 receptor occupancy 
(Farde et al. 1992; Figure 1-05).  It has been postulated that the lower D2 receptor 
occupancy and lower specificity of clozapine contributes to the antipsychotic 
efficacy with reduced extrapyramidal side effects.  Not only does this give us an 
indication of the differences between haloperidol and clozapine, but it is also a 
clear demonstration of how powerful in vivo imaging can be in improving our 
understanding of a disease state,  demonstrating the pharmacology of existing 
drugs in a clinical patient, and assisting future drug design. 
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Figure 1-05: Clinical PET imaging of D2 receptors with [11C]-raclopride 
(Reproduced from: Farde et al. 1992): a healthy medication-free volunteer (A), a 
schizophrenic treated with the typical neuroleptic haloperidol (B), and a 
schizophrenic treated with the atypical neuroleptic clozapine (C). The colour scale 
indicates D2 receptor occupancy by [11C]-raclopride and is expressed as a 
percentage of maximum occupancy. Haloperidol exhibits a high D2 receptor 
occupancy and competes for the majority of [11C]-raclopride binding sites, while 
the comparatively lesser competition for D2 receptor binding sites by clozapine is 
indicative of a much lower D2 receptor occupancy. 
 21 
 
An example of another prominent atypical neuroleptic is zotepine, which although 
is believed to exert its effects primarily through dopamine and serotonin receptors 
also has notable affinity for the noradrenaline and serotonin transporters.  The 
selectivity for the noradrenaline and serotonin transporters over the dopamine 
transporter is profound and affinities are reported as 20nM, 45nM, and 2.4µM, 
respectively (Tatsumi et al. 1999).  This raises the question as to whether 
zotepine’s mechanism of action is at least in part mediated by the blockade of the 
noradrenaline and/or serotonin transporters. 
 
Currently, it is estimated that only 13% of global schizophrenic suffering is 
effectively alleviated or managed and that, given investment to improve our current 
medical interventions, it is reasonable to anticipate just under a doubling of the 
benefits provided by medical intervention.  Unfortunately, due to limitations by 
current medical progress, current knowledge would be unable to impact up to 
three-quarters of schizophrenic disability – regardless of a theoretical unlimited 
investment in applying existing medical interventions (Andrews et al. 2004; Saha 
et al. 2005).  Clearly, the focus of the research community is required for the 
development of more specific and medical intervention with greater efficacy, and 
the first step towards doing this is to further our knowledge of the molecular 
mechanisms, failed pathways, and deranged systems that underpin this 
debilitating condition. 
 
1.2.4. Noradrenergic hypothesis 
 
The precise molecular mechanisms, pathways, and deranged systems that 
underpin the pathology of schizophrenia are largely unknown although there are 
many circulating hypotheses involving many different neurotransmitters such as 
dopamine, serotonin, glutamate, GABA, acetylcholine, brain-derived neurotrophic 
factor, and noradrenaline (Lewis & Hashimoto 2007; Martin & Freedman 2007; 
Guillin et al. 2007; Bressan et al. 2005; Yamamoto & Hornykiewicz 2004; Laruelle 
et al. 2000). The most popular and heavily researched of the theories is the 
dopaminergic hypothesis of schizophrenia, which proposes hyperactivity in the 
dopaminergic mesolimbic and/or mesocortical pathway – supported by evidence 
that the most effective pharmacological interventions to alleviate schizophrenic 
suffering to date rely upon the antagonism of dopaminergic neurotransmission 
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(Neal 2002).  However, strong evidence for a noradrenergic involvement is 
emerging. 
 
A noradrenergic hypothesis to schizophrenia was first proposed in 1971 (Stein & 
Wise) but has received insufficient attention due to the limited interpretation that 
the D2-blocking actions of clinically effective neuroleptic drugs constituted 
conclusive evidence that the dopaminergic system was the most important system 
to investigate in schizophrenia research (Yamamoto & Hornykiewicz 2004).  
 
Acute schizophrenic illness is usually accompanied by severe insomnia, and 
animal experimentation has shown that the injection of α2-adrenoceptor agonists 
and antagonists directly affect noradrenergic release, attention, sleep, exploratory 
behaviour, and locomotion (De Sarro et al. 1987; Table 1-01).  Agonists of the 
noradrenergic system have been shown to exacerbate the positive symptoms and 
amerliorate the negative symptoms of schizophrenia upon acute administration 
(Jimerson et al. 1980).  Conversely, antagonists of the noradrenergic system 
ameliorate positive symptoms and exacerbate the negative symptoms of 
schizophrenia upon acute administration (Hecht & Landy 2012; Svensson 2003) 
(Table 1-06).  In the cases of chronic abuse of compounds such as 
methamphetamine, cocaine, or ephedrine – all noradrenergic agonists – negative 
symptoms are caused rather than prevented.  Therefore, modulation or induced 
dysfunction of the noradrenergic system has been demonstrated to impose an 
influence upon both the positive and negative symptoms coupled with 
schizophrenic illness.  This integrated involvement of noradrenaline in higher brain 
function, and similar symptomatology to schizophrenia upon disruption, suggests 
that noradrenergic neurotransmission may play an important part in 
schizophrenia’s pathology (Yamamoto & Hornykiewicz 2004). 
 
As aforementioned (Table 1-02), transporters transport more than just the 
monoamine that they are most commonly, the noradrenaline transporter has been 
shown to be the dominant mechanism of dopaminergic reuptake in the prefrontal 
cortex (Moron et al. 2002) and blockers of the noradrenaline transporter increase 
levels of dopamine specifically in the prefrontal cortex region of the neocortical 
mantle (Valentini et al. 2004). 
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Table 1-06: Compounds modulating the noradrenaline system 
Method of action 
(direct or indirect) Properties Ligands 
Agonists 
• Amphetamine 
• Methamphetamine 
• Methylphenidate 
• L-DOPA 
• Cocaine 
• Monoamineoxidase Inhibitors 
Mixed 
dopaminergic/noradrenergic 
modulating ligands 
Antagonists 
• α-methylparatyrosine 
• α-methyldopa 
• Reserpine 
Agonists 
• Ephedrine 
• Yohimbine 
• Desipramine 
• Imipramine 
• Idazoxan 
Selective noradrenergic 
modulating ligands 
Antagonists 
• Clonidine 
• Propanolol 
• Oxypertine 
Table 1-06: Compounds that pharmacologically modulate the noradrenergic 
system (adapted from Yamamoto & Hornykiewicz 2004). 
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1.3. PCP-induced rat model of the metabolic hypofrontality observed in 
schizophrenia 
 
Schizophrenia is a complicated condition and furthering human knowledge of the 
disease is made that much more difficult due to the inability to perform a 
systematic characterisation of the disease in drug-free patients for ethical 
considerations.  Therefore, an animal model of the disease is required to enable a 
full array of in vitro and in vivo techniques to be brought to bear and elucidate the 
aberrant mechanisms underlying schizophrenia.  However, such is the complexity 
of the causes and progression of the disease that the field lacks universal 
agreement among schizophrenia researchers as to the best strategy for 
establishing a schizophrenic animal model and the models only mimic a aspects of 
the disease rather than schizophrenia in its entireity.  Consequently, it is a 
combination of animal models mimicking various aspects of schizophrenia that will 
contribute to the understanding of the disease. 
 
It is acknowledged that there are genetic models of the disease but, as 
aforementioned, while genetics may indeed impose a predisposition upon an 
individual to develop a schizophrenic psychosis, the evidence of monozygotic 
twins with discordance for the disease indicates that environmental factors are 
also prevalent.  On this basis, this thesis will address the environmental factors 
through the pharmacological modelling of selected aspects of schizophrenia. 
 
As with differing hypotheses as to which systems and neurotransmitters are most 
critically implicated in schizophrenia, there are also different pharmacological 
models to simulate schizophrenia – each with their advantages and 
disadvantages.  The most often applied models are those established in rat by the 
chronic or acute administration of drugs that are known to have induced or 
exacerbated schizophrenic symptoms in humans or schizophrenic patients, 
respectively. 
 
1.3.1. Phencyclidine 
 
Phencyclidine (PCP) was initially developed as a surgical anaesthetic, but was 
abandoned due to patients exhibiting unacceptable side effects – including 
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hallucinations, disordered speech, delirium, agitation, and disorientation – during 
their recovery from surgery (Morris et al. 2005).  Unfortunately, these symptoms 
proved attractive to the drug-abuse community and PCP became illicitly traded 
and abused under such names as “angel dust” and “hog”. 
 
When it came to light that some drug users were mistaken for schizophrenics and 
as a result were treated with drug therapies as schizophrenics, the greater 
awareness of this potential for misdiagnosis resulted in better treatment for PCP 
addicts and a greater interest in PCP from the research community.  PCP can 
therefore be said to induce a psychosis in normal healthy subjects and it has also 
been shown to exacerbate symptoms when administered to schizophrenic patients 
(Luby et al. 1959; Allen & Young 1978; Javitt 1987; Deutsch et al. 1989; Javitt & 
Zukin 1991; Morita et al. 2000).  PCP reproduced not only the positive symptoms 
of schizophrenia, but also negative symptoms such as cognitive deficits – 
something that was not provided by the amphetamine models of schizophrenia 
that had been relied upon up until that point (Javitt & Zukin 1991; Deutsch et al. 
1989; Javitt 1987). 
 
1.3.2 Pathways implicated in schizophrenia and the PCP model 
 
The rat was chosen for establishing the animal model due to the widespread 
acceptance, easy availability, and commonplace use in research environments.  
This regular use of rat models has provided researchers with valuable experience 
and a thorough understanding of the biology, the advantages, and the limitations 
associated with the animal model. 
 
Rats that have been subjected to PCP treatment regimes present with 
hyperlocomotion, ataxia, agitation, cognitive deficits, and impaired social 
interactions as well as decreased exploratory behaviour in a PCP-dose-dependent 
manner (Morita et al. 2000) – a behaviour that has been interpreted as modelling 
the reduced motivation seen in human schizophrenics.  It has been argued that 
the extent to which the symptoms of PCP administration emulate those of 
schizophrenia is so far unequalled by alternative pharmacology (Morris et al. 
2005).  Many of these symptoms are alleviated by neuroleptics such as 
haloperidol and clozapine not only in rat but also in the more complex brains of 
non-human primates (Jentsch et al. 1997) with similar success rates to the clinical 
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treatment of schizophrenics – giving confidence to those applying the PCP model 
in their research paradigms.   
 
The deranged pathways involved in schizophrenia involve a corticolimbothalamic 
circuitry (Figure 1-06) that is thought to also become defective following PCP 
administration, with hypometabolism in the prefrontal cortex and mediodorsal 
thalamus disturbing the circuit’s positive feedback loop.  Once disturbed, this 
positive feedback loop can prove difficult to restore.  The prefrontal cortex has 
been shown to be important to schizophrenia through deoxyglucose studies 
(Cochran et al. 2003), where the prefrontal cortex was shown to have a reduced 
metabolic activity – referred to as the ‘hypofrontality’ of the schizophrenic 
phenotype.  It is thought that the next generation of antipsychotic drugs to treat 
schizophrenia will be based on preparations that are demonstrated to be most 
capable of antagonising or reversing PCP-induced psychoses (Morita et al. 2000). 
 
The PCP-induced rat model of the metabolic hypofrontality observed in 
schizophrenia is most similar to the alternative ketamine-induced rat model. 
Although while both ketamine- (Krystal et al. 1999) and PCP-induced psychoses 
can be reversed by clozapine and not haloperidol, unlike other NMDA receptor 
antagonist models, the PCP model in particular was able to mimic the metabolic 
deficit of the prefrontal cortex that does not respond to atypical neuroleptic 
treatment in the clinic (Cochran et al. 2003). 
 
Recently, an attempt has been made to review, analyze, and standardize the 
treatment regime for the PCP model (Morris et al. 2005).  The Morris laboratory 
examined acute, chronic, high- and low-dose PCP administration for establishing a 
PCP model of schizophrenia and devised an optimised protocol for most 
accurately replicating the schizophrenic phenotype in the model.  Importantly, the 
PCP model optimised by Morris et al mimics the hypofrontality observed in 
schizophrenia without the temporal cortex lesions observed in the ketamine model 
and are not present in the clinical schizophrenic. 
 
Acute PCP exposure in rodents has been shown to impair social interaction and 
induce cognitive deficits, although acute PCP exposure in humans is less likely to 
induce a schizophrenia-like psychosis than chronic exposure – therefore indicating 
that chronic PCP exposure in rodents may yield a more accurate model.  Indeed, 
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chronic PCP exposure in rodents induces diminishing dopamine turnover within 
the prefrontal cortex, along with deficits in working memory and pathways reliant 
upon the prefrontal cortex.   
 
When PCP administration is used in high-dose regimes, it has been demonstrated 
that neurodegeneration occurs in pyramidal neurons of the retrosplenial cortex – a 
pathology not observed in the post-mortem tissue of schizophrenic patients.  In 
human schizophrenic patients, it is primarily the interneurones that are affected – 
thus indicating that high-dose PCP regimes are not appropriate for obtaining a 
PCP model of schizophrenia. 
 
In light of these discussions, the PCP model applied in this thesis will use chronic, 
low-dose drug administration (2.58mg.kg-1.day-1) in the rat to most accurately 
emulate the metabolic hypofrontality observed in both the human schizophrenic 
and the human PCP abuser (Cochran et al. 2003; Morris et al. 2005). 
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Figure 1-06: The corticolimbothalamic circuitry that becomes deranged in 
schizophrenia (adapted from Morris et al. 2005).  The hypometabolic function of 
the prefrontal cortex and mediodorsal thalamus disrupts the positive feedback of 
the corticolimbothalamic circuitry. 
 
 29 
 
1.3.3. Hypothesis and study aims: 
 
The NAT is the dominant mechanism of dopaminergic reuptake in the prefrontal 
cortex (Moron et al. 2002) and blockers of the noradrenaline transporter increase 
levels of dopamine specifically in the prefrontal cortex region of the neocortical 
mantle (Valentini et al. 2004).  It has been shown that PCP competes with [3H]-
nisoxetine binding at the NAT in the periphery (Pubill et al. 1998; Rogers & 
Lemaire 1992) and also induces a metabolic hypofunction in the prefrontal cortex 
and other brain regions (Cochran et al. 2003; Morris et al. 2005).  I therefore 
hypothesise that chronic low-dose PCP administration, as refined by Cochran et al 
2003, will down-regulate the NAT in the prefrontal cortex. 
 
In Chapter 3, the aims of the study are: 
• [3H]-nisoxetine is considered a benchmark ligand that has been 
thoroughly validated for NAT imaging, so autoradiographic imaging 
using [3H]-nisoxetine will quantitatively determine the distribution and 
specific densities of the noradrenaline transporter in the PCP model of 
schizophrenic hypofrontality to ascertain whether noradrenaline 
reuptake mechanisms are perturbed.  If changes are observed in NAT 
expression then this model may prove useful as a means of 
demonstrating the capabilities of a novel SPECT brain imaging tracer for 
the NAT. 
• Use a noradrenaline transporter-specific [35S]-labelled oligonucleotide 
probe to qualitatively assess mRNA densities and ascertain whether 
noradrenaline transporter gene expression is perturbed in the PCP 
model of schizophrenic hypofrontality. 
• Use a [3H]-nisoxetine competition assay with rat brain homogenates to 
confirm whether PCP competes for the [3H]-nisoxetine binding site on 
the noradrenaline transporter in the central nervous system as well as in 
the periphery. 
• For comparison, image other monoamine transporters by using [3H]-
WIN-35,428 and [3H]-citalopram autoradiographic imaging to 
quantitatively determine the distribution and specific densities of the 
dopamine and serotonin transporters, respectively, to ascertain whether 
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dopamine and serotonin reuptake mechanisms are perturbed in the 
PCP model of schizophrenic hypofrontality. 
• For comparison, image other monoamine transporter mRNA by using 
dopamine and serotonin transporter-specific [35S]-labelled 
oligonucleotide probes to qualitatively assess mRNA densities and 
ascertain whether dopamine and serotonin transporter gene expression 
is perturbed in the PCP model of schizophrenic hypofrontality. 
 
 
1.4 Neuroimaging 
 
1.4.1 The need for a SPECT brain imaging tracer for the NAT 
 
The noradrenergic system has wide-reaching projections throughout the brain 
(Moore & Bloom 1979), modulating both excitatory and inhibitory 
neurotransmission, with implications in diseases such as severe anxiety, clinical 
depression, disorders of sleep (De Sarro et al. 1987; Hipolide et al. 2005), and 
schizophrenia (Yamamoto & Hornykiewicz 2004).  While my investigations into the 
involvement of the NAT in a pharmacological model of schizophrenia (see Chapter 
3) did not demonstrate changes to the density or distribution of the NAT or 
changes in the expression of NAT-specific mRNA, published data shows that 
some pharmacological therapies for schizophrenia have significant affinities for the 
NAT (Tatsumi et al. 1999).   Therefore, even in instances where the aetiology of 
the disease has not been shown to induce or arise from disturbed noradrenergic 
neurotransmission, pharmacological modulation of the noradrenergic system can 
still be used to alleviate the symptoms of disease.  Consequently, the 
noradrenergic system presents itself as a logical target for pharmacological 
manipulation in the treatment of disease and a site of interest for imaging, as drug 
occupancy studies can be used to demonstrate the affinity of a newly developed 
drug at the NAT.  Similarly, a NAT-specific SPECT imaging tracer can be used to 
characterise the occupany of the NAT for drugs already in use to try to correlate 
their efficacy to NAT occupany, such as is the case in the treatment of 
schizophrenia. 
  
The NAT regulates synaptic levels of noradrenaline via uptake, so imaging the 
density and distribution of this important site will provide valuable information on 
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the potential for manipulation of the noradrenergic system by drugs targeted at the 
NAT.  Where therapeutic action has been identified as mediated by selective 
noradrenergic reuptake inhibition, the ability to image the NAT will also aid future 
drug development and can act as a biomarker to demonstrate the efficacy of both 
new and existing drugs at the NAT.  Competition for the binding site used by a 
NAT-specific tracer by emerging compounds will cause a decrease in binding by a 
NAT-specific tracer and so the affinity for the NAT by emerging compounds can be 
quantified.  Where therapeutic action has been identified as mediated by selective 
noradrenergic reuptake inhibition, those compounds with greatest affinity and 
specificity for the NAT should have the greatest therapeutic effect with the least 
side effects. 
 
As previously mentioned, there are several atypical neuroleptic drugs that show 
greater efficacy at the NAT than at the SERT or DAT (Tatsumi et al. 1999), so 
understanding the NAT occupancy of these drugs in the treatment of 
schizophrenia and even pharmacological models of the disease can further our 
understanding of how the modulation of noradrenergic neurotransmission may 
benefit schizophrenic patients and/or affect them in acute and chronic SNRI 
administration.  For example, an increase or reduction in tracer binding to the NAT 
in the locus coeruleus could be used as a marker to ascertain how, and to what 
degree, noradrenergic neurotransmission has been affected by treatment regimes.  
Following an appropriate medication-free period in a long-term patient, increased 
NAT-specific tracer binding in the locus coeruleus could imply an overall 
upregulation of the NAT in response to long-term pharmacological blockade by 
chronic SNRI administration.  Another use for a NAT-specific tracer could be to 
estimate pre- and post-medication administration NAT occupancy of the tracer to 
evaluate the NAT occupancy of the competing medication for a given dose. 
 
Successful probing of the NAT in the CNS in vitro has been accomplished with 
[3H]-nisoxetine and radio-labelled desipramine (Lee & Snyder 1981), although 
excessive non-specific binding was problematic in vivo for the latter (Eisenhofer 
2001).  In vivo imaging of the NAT with single photon emission computed 
tomography (SPECT) and/or positron emission tomography (PET) imaging has 
previously been limited to the periphery with tracers such as MIBG in SPECT- and 
PET-ligand forms and has been a useful tool in the detection of NAT-
overexpressing neuroendocrine tumors (Pryma & Divgi 2008).  Unfortunately, as 
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MIBG is unable to cross the blood-brain barrier, it cannot be used for in vivo 
neuroimaging studies (Guilloteau et al. 1983b; - French language, cited by Baulieu 
et al. 1990).   
 
1.4.2 Potential NAT-specific compounds for SPECT tracer development 
 
It might be expected that the production of successful SPECT and/or PET ligands 
for imaging of the NAT in the CNS will be derived from compounds structurally 
related to nisoxetine (Hadrich et al. 1999b).  Unfortunately, although [11C]-
nisoxetine displayed good affinity for NAT (Ki = 1.85 nM), metabolism in the serum 
was more rapid than ideal and brain uptake kinetics were too slow so this meant 
that a low brain-to-serum ratio was achieved, and in the presence of unlabelled 
nisoxetine brain uptake was higher suggesting problematic high non-specific 
binding (Tamagnan et al. 2007; Ding et al. 2005).  The measurements for uptake 
are different from the measurements for binding, and it could be that unlabelled 
nisoxetine also in the serum occupied a sequestering site at the blood-brain barrier 
to aid the uptake of more [11C]-nisoxetine into the brain, perhaps indicating an 
issue for labelled nisoxetine binding to an unintentional site at the blood-brain 
barrier.  These unfavourable kinetics of [11C]-nisoxetine, in combination with the 
short half-life of PET radiolabels and high non-specific binding hampered its use 
as an in vivo imaging agent.  Clearly, an alternative molecule for development was 
required.  Furthermore, with in vivo kinetics posing a consistent problem for PET 
imaging of the NAT, it was hoped that SPECT-applicable tracer candidates would 
offer more likelihood for successful imaging of the NAT.  Utilising [123/125I]-labelled 
ligands should enable maximal specific binding to be achieved prior to the decay 
rate of the isotope becoming problematic. 
 
Tomoxetine (aka MIPP), structurally related to nisoxetine, was also explored for its 
potential as a SPECT brain imaging tracer and displayed good in vitro affinity for 
the NAT with a KD of approximately 2nM, although only a 4.4-fold selectivity for the 
NAT over the SERT (Tatsumi et al. 1997).  The iodinated tomoxetine (Kiyono et al. 
2004; Kung et al. 2004), tomoxetine retains this lack of selectivity and the binding 
to the SERT as well as the NAT diminishes its value as a NAT-specific SPECT 
brain imaging tracer (Gehlert et al. 1995; Ding et al. 2005).  Some groups even 
proposed an iodinated tomoxetine analogue as a SERT-specific brain imaging 
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tracer, however high nonspecific binding in vivo (Chumpradit et al. 1992) made it 
unsuitable for use as a brain imaging tracer. 
 
Reboxetine is a highly selective noradrenergic reuptake inhibitor (Table 1-07) used 
in the treatment of clinical depression (Wong et al. 2000) and has been suggested 
as a basis for a NAT-specific in vivo imaging ligand.  The inhibition constants of 
reboxetine demonstrated at monoamine receptors are particularly low, in the 
micromolar range for α-adrenergic receptor subtypes, D2-4 dopaminergic receptor 
subtypes, 5-HT1A, 2A & 2C receptor subtypes, and in millimolar range for β-
adrenergic receptor subtypes, the D1 dopamine receptor subtype, and 5HT3-7 
receptor subtypes (Wong et al. 2000; Table 1-07).  At the dopamine transporter, 
there is no significant displacement noted against [3H]-WIN-35,428 (Wong et al. 
2000; Table 1-07).  Reboxetine exhibits notable affinity at the serotonin transporter 
in the hundred nanomolar range, although given the strong affinity at the 
noradrenaline transporter, the selectivity ratio of reboxetine is still greater than 
120:1 (Wong et al. 2000; Table 1-07).   
 
Recent research attention has therefore been focused upon the development of 
reboxetine-like compounds for in vivo imaging (Table 1-08).  Many of the 
compounds labelled with the short half-life isotopes 11C or 18F are for PET imaging, 
and the relevant compounds for SPECT imaging have been labelled with the 
longer half-life isotopes 123I or 125I. 
 
For example, [123/125I]- (S,S)-2-(α-(2-iodophenoxy)benzyl)morpholine, known by the 
acronyms INER and IPBM, has been determined to have good affinity for NAT 
(0.84nM and 4.22nM, Table 1-08) and good blood-brain barrier penetration at a 
favourable rate enabled maximum uptake at 30 minutes with a gradual decreases 
in brain concentration while serum concentrations were cleared more quickly – 
reaching a brain-to-blood ratio of 15.9:1 after an hour (Tamagnan et al. 2007; 
Kanegawa et al. 2006).  Nisoxetine was also shown to displace specific binding in 
INER/IPBM ex vivo autoradiograms and it therefore shows some promise as a 
SPECT imaging tracer. 
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Table 1-07: Monoaminergic Binding Profile of Reboxetine 
Monoamine Binding Site Ki (nM) 
Noradrenaline Transporter 
(displacing [3H]-nisoxetine) 
 
1.1 ± 0.2 
Adrenergic Receptors: 
α1 Adrenergic 
α2 Adrenergic 
β1 Adrenergic 
β2 Adrenergic 
 
10,000 ± 2,000 
43,000 ± 3,000 
 10,300,000 
>10,000,000 
Dopamine Transporter 
(displacing [3H]-WIN-35,428) 
 
No significant displacement at 10,000 
Dopaminergic Receptors: 
D1 Dopamine 
D2 Dopamine 
D3 Dopamine 
D4 Dopamine 
 
>10,000,000 
9,000 ± 5,000 
20,000 ± 2,000 
>49,000 
Serotonin Transporter 
(displacing [3H]-citalopram) 
 
129 ± 13 
Serotonin Receptors: 
5-HT1A 
5-HT2A 
5-HT2C 
5-HT3 
5-HT4 
5-HT6 
5-HT7 
 
18,000 ± 3,000 
7,300 ± 400 
1,500 ± 500 
>10,000,000 
>10,000,000 
>10,000,000 
>10,000,000 
Table 1-07: The monoaminergic binding profile of the selective noradrenergic 
reuptake inhibitor, reboxetine, established by the competitive displacement of 
various selective ligands (Adapted from: Wong et al. 2000). 
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Table 1-08: Candidate Compounds for in vivo imaging of the NAT 
Compound Ki (nM) Isotope Technique Reference 
2β,3α-(substituted 
phenyl) nortropanes 0.43 – 4.67 [
11C] PET (Zeng et al. 2007) 
Methylreboxetine / 
MRB / MeNER 4.63 * [
11C] PET (Logan et al. 2007; Ding et al. 2005) 
3-Cl-
methylreboxetine 6.11 * [
11C] PET (Ding et al. 2005) 
Fluororeboxetine  [18F] PET (Ding et al. 2005) 
Nisoxetine 1.85 [11C] PET (Tatsumi et al. 1997) 
Oxaprotiline 9.07 * [11C] PET (Ding et al. 2005) 
Lortalamine 0.37 * [11C] PET (Ding et al. 2005) 
(R)-MIPP / 
tomoxetine 1.16 [
125I] SPECT 
(Kiyono et al. 2004; 
Kung et al. 2004; 
Gehlert et al. 1995; 
Chumpradit et al. 
1992) 
Iodoreboxetine: 
a.k.a. INER; 
a.k.a. IPBM 
 
0.84; 
4.22 
 
[123I]; 
[125I] 
SPECT 
(Tamagnan et al. 
2007; Kanegawa et 
al. 2006) 
Table 1-08: Candidate compounds for in vivo imaging of the NAT, their affinity for 
the NAT as defined by competition assays, their labelling isotope, and applicable 
imaging technology. 
* Reported relative to nisoxetine affinity and corrected here for an approximated Ki. 
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The qualities required of a successful ligand are high affinity (Kd <10nM) and 
selectivity (≥10-fold) for the NAT, as well as stability in circulation (i.e. low rate of 
metabolism), blood-brain barrier penetrability, low in vivo non-specific binding, and 
favourable kinetics in vivo (i.e. rapid brain uptake).  The isotope should also have 
a favourably low rate of decay, so as to permit maximum brain uptake prior to 
image acquisition and using SPECT-specific isotopes will provide this advantage 
over PET alternatives. 
 
Schou et al (2007) examined previously successful PET brain imaging tracers for 
a variety of targets and determined that a simple binding potential estimation (Bmax 
of target / Kd of ligand) greater than or equal to 12 would enable a ligand to yield 
valuable data from within a structure.  Image acquisition is different on a PET 
scanner than it is on a SPECT scanner and there is the disadvantage of a more 
rapid rate of decay for the radioisotope sometimes necessitating image capture at 
a moment prior to that of ideal.  A SPECT scanner, without this disadvantage, may 
not require a binding potential as great as 12 for valuable imaging of the NAT.  
However, as I am unable to determine what value would be appropriate 12 is an 
acceptable approximation for a simple analysis of INER/IPBM (Table 1-09). 
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Table 1-09: NAT distribution in human brain and imaging tracer 
requirements 
Simple Binding Potential 
Estimation (Bmax/Kd) 
Brain Structure 
NAT Bmax  
as pmol/g 
wet weight, 
~nM 
(Donnan et 
al. 1991) 
Required Kd 
to achieve 
simple 
binding 
potential 
estimations 
≥12 
INER  
(aka IPBM) 
Kd = 0.84nM 
(Tamagnan 
et al. 2007) 
IPBM 
(aka INER) 
Kd = 4.22nM 
(Kanegawa 
et al. 2006) 
Globus Pallidus 8.7 0.73 10.4 2.1 
Ventral Pallidum 2.0 0.17 2.4 0.5 
Bed Nucleus of the 
Striatus Terminalis 8.0 0.67 9.5 1.9 
Thalamus 10.5 0.88 12.5 2.5 
Hypothalamus 36.7 3.06 43.7 8.7 
Red Nucleus 7.6 0.63 9.0 1.8 
Substantia Nigra 
pars compacta 
pars reticulata 
 
- 
5.4 
- 
0.45 
- 
6.4 
- 
1.3 
Edinger-Westphal 
Nucleus 18.4 1.53 21.9 4.4 
Rostral Linear Nucleus 7.2 0.60 8.6 1.7 
Caudal Linear Nucleus 50.5 4.21 60.1 12.0 
Parabrachial 
Pigmented Nucleus 1.0 0.08 1.2 0.2 
Paranigral Nucleus 4.6 0.38 5.5 1.1 
Central Grey 18.0 1.50 21.4 4.3 
Dorsal Raphe Nucleus 60.8 5.07 72.4 14.4 
Medial Raphe Nucleus 47.3 3.94 56.3 11.2 
Raphe Magnus 
Nucleus 7.1 0.59 8.5 1.7 
Raphe Obscurus 
Nucleus 21.0 1.75 25.0 5.0 
Raphe Pallidus 
Nucleus 10.2 0.85 12.1 2.4 
Paramedian Raphe 68.6 5.72 81.7 16.3 
Locus Coeruleus 70.8 5.90 84.3 16.8 
Cerebellum 6.6 0.55 7.9 1.6 
Dorsal Tegmental 
Nucleus 27.5 2.29 32.7 6.5 
Subpenduncular 
Pigmented Nucleus 20.3 1.69 24.2 4.8 
Table 1-09: The distribution of NAT in the human brain and simple estimations of 
binding potentials for NAT-specific prospective SPECT brain imaging tracers.  
Green shading indicates a simple binding potential estimation ≥12, and therefore 
indicative of a structure likely to be imaged successfully by the prospective tracer 
according to Schou et al (2007). 
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1.4.3 Objectives for new iodoreboxetine analogues 
 
Candidate compounds, shown in Table 4-04, synthesised along novel routes by 
Nicola K. Jobson in the Sutherland Chemistry Laboratory (Jobson et al. 2008a; 
Jobson et al. 2008b; Jobson et al. 2009) are also structurally related to reboxetine 
and the iodophenoxy ring compounds have particularly strong structural 
similarities to [123/125I]-INER/IPBM.  However, these compounds have novel routes 
of synthesis and some structural differences that distinguish them from previously 
reported molecules.  The compounds were produced in three main groups (Table 
4-04) with one group examining isomers of iodophenyl ring analogues, isomers of 
benzyl alcohol iodoamine analogues to determine the effect of deleting the 
phenoxy ring on binding properties, and the iodophenoxy ring analogues which 
examined iodine placement in a structural (R,S) confirmation that had not yet been 
fully explored by previous investigations in published literature. 
 
As Tamagnan et al (2007) tested the (S,S)-isomer for the iodophenoxy ring 
reboxetine analogues, my investigations were of the (R,S)-isomer of these 
analogues to determine which of the reboxetine analogue isomers have the 
greatest potential as radioiodinated NAT-specific SPECT brain imaging tracers.  
The difference between each of the (R,S)-isomer analogues was the position of 
the iodine atom on the molecule, which will potentially influence the affinity and 
selectivity for NAT. 
 
In Chapter 4, the affinity and selectivity for the NAT are determined via competitive 
radioligand binding assays with reference to structural differences in the chemistry 
of the candidate compounds.  This will be accomplished by determining: 
• Inhibition constants for all three monoamine transporters (NAT, SERT, and 
DAT) for the iodophenyl ring compounds to assess which isomers yield the 
greatest affinity and selectivity. 
• Inhibition constants for benzyl alcohol amide intermediate compounds at all 
three monoamine transporters to discover whether the phenoxy ring is 
critical to molecular binding properties of iodinated reboxetine-analogues. 
• Inhibition constants will be determined at all three monoamine transporters 
for the iodophenoxy ring compounds, how these compare to other 
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iodophenoxy ring compounds in the literature, and whether the position of 
the iodine atom greatly influences affinity and selectivity. 
 
1.5 Principles of In Vivo Neuroimaging 
 
1.5.1 Advantages of non-invasive SPECT and PET techniques 
 
SPECT and PET imaging relies upon the development of radiolabelled ‘tracer’ 
compounds with which to probe binding sites of interest.  For neuroimaging 
studies, these binding sites are usually found on neurotransmitter receptors or 
transporters and tracer ligands are normally administered in doses that are far 
exceeded by their KD values for the sites of interest, so as not to perturb the 
system being studied either pharmacologically or become harmful in terms of the 
quantity of radioactivity being injected into the patient.  Otherwise, the 
pharmacological effect of the ligand could modify the system under examination, 
too high a specific activity could inflict cellular damage, and would either be 
detrimental to the patient or fail to give a true reflection of the brain in its natural 
state – whether it is currently in good health or afflicted.  In terms of the imaging 
itself, excessive binding of a ligand to noradrenaline transporters could have a 
pharmacological effect in the periphery to modulate vascular constriction and 
could have adverse effects upon the patient.  Naturally, if the patient is stressed, 
then this could affect the results of the examination of occupany and displacement 
studies upon targets in the noradrenergic system, which is implicated in stress and 
anxiety. 
 
Selecting a non-invasive in vivo technique such as SPECT or PET provides the 
direct benefit of the imaging procedure being readily applied to patients in the 
clinic, and these neuroimaging techniques will take on an increasing importance in 
drug discovery in two main ways.  Firstly, displacement of a tracer from a binding 
site by an existing therapeutic drug to treat disease will confirm the mechanisms of 
action for existing drugs.  The mechanisms of action and specificities identified can 
be correlated with the known benefits and drawbacks of the therapeutic drug – 
thus identifying the most important targets in the brain for drug discovery and to 
what extent they must be manipulated to have the desired effect.  Secondly, the 
displacement of a tracer from a binding site by a new drug candidate can be used 
as a biomarker to demonstrate the specificity for target site of the new compound 
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and demonstrate any long-term effects of the compound upon the system with 
follow-up scans. 
 
1.5.2 SPECT and PET Theory 
 
Single photon emission computed tomography (SPECT) and positron emission 
tomography (PET) scanners are able to the detect gamma emissions from 
radiolabelled compounds that bind to receptors or transporters.  The accumulation 
of compound in regions of the brain that express these functional protein 
structures results in an increased intensity of signal detected by the scanner and 
so reveals the distribution of the site of interest. 
 
The theory of SPECT and PET neuroimaging (Frankle et al. 2005b) can be likened 
to a three-dimensional in vivo version of the in vitro technique autoradiography, 
although it is far more dynamic in nature.  The difference between in vitro 
autoradiography and in vivo SPECT or PET is that, whilst using trace 
concentrations of ligand, it is not possible to directly calculate Bmax or KD values if 
neither value is predetermined.  The measure actually obtained via SPECT or PET 
scanner – termed the binding potential (BP) – is representative of Bmax and KD and 
is equal to Bmax/KD (Mintun et al. 1984).  It is from this value, knowing the KD of the 
tracer in vitro, that we are able to derive the Bmax of the tracer in vivo based on the 
assumption that the KD of the tracer for the target site remains unchanged in the 
brain being imaged.  Furthermore, a compound with a greater affinity will result in 
a greater binding potential during a scan for a given target site. 
 
Neuroimaging with SPECT and PET theoretically segregates tracer concentrations 
into a compartmentalised system, with each compartment defined as an area 
where the concentration of radioactive tracer is assumed to be homogeneous 
(Frankle et al. 2005b). 
 
The compartmental model (Figure 1-13) has representations for the homogenous 
tracer concentration in the plasma (C1), free tracer in the intercerebral interstitium 
(C2), nonspecifically brain-bound tracer (C2’) and the specifically bound tracer at 
the brain site of interest (C3).  Fractional rate constants K1-6 are said to be the 
fraction of the tracer concentration that moves from one compartment to the next 
in a given timeframe.  K1 and K2 represent the fractional rate constants for 
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transversing the blood-brain barrier and are dependent upon blood flow and 
permeability (Frey et al. 1985; Gjedde & Wong 1990).  K3 and K4 represent the 
fractional rate constant for association and dissociation from specific binding, 
while K5 and K6 represent the fractional rate constants for association and 
dissociation from nonspecific binding. 
 
While the four-compartment model is the best representation for the theory of 
SPECT and PET imaging, the large number of parameters and variables for which 
to compensate make it difficult to put into practice - therefore, this is simplified to 
the three-compartment model (Figure 1-14).  In the simplified three-compartment 
model, the plasma compartment (C1) is given the new designation of Ca to 
represent arteriole and capillary tracer concentrations.  This is a practical 
improvement upon the full model in which tracer concentration is not deemed to 
be homogeneous between arteriole and capillary compartments, requiring 
modelling of arteriole concentrations, arteriole blood flow, capillary concentrations, 
and capillary flow (Frey et al. 1985).  The assumption in the simplified model is 
that the equilibrium between free tracer in plasma and tracer bound to plasma 
proteins is rapidly reached and stable.  Therefore, the assumed fraction of the 
total tracer free in the plasma is equivalent to Ca in the simplified model (Frankle et 
al. 2005b).  Another assumption in the three-compartment model of neuroreceptor 
imaging is that immediately following tracer distribution the signal from the free 
fraction of tracer in the brain interstitium will be indistinguishable from the 
nonspecifically bound – especially in a PET analysis, which is conducted over a 
short time frame.  Consequently, the assumed ‘free fraction’  is the combination of 
both the free tracer in brain interstitium (C2) and nonspecifically brain-bound tracer 
(C2’) to become the newly re-defined C2 (Frankle et al. 2005b).   
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Figure 1-07: The Compartmental Model (adapted from Frankle et al. 2005).  In 
vivo imaging with SPECT and PET separates concentrations of radiotracer into 
the theoretical compartments plasma (C1), free (C2), non-specifically bound (C2’), 
and specifically bound (C3), with fractional rate constants K1-6 representing the 
rate of movement between the compartments. 
 
 
 
 
 
 
Figure 1-08: The Simplified Three-compartment Model (adapted from Frankle et 
al. 2005).  In vivo imaging with SPECT and PET separates concentrations of 
radiotracer into the workable theoretical compartments plasma (Ca), free (C2), and 
specifically bound (C3), with fractional rate constants K1-4 representing the rate of 
movement between the compartments. 
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1.5.3 SPECT vs. PET 
 
PET imaging requires isotopes with rapid rates of decay, often measured in hours 
or days rather than weeks (Schmitz 2011), meaning that close proximity of the 
scanner to a cyclotron and a radiolabelling facility is necessary, adding expense to 
the method.  SPECT imaging uses isotopes with a slower decay rate, enabling 
isotopes and radiolabelled ligands to be shipped after production.  As such SPECT 
is less expensive and requires less computational modelling to interpret it.  
Currently, PET scanners have greater spatial resolution than SPECT scanners but 
investments in and advances of SPECT scanner hardware are negating that 
advantage and the lower costs involved with using longer-lived isotopes and less 
expensive hardware make SPECT imaging systems more affordable than their 
PET equivalents (Pimlott & Sutherland 2011). 
 
Unfortunately, the half-life of a PET isotope also means signal to noise ratios will 
decrease dramatically if sufficient time elapses for free tracer clearance prior to 
image acquisition.  Therefore, PET image acquisition must take place relatively 
quickly after injection and extensive computer modelling is used determine what 
proportion of radioligand is bound and which is free.    This makes distinguishing 
the specific binding from the free fraction (including nonspecific binding) more 
difficult with PET.   The greater half-life of SPECT isotopes over those used in PET 
allow scans to be conducted over a longer period of time, enabling metabolism 
and systemic clearance mechanisms to reduce the concentration of free tracer 
(Pimlott & Sutherland 2011).  The advantage inherent in SPECT is that before the 
isotopic decay rate becomes the limiting factor for completing image acquisition, 
the nonspecifically bound will constitute a greater proportion of the free fraction 
than in PET imaging.  With computational modelling bearing greater importance in 
a PET assay than with SPECT, the reduced complexity of the modelling 
associated with SPECT can be thought of as a purer form of imaging and that 
provides greater confidence in the measurements. 
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1.5.4 Requirements for a SPECT brain imaging tracer for the noradrenaline 
transporter 
 
Tracer development itself can have many parallels to drug discovery.  One 
approach is to take a molecule with known affinity for the target site, such as a 
well-characterised therapeutic drug that has high selectivity, and radiolabel the 
compound.  However, the introduction of radioisotopes into the molecular structure 
of SPECT compounds can interfere with or modify the drug’s binding properties 
and behaviour in vivo.  Therefore, various analogues of the modified drug could be 
synthesised and applied through a series of experiments to determine which 
analogue has the greatest likelihood of success as an in vivo imaging agent. 
 
SPECT imaging relies upon the development of radiolabelled ‘tracer’ compounds 
with which to probe binding sites of interest without perturbing the system being 
studied.  For neuroimaging studies, these binding sites are usually found on 
neurotransmitter receptors or transporters.  The dopamine and serotonin 
transporters have routinely been imaged with SPECT and PET in both clinical and 
research contexts (Varrone & Halldin 2010; Kupers et al. 2011).  However, to date, 
there are no clinically used SPECT tracers for imaging the noradrenaline 
transporter in the CNS. 
 
To briefly recap the qualities required of a successful SPECT tracer, they are: high 
affinity and selectivity for the target site, stability in circulation (i.e. low rate of 
metabolism), blood-brain barrier penetrability, low in vivo nonspecific binding, 
favourable radiological half-life (sufficiently long for uptake and image acquisition), 
and promising kinetics in vivo (i.e. rapid brain uptake, low metabolism).  The in 
vitro affinity and selectivity of the ligand for the target site, as well as in vitro 
nonspecific binding should be ascertained via radioligand binding experiments.  
SPECT isotopes (e.g. [123/125I]) typically have long half-lives and are not limiting 
factors in image acquisition.  The challenges of predicting the in vivo behaviour 
can be addressed by utilisation of rapid in vitro methodologies for compounds that 
have shown promise during earlier in vitro pharmacological testing. 
 
A candidate compound likely to become a successful SPECT brain imaging tracer 
should satisfy the following general criteria (Chauveau et al. 2008; Kula et al. 
1999; Petit-Taboue et al. 1991; Waterhouse 2003): 
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• Log P or log D < 3.5: while compounds require sufficient 
lipophilicity to cross the blood-brain barrier, higher lipophilicity and 
phospholipophilicity are associated with higher non-specific binding 
that would decrease the signal-to-noise ratio of a tracer and thus 
limit its utility. 
• Molecular weight < 450 g/mol: smaller molecules are more likely to 
cross the blood-brain barrier through passive diffusion. 
• An absence of functional groups that will strongly ionize at 
physiological pH: strongly ionized molecules are more likely to 
conjugate with lipid bilayers and the proteins comprising the blood-
brain barrier and so are less likely to penetrate the brain. 
• No appreciable affinity for efflux pumps (e.g. PGP): active transport 
interferes with the kinetics of the tracer penetrating and remaining 
in the brain.  Affinity for an efflux pump would decrease the 
availability of an imaging tracer in the brain by returning it across 
the blood-brain barrier to the plasma. 
• No appreciable affinity for specific binding sites for high capacity 
peripheral sites, including albumin or other plasma proteins: such 
an affinity would reduce the free concentration of tracer in the 
plasma and so decrease the amount of tracer to penetrate the 
brain. 
• Not a substrate for enzymes at the blood-brain barrier: enzymatic 
metabolism of the tracer would remove its ability to bind to the 
target site in the brain and any metabolites that did cross the 
blood-brain barrier may just decrease the signal-to-noise ratio if the 
metabolites appear to the scanner as nonspecifically bound ligand. 
 
These criteria would be very time-consuming to test for numerous compounds, 
and HPLC offers a high-throughput in vitro process by which to select the most 
likely compounds to be successful in vivo by measuring these various 
characteristics commonly associated with successful in vivo compounds.  
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1.6 Introduction to HPLC testing in tracer development 
 
High-performance liquid chromatography (HPLC) is a quick, precise, and reliable 
technique that, through determining the binding properties of ligands to lipids and 
proteins that will be encountered in vivo, can model biological distribution of a 
drug.  For example, among the main advantages to HPLC (measuring 
chromatographic hydrophobicity indexes to calculate log P) over traditional bench-
top methodologies (measuring octanol-water partition coefficients to calculate log 
P) for the determination of lipophilicity are that very large numbers of samples can 
be assayed in a short space of time, sample concentration and purity does not 
greatly affect the outcome, and vastly increased precision and reproducibility that 
does not rely on the bench-top proficiency of an individual experimenter (Valkó et 
al. 1997; Valkó 2004).  Using gradient elution protocols, the strength of the mobile 
phase is increased throughout the analysis to shorten the retention times of 
compounds that are strongly retained on the column – this reduces total analysis 
time, improves resolution, and maximises sensitivity (Valkó et al. 1997; Johnson & 
Stevenson 1978).  The main disadvantage is that HPLC-derived measurements 
are not yet standardised and universally accepted in all circles of the scientific 
community, and the same terms (e.g. log P or log D) when determined under 
different conditions and using different formula are often not directly comparable.  
There is also great expense involved in the purchase and maintenance of an 
HPLC system, and retention times are not even directly comparable on the same 
system – though this is compensated for by calibrating every chromatographic run 
against known standards (Valkó et al. 1997; Valkó 2004).  While time-consuming 
and highly dependent upon the proficiency of the individual experimenter, the 
octanol-water partition experiments have historically yielded Log P values that are 
more directly comparable between labs, and the equipment involved presents a 
smaller investment. 
 
Recent efforts have attempted to bring greater standardisation to the terms 
calculated via HPLC and these techniques can be applied to screening tracer 
candidates as well as therapeutic drugs acting on the central nervous system.   
Commercially available columns immobilise lipids, phospholipids, albumins, and 
glycoproteins into the stationary phases of each column and longer retention times 
are indicative of greater interaction by tracer candidate with the stationary phase.  
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Compounds with known chromatographic hydrophobicity indexes and protein 
binding characteristics are run on the columns to act as standards and calibrate 
the system.  The chromatographic hydrophobicity index (CHI) is the volumetric 
percentage of organic mobile phase necessary equally distribute a given 
compound between the mobile and stationary phases (Valkó et al. 1997).  For 
most compounds, this will be between 0 and 100, though some can have 
extrapolated theoretical values outside of this range.  This allows the conversion of 
retention times, which are arbitrary values and not comparable between two 
systems, into useful quantitative values such as: 
• lipophilicity for uncharged molecules: log
 
P
 
or log POCT  (Valkó 2004) 
• phospholipophilicity interpreted as a nonspecific binding predictor: 
log D7.4 IAM (Valkó 2004; Hollósy et al. 2006) 
• relative blood-brain barrier penetration predictor: clog BB (K. Valkó, 
2008 - Personal Communication; Garg et al. 2008) 
• plasma protein binding to predict availability in serum: c%PPB 
(Valkó 2008; Oravcová et al. 1996). 
 
1.6.1 Lipophilicity (log P or log POCT) – blood-brain barrier penetration and 
nonspecific binding 
 
Lipophilicity (log P) is a measurement of compound affinity for lipid layers (Valkó 
2004) and is measured using three C-18 lipid columns across three pH ranges: 
acidic (pH 2.5), neutral/physiological (pH 7.4), and alkaline (pH 10.5).  If it is 
defined via octanol-water partitioning – the assay against which new 
methodologies are often measured – then it is generally expressed as log POCT 
and will generally return a slightly higher value than one expressed in terms of log 
P (Avdeef & Testa 2002).  While the most easily comparable value for examining 
lipophilicity is log P (often derived from computational modelling or HPLC), log D 
(a common bench-top value) can also be encountered and is an expression of the 
lipophilicity for all species of a compound in a solution, usually at a given pH and 
returning a lower value than log P (Avdeef & Testa 2002) when the molecule 
carries a charge. 
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The log POCT term is also applied to the HPLC technique when it is attempting to 
mimic the result of an octanol-water determination and the results are intended to 
be directly comparable, as with this thesis. 
 
It is important to know whether a compound is lipophilic, because it is this property 
that will allow it to cross the blood-brain barrier and penetrate the brain.  However, 
a compound that is too highly lipophilic may have a tendency to exhibit excessive 
levels of nonspecific binding – and thus would not be advantageous.  An ‘ideal’ log
 
POCT range, calculated from the chromatographic hydrophobicity index for the 
uncharged form of the compound is considered to be 1-3.5 (Waterhouse 2003; 
Valkó 2004), with blood-brain barrier penetration related to log
 
POCT in a parabolic 
nature.  Insufficient lipophilicity (below log POCT 1) will result in insufficient 
permeability for compounds through the blood-brain barrier, and excessive 
lipophilicity (above log POCT 3.5) is associated with elevated levels of nonspecific 
binding. 
 
1.6.2 Phospholipophilicity (log D7.4 IAM) – predicting in vivo nonspecific 
binding 
 
Membrane binding in vivo can be a significant proportion of nonspecific binding for 
otherwise highly selective compounds, and this property is predicted using HPLC 
via an immobilized artificial membrane (IAM) column composed of phospholipids.  
It is important to note that the log D7.4 IAM value is very different from the log D7.4 
lipophilicity calculation, with the addition of the phosphate heads in the column 
providing a very different surface in the stationary phase for the compounds 
suspended in the mobile phase to interact with. 
 
Primarily, the binding to the phosphate heads models nonspecific binding to 
surface membranes in vivo and the log D7.4 IAM value can be used as a reference 
point to predict whether the membrane binding of a compound will be excessive 
and therefore problematic (Valkó 2004).  This technique differs to the calculation 
for lipophilicity in that, while non-ionised compounds will roughly reflect the log P 
result, positively charged molecules will bind more strongly to an IAM column 
(Hollósy et al. 2006) and fills a gap left by the log P determination in our 
knowledge about positively charged tracer candidates. When a sufficiently 
comprehensive database is constructed containing these values in relation to 
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membrane binding contributing to overall nonspecific binding, ranges can be 
established to rapidly select for compounds that have a high probability of 
acceptable levels for nonspecific binding. 
 
1.6.3 clog BB – predicting blood brain barrier penetration 
 
Blood brain barrier penetration can also be estimated using a formula 
incorporating data from the alkali C-18 acetonitrile-eluted column and a 
physiological pH C-18 with a methanol elution (K. Valkó, 2008 - Personal 
Communication).   
 
Higher clog BB values are interpreted as indications of greater potential for 
successful brain penetration, whilst lower values are interpreted as a reduced 
potential for brain penetration (Garg et al. 2008).  Negative values are theoretical 
numbers and are interpreted as an inability to cross the blood-brain barrier.  The 
reason for incorporating a methanol elution into this estimation is to compensate 
for any relative variability in acetonitrile solubility between compounds by providing 
an alternative solvent for elution from the column (Kalendarev et al. 2001). 
 
1.6.4 Immobilised protein chromatography (c%PPB) – predicting plasma 
protein binding in vivo 
 
Drug and ligand binding to plasma transport proteins such as human serum 
albumin (HSA) and α-acid glycoprotein (AGP) is an important part of the 
pharmacokinetic profile for the drug or ligand in clinical use (Oravcová et al. 1996; 
Valkó 2008; K. Valkó, 2008 - Personal Communication).   
 
Plasma protein binding is directly correlated with lipophilicity and so availability of 
free tracer for the blood brain barrier penetration of a highly lipophilic compound 
may be compromised by excessive plasma protein binding (Vallabhajusola 2009).  
Benchtop methodologies including equilibrium dialysis, ultrafiltration, and 
ultracentrifugation can be used to determine protein-drug interactions – with 
equilibrium dialysis considered one of the ‘standard methods’.  However, HPLC 
methods provide advantages such as speed, greater resolution, greater precision, 
and improved reproducibility without the traditional benchtop method drawbacks 
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such as ligand stability over time, leakage of drug or protein through membranes, 
and adsorption of ligands to the surface of dialysis devices and membranes.  If 
high-throughput screening is to be rapid and cost-effective, then HPLC-based 
methods have the advantage over traditional benchtop assays. 
 
Protein-binding displacement phenomena (Oravcová et al. 1996) may prove 
clinically significant for compounds that are highly bound to protein (>95% binding) 
and have small distribution volumes.  Excessive protein binding such as this has 
been linked to reduced compound brain penetration (Valkó 2004) to the detriment 
of a compound’s application to SPECT neuroimaging. 
 
1.6.5 Reference Compounds: Successful and failed imaging tracers 
 
To provide a basis for comparison to the newly synthesised iodinated reboxetine 
analogues, it is important to examine a library of reference compounds comprised 
of both successful and failed brain imaging tracers (Table 1-10).  Therefore, where 
similar values are found for each HPLC predictor, interpretations can be made as 
to the likelihood that the reboxetine analogues might behave in a similar manner. 
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Table 1-10: Reference Compounds for Interpreting Predictors of in vivo 
Molecular Behaviour 
Reference 
Compound 
Blood-Brain 
Barrier 
Penetration 
Non-
specific 
Binding 
Is 
Plasma 
Protein 
Binding 
<95%? 
References 
5-I-A-85380 Yes Low  Yes 
(Fujita et al. 2000; 
Zoghbi et al. 2001; 
Ogawa et al. 2009) 
β-CIT Yes Low Yes 
(Al-Tikriti et al. 1995; 
Zogbhi SS et al 1998 - 
cited by Scanley et al. 
2000; Kula et al. 1999; 
Scanley et al. 2000) 
I-QNB Yes Moderate  (Varastet et al. 1992; Piggott et al. 2003) 
CNS-1261 Yes High Yes (Erlandsson et al. 2003; Knol et al. 2009) 
PK11195 Yes High Yes 
(Petit-Taboue et al. 
1991; Lockhart et al. 
2003; Chauveau et al. 
2008) 
MK-801 Yes 
 
Not known 
(not a brain 
imaging 
agent) 
Yes 
(Wong et al. 1986; 
Owens et al. 1997; 
Murray et al. 2000; 
Erlandsson et al. 2003) 
α-3-iodo-2-
methyltyrosine 
Yes 
(Active 
Transport) 
Low Yes 
(Langen et al. 1991; 
Reimann et al. 2001; 
Shikano et al. 2004; 
Hellwig et al. 2008) 
MIBG No 
Not 
discussed 
(not a brain 
imaging 
agent) 
 
(Guilloteau et al. 
1983b; Baulieu et al. 
1990; DeGrado & 
Wang 1998; Raffel & 
Wieland 2001a; Tytgat 
et al. 2002) 
FIAU No 
Not 
discussed 
(not a brain 
imaging 
agent) 
 
(Tovell et al. 1988; 
Jacobs et al. 2001) 
5-iodo-2’-
deoxyuridine No 
Not 
discussed 
(not a brain 
imaging 
agent) 
Too 
unstable 
to 
measure.  
(Ghosh & Mitra 1991; 
Tjuvajev et al. 1994; 
Vaidyanathan & 
Zalutsky 1998; Khalili 
et al. 2003) 
Table 1-10: Reference compounds, comprised of both successful and failed brain 
imaging tracers, to provide a basis for comparison of in vivo predictors to the 
newly synthesised iodinated reboxetine analogues. 
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1.7  Thesis Aims 
 
The aim of this thesis is to develop a novel SPECT brain imaging tracer for the 
noradrenaline transporter, using compounds structurally related to reboxetine.  
This will be accomplished by: 
 
1. Imaging the noradrenaline transporter in a model of psychiatric 
disease (Chapter 3).  Autoradiography and in situ hybridisation will 
confirm the distribution of the NAT, investigate its potential role in the 
aetiology of the model, and highlight an instance where a SPECT 
tracer for the NAT would be beneficial.  This model could then be used 
to demonstrate the in vivo capability of a SPECT imaging tracer for the 
noradrenaline transporter if the development of one is successful. 
 
2. Ascertaining the NAT affinity and selectivity over other monoamine 
transporters for each candidate in a library of iodinated compounds 
that are structurally related to reboxetine (Chapter 4).  Radioligand 
competition experiments will be used to select the molecule with the 
most desirable pharmacology for use as a SPECT brain imaging tracer 
for the NAT. 
 
3. Using in vitro HPLC techniques to predict the in vivo molecular 
behaviour for the library of iodinated reboxetine-like compounds 
(Chapter 5).  These experiments will be used to determine which of the 
molecules has the best balance of characteristics with regard to 
availability in the plasma for blood-brain barrier penetration, brain 
penetration kinetics, and measures to estimate in vivo non-specific 
binding. 
 
4. Combining the data to recommend, if any are suitable, a lead 
candidate compound to be taken forward through development into a 
novel SPECT brain imaging tracer for the noradrenaline transporter 
(Chapter 6 – Conclusions). 
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Chapter 2 
Methods 
 
2.1 PCP Study Methods 
 
2.1.1 Treatment regime 
 
Adult male Hooded Long Evans rats (Harlan-Olac, UK) weighing approximately 
240g were randomised into PCP-treated and control groups by assigning each rat 
a number with as little handling bias as possible and allocating the numbered rats 
to each group using a list of randomly generated numbers.  The Hooded Long 
Evans rat strain was used because it was in this rat strain that the PCP-induced 
model for metabolic hypofrontality was established in the literature.  PCP-treated 
animals (n=10) received single i.p. injections of 2.58mg.kg-1.day-1 PCP (Sigma-
Aldrich) in normal saline for 5 days while control animals (n=10) received 
equivalent volumes of normal saline (Cochran et al. 2003).  Normale saline is 
154mM NaCl solution.  The injection preparations were prepared by Susan 
Cochran using blinding codes to ensure my impartiality for the later data analysis.  
The brains were harvested two days after the final injection to allow sufficient time 
for the metabolism and clearance of the PCP from the brains.  The rats underwent 
a Schedule 1 kill (Figure 2-01) in order to remove the brains, which were then 
coated in tissue tech, frozen in isopentane (-42°C), wrapped in tin foil, placed in an 
airtight plastic bag, and stored at -70°C until sectioning. 
 
 
Figure 2-01: PCP administration regime to establish the rat 
model of schizophrenic hypofrontality. 
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2.1.2 Section Preparation 
 
Frozen coronal sections, of 20µM thickness, were cut in a cryostat and thaw-
mounted onto glass slides coated with poly-L-lysine for autoradiography or 
RNAase-free poly-L-lysine-coated glass slides for in situ hybridisation. Sections for 
autoradiography were air-dried for approximately 1 hour at room temperature and 
then stored at -70°C.  Sections for in situ hybridisation were air dried for 
approximately 1 hour at room temperature, fixed in ice-cold 4% (w/v) 
paraformaldehyde solution (Sigma-Aldrich), processed through PBS, 70% EtOH, 
95% EtOH, and 100% EtOH before storage in 100% EtOH at 4°C. 
 
2.1.3 Quantitative ligand binding autoradiography 
 
The noradrenaline transporter (NAT), the dopamine transporter (DAT), and the 
serotonin transporter (SERT) were labelled in selected sections throughout the 
brain with 3.0nM [3H]-nisoxetine (71.0 Ci/mmol, GE Healthcare), 10.0nM [3H]-WIN-
35,428 (85.9 Ci/mmol, Perkin-Elmer), and 2.0nM [3H]-citalopram (83.0 Ci/mmol, 
GE Healthcare), respectively.  Nonspecific binding was defined in adjacent 
sections in the presence of 10µM nortriptyline hydrochloride, 30µM nomifensine, 
and 20µM fluoxetine, respectively. Structures analysed included the prefrontal 
cortex (PFC), caudate putamen (CPu), anterior cingulate cortex (ACg), nucleus 
accumbens (N. acc.), bed nucleus of the striatus terminalis (BNST), anteroventral 
thalamic nucleus (AVTN), reticular thalamic nucleus (RTN), hippocampal 
structures CA1, CA2, CA3, and dentate gyrus (DG), ventral tegmental area (VTA), 
dorsal raphe nuclei (DRN), locus coeruleus (LC), and cerebellum (CBL).  Due to 
the very high density of NAT in the locus coeruleus, sections containing this 
structure were incubated with 1.5nM [3H]-nisoxetine.  Sections alongside 
calibrated [3H] microscales (Amersham Bioscience) were exposed to Kodak 
BioMax MR for 7-weeks for sections labelled with [3H]-nisoxetine or [3H]-WIN-
35,428, and for 5-weeks for sections labelled with [3H]-citalopram.   Experimental 
schedules are presented in full in Table 2-01.  Anatomical structures were 
identified in consultation with the Paxinos and Watson Rat Brain Atlas (2004) and 
delineated using MCID 7.0 Basic, the image analysis system.  Prior to image 
analysis, a flat field correction was performed to account for any environmental 
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influences to the image or imperfections in, for example, the lightbox surface.  The 
MCID 7.0 Basic image analysis system was used to convert average optical 
densities for delineated regions of each coded subject into fmol of bound ligand 
per mg of wet weight tissue by calibrating the measured optical densities with the 
delineations of [3H] microscales (Amersham Bioscience) exposed to the same 
piece of film.  Corrections to account for the decay of the isotope in the ligand and 
in the micoscales were performed via consultation of the specific product 
information sheet to each [3H] miscroscale – this included the manufacturer’s data 
on the wet weight tissue equivalence of radioactivity, precise date of manufacture, 
and the known decay profile for [3H], to ensure an accurate quantification of bound 
ligand.  The ligand used was also corrected for isotopic decay, assuming standard 
rate of [3H] decay from the manufacture date of the ligand.  Sections representing 
total binding were aligned in MCID 7.0 Basic’s digital Channel 1 with adjacent 
sections representing nonspecific binding in MCID 7.0 Basic’s digital Channel 2, 
so that identical coordinates were simultaneously assayed on each section when 
identified structures were delineated in the sections representing total binding.  For 
measurements in the Caudate Putamen, thresholding was used to exclude white 
matter tracts that run through this structure.  Blinding was used to ensure 
impartiality during image acquisition and data analysis, and each coded animal 
was represented by 6 measurements of each structure delineated from three sets 
of aligned total binding and non-specific binding sections.  Microsoft Excel 2003 
was used to perform the subtraction of nonspecific binding from total binding to 
ascertain specific binding and, for each coded animal, the specific binding 
measurements for each structure were averaged. 
 
For each structure, each animal was assayed thusly: 
 
total binding 1 – Nonspecific binding 1 = specific binding 1 
total binding 2 – Nonspecific binding 2 = specific binding 2 
total binding 3 – Nonspecific binding 3 = specific binding 3 
total binding 4 – Nonspecific binding 4 = specific binding 4 
total binding 5 – Nonspecific binding 5 = specific binding 5 
total binding 6 – Nonspecific binding 6 = specific binding 6 
 
Measurements 1 and 2 were derived from the left and right hemispheres of the 
same aligned sections, measurements 3 and 4 were derived from the left and right 
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hemispheres of the same aligned sections, and measurements 5 and 6 were 
derived from the left and right hemispheres of the same aligned sections.  For 
each animal, the measurements were averaged thusly: 
 
( specific binding 1 + specific binding 2 + specific binding 3 + specific binding 
4 + specific binding 5 + specific binding 6 ) / 6 = average specific binding 
 
The average specific binding in fmol.mg-1 for each structure was taken as a single 
data point for that animal, and contributed to the group data.  For analysing the 
group data, GraphPad Prism 4.0 was used to apply the Mann-Whitney statistical 
test, a non-parametric test due to the variances between the groups being unequal 
as determined by F-test, to determine whether differences between the groups are 
significant.  F-test results, which determined that a parametric analysis would be 
inappropriate, are displayed in appendix I and autoradiograms are in Chapter 3. 
 57 
 
METHOD 
FOR NAT IMAGING 
(modified from: 
Hipolide et al. 2005) 
FOR DAT IMAGING 
(modified from: 
Andersen et al. 
2005) 
FOR SERT 
IMAGING 
(modified from: 
Hebert et al. 2001) 
BINDING 
BUFFER 
50mM Tris-HCl 
300mM NaCl 
5mM KCl 
pH 7.4 
25mM Na2HPO4 
25mM NaH2PO4 
50mM NaCl 
pH 7.7 
50mM Tris-HCl 
120mM NaCl 
5mM KCl 
pH 7.4 
PREINCUBATION 30 minutes at 4°C in binding buffer 
20 minutes at 4°C in 
binding buffer 
15 minutes at ~25°C 
(RTP) in binding 
buffer 
INCUBATION 
4 hours (240 
minutes) at 4°C in 
binding buffer with: 
 
Ligand: 
3.0 nM [3H]-
nisoxetine 
 
Displacer: 
10.0 µM Nortriptyline 
Hydrochloride 
2 hours (120 
minutes) at 4°C in 
binding buffer with: 
 
Ligand: 
10.0 nM [3H]-WIN-
35,428 
 
Displacer: 
30.0 µM 
Nomifensine 
2 hours (120 
minutes) at ~25°C 
(RTP) in binding 
buffer with: 
 
Ligand: 
2.0 nM [3H]-
citalopram 
 
Displacer: 
20.0 µM Fluoxetine 
WASH 1 5 minutes in buffer 
solution at 4°C 
30 seconds in buffer 
solution at 4°C 
2 minutes in buffer 
solution 4°C 
WASH 2 5 minutes in buffer 
solution at 4°C 
30 seconds in buffer 
solution at 4°C 
2 minutes in buffer 
solution 4°C 
WASH 3 5 minutes in buffer 
solution at 4°C 
30 seconds in buffer 
solution at 4°C 
2 minutes in buffer 
solution 4°C 
WASH 4 
Rapid dip (10 
seconds maximum) 
in dH2O at 4°C 
Rapid dip (10 
seconds maximum) 
in dH2O at 4°C 
2 minutes in buffer 
solution 4°C 
WASH 5 N/A N/A 
Rapid dip (10 
seconds maximum) 
in dH2O at 4°C 
DRYING Dry overnight under 
cool fan 
Dry overnight under 
cool fan 
Dry overnight under 
cool fan 
FILM EXPOSURE 
7 weeks on Kodak 
BioMax MR with 
calibrated [3H] 
microscales 
(Amersham 
Bioscience) at 
~25°C (RTP). 
7 weeks on Kodak 
BioMax MR with 
calibrated [3H] 
microscales 
(Amersham 
Bioscience) at 
~25°C (RTP). 
5 weeks on Kodak 
BioMax MR with 
calibrated [3H] 
microscales 
(Amersham 
Bioscience) at 
~25°C (RTP). 
IMAGE 
ANALYSIS 
MCID 7.0 Basic / 
Microsoft Excel 2003 
/ GraphPad Prism 
4.0 
MCID 7.0 Basic / 
Microsoft Excel 2003 
/ GraphPad Prism 
4.0 
MCID 7.0 Basic / 
Microsoft Excel 2003 
/ GraphPad Prism 
4.0 
Table 2-01: Monoamine transporter autoradiography reagents, buffers, and 
experimental schedules. 
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2.1.4 Radioligand binding 
 
For determination of KD values, triplicate aliquots of membrane suspensions (750-
850µg of protein) were incubated in 0.5mL volumes in increasing concentrations of 
[3H]-nisoxetine (71.0 Ci/mmol, GE Healthcare) and [3H]-citalopram (83.0 Ci/mmol, 
GE Healthcare) for NAT and SERT, respectively.  Non-specific binding was 
defined in the presence of 10µM Reboxetine (Tocris) and 20µM Fluoxetine 
(Tocris) for NAT and SERT, respectively.  Reactions were terminated by rapid 
vacuum filtration through Whatman GF/B glass fibre filters pre-soaked in 0.5% 
polyethylenimine (PEI) in relevant binding buffer (Table 2-01) using a 24-well 
Brandel cell harvester.  Filters received three rapid washes in ice-cold binding 
buffer, filter circle impressions were separated from the filter sheet and placed in 
glass scintillation vials containing 10mL liquid scintillant (National Diagnostics 
Ecoscint A).  20µL aliquots of the radioligand dilutions applied were added to 
additional glass scintillation vials containing 10mL liquid scintillant each, so that 
precise concentrations of each dilution could be confirmed.  All vials were then 
vortexed 3 times for 3 seconds each and left for 24 hours to ensure 
chemiluminescence did not artificially inflate the liquid scintillation analysis.  Liquid 
scintillation analysis was performned on a Packard 1900CA Tri-Carb Liquid 
Scintillation Analyzer that is calibrated against known [3H] standards, automatically 
performs background subtraction, and presents raw data in disintegrations per 
minute (dpms). 
 
Specific binding was expressed as fmol.mg-1 protein, and the protein 
determination performed using a BioRad kit.  KD values for [3H]-nisoxetine and 
[3H]-citalopram were derived from nonlinear regression analysis using GraphPad 
Prism Version 4 (GraphPad Software Inc.).  A KD estimation for [3H]-WIN-35,428 
(5.0nM) binding to the high affinity site on the DAT was selected by a review of 
published literature (Reith & Coffey 1994; Kirifides et al. 1992).  Data is presented 
as mean ± SEM for at least three independent competition experiments with [3H]-
nisoxetine and at least two independent competition experiments with [3H]-
citalopram and [3H]-WIN-35,428. 
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2.1.5 In situ hybridisation 
 
Oligonucleotide probes were designed to be specific for the mRNA of each of the 
transporters studied by means of ligand binding autoradiography.  The sequence 
for the mRNA of the rat noradrenaline transporter (Slc6a2 – Solute carrier family 6 
member 2) was obtained via the NCBI Entrez Nucleotide online database.  I 
selected a portion of the code that was a non-repeating part of the coding 
sequence of the mRNA for the NAT and the NCBI BLAST (Basic Local Alignment 
Search Tool) was used to confirm that this selected sequence would be specific 
for that specific gene only and that the secondary structure would be weak to 
prevent it from binding to itself.  The reverse complementary sequence was 
obtained via extrapolations made by me as per figures 2-02, 2-03, and 2-04. 
 
The rat dopamine transporter (Slc6a3) and rat serotining transporter (Slc6a4) 
mRNA sequences were obtained and checked by the same procedure, and their 
oligonucleotide probes designed in the same manner.  Once designed by me, the 
probe sequences were used to create Sigma-Genosys Oligonucleotides (Sigma-
Aldrich, United Kingdom), which were purchased. 
 
Probes were [35S]-labelled for in situ hybridisation using a Pharmacia enzyme kit.  
Each probe was supplied as a powder, which was then combined with diethyl-
pyrocarbonate (DEPC, Sigma-Aldrich) treated water and vortex mixed to obtain a 
100µM (1pmol/µl) stock solution.  The stock solution was diluted to obtain a 
working concentration of 3.3nM (0.3pmol/µl or 5µg/µl) and concentration was 
precisely determined via measurement of optical density.  Optical density was 
ascertained with 15µl samples using a pathlength of 10mm, compensation of 
320mm, factor ssDNA of -37.0, probe length of 45mer, and background calibrated 
against DEPC-treated water.  Probe concentration was determined in ng/µl (Table 
2-02).
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Figure 2-02: NAT transporter-specific oligonucleotide probe sequences.  Targeted 
section of mRNA is shown highlighted in green and the reverse complementary 
sequence (the probe) is highlighted in yellow.  The probe has a molecular weight 
of 13936.84, a melting temperature of 84.29°C, a percentage of GC content of 
51.12, and a weak secondary structure. 
 
 
 
 
Figure 2-03: DAT transporter-specific oligonucleotide probe sequences.  Targeted 
section of mRNA is shown highlighted in green and the reverse complementary 
sequence (the probe) is highlighted in yellow.  The probe has a molecular weight 
of 13816.87, a melting temperature of 76.74°C, a percentage of GC content of 
40.00, and a weak secondary structure. 
 
 
 
 
Figure 2-04: SERT transporter-specific oligonucleotide probe sequences.    
Targeted section of mRNA is shown highlighted in green and the reverse 
complementary sequence (the probe) is highlighted in yellow.  The probe has a 
molecular weight of 13765.71, a melting temperature of 76.08°C, a percentage of 
GC content of 42.23, and a weak secondary structure. 
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[35S]-d-ATP for the probe labelling was thawed from freezer storage at -20°C in a 
water bath heated to 37°C.  The Pharmacia kit labelling reaction was prepared in 
RNAase-free Eppendorf tubes as follows, taking into account the unequal 
concentrations of the various probe preparations (Table 2-03): 
 
The reaction mixture was vortex mixed and briefly centrifuged for a few seconds at 
low speed to aggregate the solution in the bottom of the reaction tubes.   Terminal 
deoxynucleotide transferase (TdT) was kept on ice at all times until 0.6µl was 
added to each labelling mixture, taking extreme care not to introduce air bubbles 
which would degrade the enzyme.  The completed reaction mixture was briefly 
stirred (not vortex mixed) and incubated in a water bath at 37°C for 30 minutes.  
The reaction was terminated at the end of the incubation with the addition of 40µl 
of room temperature DEPC-treated water. 
 
Labelled probe was separated from the rest of the solution with the QIAquick 
Nucleotide Removal Kit (QIAGEN), consisting of columns and solutions PN, PE, 
and EB.  This commercially available kit purifies the labelled probes by separating 
them from the remnants of the enzymatic reaction to label the oligonucleotides 
with the [35S].  The precise details of each solution are proprietary information of 
the manufacturer and are unavailable.  10 volumes of kit solution PN were added 
to 1 volume of terminated reaction and vortex mixed.  Kit columns were set up with 
RNAase-free collection tubes and the sample-PN mixture was applied.  The 
columns were centrifuged for 1 minute at 2,000 g and the elution was discarded.  
500µl of kit solution PE was applied to the column before centrifuging for 1 minute 
at 2,000 g and the elution was discarded.  The column was centrifuged for 1 
minute at 9,500 g and the elution was discarded if any was found.  New RNAase 
free Eppendorf tubes were prepared beneath the columns and 100µl of kit solution 
EB was applied to the column.  After sitting for 30 seconds, each column was 
centrifuged for 1 minute at 9,500 g and the elution (containing the [35S]-labelled 
probe) was retained. 
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Oligonucleotide probe concentrations 
Equation Optical density * cDNA co-efficient * pathlength correction = 
concentration (ng/µl) 
DAT-specific 
oligonucleotide 
probe 
0.094 * 30 * 2 = 5.64 ng/µl 
NAT-specific 
oligonucleotide 
probe 
0.092 * 30 * 2 = 5.52 ng/µl 
SERT-specific 
oligonucleotide 
probe 
0.116 * 30 * 2 = 6.96 ng/µl 
Table 2-02: The calculations applied to determining the oligonucleotide probe 
concentrations via optical density. 
 
 
Reagent General rule 
of thumb 
For DAT 
probe 
For NAT 
probe 
For SERT 
probe 
DEPC-
treated 
water 
0.9 1.18 1.14 1.60 
5x tailing 
buffer 1.2 1.2 1.2 1.2 
12.5µg probe 2.5 (at 5ng/µl) 2.22 2.26 1.80 
[35S]-d-ATP 1.5 1.5 1.5 1.5 
Table 2-03: Reagents and quantities (in µL) used with the Pharmacia probe 
labelling kit, for preparing each RNAase-free Eppendorf tube. 
 
 
Reaction preparations per slide 
Reactant 
For slides with 
sections defining total 
binding 
For slides with 
sections defining non-
specific binding 
Labelled probe 
preparation 4µl 4µl 
1M DTT 16µl 16µl 
Hybridisation buffer 200µl 200µl 
Unlabelled probe from 
100µM (1pmol/µl) 
stock preparation 
none 16µl 
Table 2-04: Reaction proportions for each slide containing 2-3 sections.  These 
volumes were scaled up as needed to cover all slides. 
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2µl of each probe sample was transferred into 4ml liquid scintillant (National 
Diagnostics Ecoscint A) in a scintillation tube and disintegrations per minute were 
determined to ensure that the probes had been labelled successfully with [35S].  
Probes that were labelled successfully were combined with 4µl 1M Diothiothreitol 
(DTT, 1.5495g in 10ml DEPC-treated water), vortex mixed, and stored in a freezer 
at -20°C. 
 
For in situ hybridisation, nonspecific labelling was defined in the presence of 1000-
fold excess of unlabelled oligonucleotide probe and each slide required the 
preparation of reaction solutions (Table 2-04).  Sections were removed from 
storage in 4°C ethanol and air dried for 30 minutes.  
 
Selected slides were placed inside Petri dishes on horizontal toothpicks. The 
reaction mixtures were briefly vortex mixed just prior to application to sections.  
The sections were then covered with Parafilm, ensuring no air bubbles.  20x 
concentration saline-sodium citrate (SSC, containing 3M NaCl and 0.3M 
monosodium citrate) was prepared in DEPC-treated water.  4xSSC was used to 
soak paper towel wads to provide humidity inside the Petri dish during incubation.  
Petri dishes were sealed with Parafilm and incubated in and incubated overnight 
(approximately 18 hours) in an oven set to 42°C. 
 
Following incubation, slides were removed from the Petri dishes, immersed in 
room temperature 1xSSC and the Parafilm strips covering the sections were 
removed.  Slides were then incubated with gentle agitation in 60°C 1xSSC before 
being rinsed with gentle agitation in room temperature 1xSSC for 20 seconds, 
rinsed with gentle agitation in RTP 0.1xSSC for 20 seconds, rinsed with gentle 
agitation in RTP 70% EtOH for 20 seconds, rinsed with gentle agitation in RTP 
95% EtOH for 20 seconds, and then air dried for 1 hour at RTP.  Images were 
generated by exposing labelled sections to Kodak BioMax MR film for 10-14 days 
and processing with an automatic developer.   
 
Anatomical structures were identified in consultation with the Paxinos and Watson 
Rat Brain Atlas (2004), the Allen Brain Atlas (Lein et al. 2007) and delineated 
using MCID 7.0 Basic, the image analysis system.  The MCID 7.0 Basic image 
analysis system was used to measure average optical densities for delineated 
regions of each coded subject.  Sections representing total binding were aligned in 
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digital Channel 1 with adjacent sections representing nonspecific binding in digital 
Channel 2, so that identical coordinates were simultaneously assayed on each 
section when identified structures were delineated in the sections representing 
total binding.  Blinding was used to ensure impartiality during image acquisition 
and data analysis, and each coded animal was represented by 6 measurements of 
each structure delineated from three sets aligned total binding and non-specific 
binding sections.  Microsoft Excel 2003 was used to perform the subtraction of 
nonspecific binding from total binding to ascertain specific binding.  The qualitative 
specific binding measurements for each structure from each subject were 
averaged and contributed to the group data.  GraphPad Prism 4.0 was used to 
apply the Mann-Whitney statistical test, a non-parametric test due to being unable 
to assume equivalent variances between the groups.  The aforementioned blinding 
of the treatment groups was still in effect to ensure impartiality during image 
acquisition and data analysis, and the qualitative presentation as a percentage 
relative to the control group was done only after the blinding was lifted. 
 
2.2 Radioligand Development 
 
All novel compounds (Table 2-05) were synthesised by Nicola Jobson (Sutherland 
Chemistry Laboratory, Glasgow University) and dissolved by Nicola Jobson to a 
concentration of 1mM in relevant binding buffer provided by me.  These were 
transported to the Wellcome Surgical Institute at room temperature in a sealed 
glass vial. 
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Table 2-05: Iodoreboxetine Analogues and their Structure 
Type Structure * Names 
Reference 
(Commercially 
Available) 
 
Reboxetine, prepared as racemic mix: 
(S,S)/(R,R) 
 
(2S,3S)/(2R,3R) -2-[(2-Ethoxyphenoxy)phenylmethyl] 
morpholine 
 
(S,R)-iodoreboxetine 
 
(2S,3R)-2-[(4-Iodophenyl)-(2-ethoxyphenoxy)methyl] 
morpholine 
 
(R,S)-iodoreboxetine 
 
(2R,3S)-2-[(4-Iodophenyl)-(2-ethoxyphenoxy)methyl] 
morpholine 
 
(S,S)-iodoreboxetine 
 
(2S,3S)-2-[(4-Iodophenyl)-(2-ethoxyphenoxy)methyl] 
morpholine 
Iodo-phenyl ring 
reboxetine 
analogues 
 
(R,R)-iodoreboxetine 
 
(2R,3R)-2-[(4-Iodophenyl)-(2-ethoxyphenoxy)methyl] 
morpholine 
I
HO O
N
H
O
1
2
3
6
 
NKJ-38 
 
(2S,3S)-2-[α-Hydroxy-(4-iodophenyl)methyl]morpholine-
5-one Benzyl alcohol 
iodo-amide 
analogues 
I
HO O
N
H
O
2
3
6
 
NKJ-50 
 
(2R,3R)-2-[α-Hydroxy-(4-iodophenyl)methyl]morpholine-
5-one 
 
NKJ-64 
 
(2R,3S)-2-[(2-Iodophenoxy)phenylmethyl] 
morpholine 
 
NKJ-67 
 
(2R,3S)-2-[(3-Iodophenoxy)phenylmethyl] 
morpholine 
Iodo-phenoxy ring 
reboxetine 
analogues 
 
NKJ-68 
 
(2R,3S)-2-[(4-Iodophenoxy)phenylmethyl] 
morpholine 
Table 2-05: Summary of the structures for Glasgow-synthesised iodoreboxetine 
analogues for binding to the noradrenaline transporter. 
* Note: Structures obtained from Jobson, NK (Ph.D. Thesis 2008). 
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2.2.1 Homogenate preparation protocol 
 
Brains were obtained via Schedule 1 kill from male adult Sprague-Dawley rats 
(Charles River) and the cerebellum removed.  Sprague-Dawley rats were used 
because the expense of sourcing Hooded Long-Evans rats for these assays was 
not necessary as this homogenate was intended for ligand analysis and not 
investigations into the model of schizophrenic hypofrontality.  Tissue was pooled 
and homogenised using a Polytron in ice-cold binding buffer (1g:10mL) for the 
relevant transporter (Table 2-06).  Homogenates were centrifuged at 25,400g for 
15 minutes at 4°C and the resulting pellet was washed in binding buffer three 
further times by centrifugation and resuspension.  The final resuspension in 
binding buffer was stored in 500µL aliquots at -50°C until use. 
 
Protein concentration of randomly selected sample aliquots was determined via a 
BioRad kit based upon the Bradford protein assay.  Standards of known 
concentration (0mg/ml, 0.05mg/ml, 0.1mg/ml, 0.2mg/ml, 0.5mg/ml, and 0.6mg/ml) 
were prepared using bovine serum antigen (BSA).  Sample aliquots were thawed, 
vortex mixed, sonic probed, and vortex mixed again.  Reaction tubes contained 
1.0ml mixed BioRad protein assay reagent with 5µl of BSA standard or 50µl 
sample homogenate.  Reaction solutions were vortex mixed and incubated at 
37°C for 30 minutes, cooled at room temperature for 5 minutes, poured into glass 
cuvettes and the absorbance at a wavelength of 562nm was read from a 
spectrophotometer. 
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Transporter Assay Radioligand Binding Buffer and Incubation Conditions 
Noradrenaline 
Transporter 
(modified from 
Hipolide et al. 2005) 
1.2nM [3H]-nisoxetine 
(71.0 Ci/mmol, 
GE Healthcare) 
50 mM Tris-HCl, pH 7.4 
300 mM NaCl 
5 mM KCl 
Incubation: 4 hours at 
4°C 
Serotonin Transporter 
(modified from 
Andersen et al. 2005) 
2.0nM [3H]-citalopram 
(83.0 Ci/mmol, 
GE Healthcare) 
50 mM Tris-HCl, pH 7.4 
120 mM NaCl 
5 mM KCl 
Incubation: 2 hours at 
RTP 
Dopamine Transporter 
(modified from Hebert 
et al. 2001; Reith & 
Coffey 1994; Kirifides 
et al. 1992) 
4.7nM [3H]-WIN-35,428 
(85.9 Ci/mmol, 
Perkin-Elmer) 
25 mM NaH2PO4 
25 mM Na2HPO4 
50 mM NaCl 
pH 7.70 
Incubation: 2 hours at 
4°C 
Table 2-06:  Assay conditions for radioligand competition experiments to 
determine the Ki at monoamine transporters for iodoreboxetine compounds. 
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2.2.2 Competition binding experiments 
 
For determination of Ki values, membrane suspensions (750-850µg of protein) 
were incubated with the appropriate radioligand in the presence or absence of 12-
20 concentrations of the competitor (range 1pM - 300µM).  The range of 
competitor concentrations was chosen to most accurately assay the range of Ki 
values expected from a compound with the potential to be taken forward in 
development as a tracer candidate.  Assays were performed in triplicate and the 
total incubation volume was 0.5ml.  Non-specific binding was defined in the 
presence of 10µM reboxetine (Tocris), 20µM fluoxetine (Tocris), and 30µM 
nomifensine (Sigma-Aldrich) for NAT, SERT, and DAT assays, respectively.  
Reactions were terminated by rapid vacuum filtration through Whatman GF/B 
glass fibre filters pre-soaked in 0.5% polyethylenimine (PEI) in relevant binding 
buffer using a 24-well Brandel cell harvester.  Filters received three rapid washes 
in ice-cold binding buffer then were added to 10ml liquid scintillant (National 
Diagnostics Ecoscint A), and [3H] disintegrations per minute, including automatic 
background subtraction, were determined by liquid scintillation analysis (average 
over 3 cycles of 4 minutes count per vial). 
 
2.2.3 Ki calculation and analysis 
 
Specific binding was expressed as a percentage of specific binding in the absence 
of competitor and Ki values were derived from nonlinear regression analysis using 
GraphPad Prism Version 4 (GraphPad Software Inc.), which to calculate the Ki 
from the IC50 uses the following equation (Cheng & Prusoff 1973): 
 
Ki = IC50 / ( 1+ ( Ligand Concentration / KD ) ) 
 
The Kd values determined under the same assay conditions for [3H]-nisoxetine 
(1.7nM) and [3H]-citalopram (2.1nM) binding to the NAT and SERT, respectively, 
were used in the calculation.  A Kd value (5.0nM) for binding to the high affinity 
[3H]-WIN-35,428 site on the DAT was selected by a review of published literature 
(Reith & Coffey 1994; Kirifides et al. 1992).  Ki data is presented as mean ± SEM 
for at least three independent competition experiments with [3H]-nisoxetine and at 
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least two independent competition experiments with [3H]-citalopram and [3H]-WIN-
35,428.   
 
2.3 In Vitro High Performance Liquid Chromatography (HPLC) 
Methodology 
 
2.3.1 Chromatography System and Methods 
 
Determination of retention times were performed by reverse phase high 
performance liquid chromatography (HPLC) on an Agilent series 1200 HPLC 
system consisting of pump, degasser, autosampler, microinjector, and diode array 
detector.  The diode array detector is a UV detector capable of recording variable 
wavelengths simultaneously, thus enabling UV peaks to be examined for purity – 
whether they are comprised of a single compound or more than one.  The diode 
array detector also enables the clearest wavelength found to be used for analysis, 
which can be useful if the lambda max, the wavelength of greatest UV 
absorbance, is not known at the outset of the assay of the compound of interest.  
Each column used (Table 2-07) was temperature controlled to 30°C. 
 
HPLC analysis used gradient methodology (Figure 2-05) to elute compounds.  
Details of the methodology for each column is outlined in Table 2-09, including 
column identification, mobile phase conditions, and gradient methodology flow 
rates for organic mobile phase.  The conditions and flow rate gradients are 
identical to those used in the formulation of each equation by Klara Valkó and they 
were optimised for each column to be a standard procedure to enable repeated, 
high-throughput analyses.  Wavelengths recorded on all columns were 210nm, 
230nm, 245nm, 254nm, 275nm, 285nm, and 310nm – these were chosen by me 
to enable the retention times to be taken from the acquired wavelength closest to 
the λMAX for each sample.  Software utilized for HPLC operation and analysis was 
Agilent ChemStation, which recorded the absorbances across the aforementioned 
wavelengths throughout the runs and allowed accurate determination of the 
retention times for each compound.  After all runs on a particular column were 
completed, the column was flushed through with dH2O for 30 minutes prior to 
disconnection from the HPLC system, capping at both ends, and storage. 
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Standards of known CHI values (Tables 2-08 and 2-09) were prepared as 
~1mg.mL-1 solutions in a 50:50 mix of organic and aqueous mobile phase.  These 
were filtered through a Whatman filter (0.45µm) prior to injection onto the column 
to prevent blockages caused by large particles or debris.  HPLC is not dependent 
on concentration to achieve an accurate retention time so concentration and 
injection volumes are not important to standardize, provided the injection volume is 
not excessive (e.g. <50µL) so as not to displace too much of the mobile phase and 
so as not to saturate the column.  I selected 1-20µL volumes for each compound 
to achieve sharp peaks and absorbance intensities of ~200-1000mAU without 
saturating the column – the retention times of these molecules were used to 
calibrate the column.  Calibration curves are displayed in Appendix II.  The 
standards were run at the start and end of every automated sequence to ensure 
that the result was consistent throughout an assay.  The standards always 
returned consistent retention times at the start and end of all runs. 
 
Commercially available compounds were similarly prepared, however 
iodoreboxetine analogues were only available in binding solutions (50mM Tris-
HCl, 120mM NaCl, 5mM KCl, pH 7.4) and compounds NKJ-64, NKJ-67, and NKJ-
68 were heated to 70°C in a water bath for 20 minutes to ensure compound 
solubility.  All iodoreboxetine compounds were injected in 1-20µL volumes to 
achieve absorbance peaks of approximately 800-1000mAu.  All preparations were 
filtered using a Whatman filter (0.45µm) prior to installation in the autosampler, 
and all samples were run concurrently on each run to ensure they were assayed 
under the same conditions and calibration. 
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Table 2-07: Technical specifications of HPLC columns used for in vivo behaviour 
predictors.  The LUNA C-18 columns were used in the calculation of log POCT and 
c log BB.  The Rexchrom Immobilized Artificial Membrane Column was used in the 
calculation of log D7.4(IAM).  The Human Serum Antigen and α-Acid Glycoprotein 
columns were used in the calculation of c%PPB. 
 
 
 
 
Table 2-08: Calibration standards for lipid and phospholipid columns 
Standard 
Acidic 
Luna CHI 
(pH 2.5) 
‘Physiological’ 
Luna CHI 
(pH 7.4) 
Alkali 
Luna CHI 
(pH 10.5) 
MeOH 
Luna 
CHI 
IAM 
CHI 
Acetanilide    54.50 11.50 
Benzimidazole  34.30 30.61   
Indole 72.10 71.50 70.07   
Phenyltetrazole  23.60 15.98   
Phenyltheophylline 51.70 51.20 51.30   
Theophylline 6.30 18.40 4.97   
Acetophenone 64.10 65.10 64.12 69.17 17.20 
Butyrophenone 87.30 87.50 87.33 83.53 32.00 
Heptanophenone    93.95 45.70 
Hexanophenone    91.32 41.80 
Octanophenone    96.11 49.40 
Propriophenone 77.40 77.40 77.42 78.29 25.90 
Valerophenone 96.40 96.20 96.36 54.50 37.30 
Table 2-08: Standards used to calibrate lipid and phospholipid columns and their 
respective CHI values for each compound in the conditions of the relevant column.  
These were run before and after every programmed autosampling run of each 
column.  These CHI values were plotted against the retention time of each 
compound and the linear equation derived from that was used to convert the 
retention time of samples into CHI values. 
 
 
 
Column Dimensions Supplier Manufacturer Product Reference/Number 
LUNA C-18 50 x 3mm, 5 microns Phenomenex 00B-4252-Y0 
Rexchrom 
Immobilized 
Artificial 
Membrane 
(IAM) 
10cm x 4.6mm, 
12 microns Regis IAM.PC.DD.2 / 774011 
Human Serum 
Antigen (HSA) 
50 x 3mm, 
5 microns ChromTech Ltd HSA 50.3 07-G: 2506 
α-acid 
glycoprotein 
(AGP) 
50 x 3mm, 
5 microns ChromTech Ltd AGP 50.3 07-33: 2407 
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Table 2-09: Calibration standards for protein columns 
Standard % Bound to HSA % Bound to AGP 
Propanolol  86 
Nizatidine 35  
Nicardipine 95 92 
Warfarin (2nd Peak) 98  
Carbamazepine 75 24 
Piroxicam 94.5  
Imipramine  91 
Table 2-09: Standards used to calibrate protein columns and their respective 
know percentage of protein binding for the protein immobilized in each column. 
These were run before and after every programmed autosampling run of each 
column.  These were converted into log scale (as linearised log k) and plotted 
against the log of their retention times.  Log k = log ( %PPB / 101 - %PPB ).  
Sample retention times were then able to be processed by reverse of those steps. 
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Figure 2-05: Graphical representation of a Generic HPLC Run Timetable.  Time 
point A: injection and the start of the gradient elution.  Time point B: the maximum 
percentage of organic mobile phase to be used has been reached.  Time point C: 
the end of the plateau of maximum organic mobile phase.  Time point D: organic 
mobile phase is discontinued and aqueous mobile phase is restored to the 
column.  Time point E: U.V. absorbance recordings were stopped for a given run.  
Time point F: re-equilibration of the column to prepare for the next automated 
injection occurred between points E and F, during which flow of aqueous mobile 
phase in the absence of organic mobile phase was utilised. 
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Column Mobile Phase 
Flow 
Rate 
(mL 
/min) 
Time 
Point A 
and  
Organic 
Time 
Point B 
and % 
Organic 
Time 
Point C 
and % 
Organic 
Time 
Point D 
and % 
Organic 
Time 
Point E 
and % 
Organic 
Time 
Point F 
and % 
Organic 
Acidic 
LUNA 
Aqueous: 
10mM 
Phosphoric 
Acid, 
pH 2.5 
Organic: 
100% 
Acetonitrile 
1.0 
0.00 
minutes 
 
(0%) 
2.50 
minutes 
 
(100%) 
3.00 
minutes 
 
(100%) 
3.20 
minutes 
 
(0%) 
4.00 
minutes 
 
(0%) 
10.00 
minutes 
 
(0%) 
Alkali 
LUNA 
Aqueous: 
50mM 
Ammonium 
Acetate, 
pH 10.5 
Organic: 
100% 
Acetonitrile 
1.0 
0.00 
minutes 
 
(0%) 
2.50 
minutes 
 
(100%) 
4.00 
minutes 
 
(100%) 
4.20 
minutes 
 
(0%) 
5.00 
minutes 
 
(0%) 
10.00 
minutes 
 
(0%) 
LUNA 
Aqueous: 
50mM 
Ammonium 
Acetate, 
pH 7.4 
Organic: 
100% 
Acetonitrile 
1.5 
0.00 
minutes 
 
(0%) 
2.50 
minutes 
 
(100%) 
3.00 
minutes 
 
(100%) 
3.20 
minutes 
 
(0%) 
4.00 
minutes 
 
(0%) 
8.00 
minutes 
 
(0%) 
IAM 
Aqueous: 
50mM 
Ammonium 
Acetate, 
pH 7.4 
Organic: 
100% 
Acetonitrile 
2.549 
0.00 
minutes 
 
(0%) 
2.50 
minutes 
 
(70%) 
3.00 
minutes 
 
(70%) 
3.20 
minutes 
 
(0%) 
4.00 
minutes 
 
(0%) 
10.00 
minutes 
 
(0%) 
MeOH 
LUNA 
Aqueous: 
50mM 
Ammonium 
Acetate, 
pH 7.4 
Organic: 
100% 
Methanol 
1.5 
0.00 
minutes 
 
(0%) 
2.50 
minutes 
 
(100%) 
3.00 
minutes 
 
(100%) 
3.20 
minutes 
 
(0%) 
4.00 
minutes 
 
(0%) 
6.00 
minutes 
 
(0%) 
Table 2-10 (continued below): Column run timetables showing column 
identification, mobile phase conditions, and gradient methodology flow rates for 
organic mobile phase (Smith & Valkó-Slegel 2004; Valkó-Slegel 2004; Valkó 2008; 
K. Valkó, 2008 - Personal Communication).  In conjunction with figure 2-05. 
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Column Mobile Phase 
Flow 
Rate 
(mL 
/min) 
Time 
Point A 
and % 
Organic 
Time 
Point B 
and % 
Organic 
Time 
Point C 
and % 
Organic 
Time 
Point D 
and % 
Organic 
Time 
Point E 
and % 
Organic 
Time 
Point F 
and % 
Organic 
AGP 
Aqueous: 
50mM 
Ammonium 
Acetate, 
pH 7.4 
Organic: 
100% 
Propan-2-
ol 
1.5 
0.00 
minutes 
 
(0%) 
3.00 
minutes 
 
(25%) 
5.00 
minutes 
 
(25%) 
5.10 
minutes 
 
(0%) 
6.00 
minutes 
 
(0%) 
10.00 
minutes 
 
(0%) 
HSA 
Aqueous: 
50mM 
Ammonium 
Acetate, 
pH 7.4 
Organic: 
100% 
Propan-2-
ol 
1.8 
0.00 
minutes 
 
(0%) 
3.00 
minutes 
 
(25%) 
5.00 
minutes 
 
(25%) 
5.10 
minutes 
 
(0%) 
6.00 
minutes 
 
(0%) 
10.00 
minutes 
 
(0%) 
Table 2-10 (Continued from above): Column run timetables showing column 
identification, mobile phase conditions, and gradient methodology flow rates for 
organic mobile phase (Smith & Valkó-Slegel 2004; Valkó-Slegel 2004; Valkó 2008; 
K. Valkó, 2008 - Personal Communication).  In conjunction with figure 2-05. 
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2.3.2 Determination of lipophilicity using C-18 column data 
 
The retention times for the iodoreboxetine compounds are compared to the C-18 
column retention times of ‘standard’ compounds for which the chromatographic 
hydrophobicity index (CHI) was known.  The CHI for a test compound is derived 
from comparing the retention time of the test compound to that of the retention 
times for a series of compounds with known CHI values. The CHIN is the CHI of 
the uncharged molecule and will be the greatest measured CHI across acidic 
(2.5), physiological (7.4), and alkaline (10.5) pH levels (Table 2-09) – as non-polar 
molecules will more readily transverse both the positive and negative regions of 
lipid layers.  
 
The log D at a given pH can be calculated via the following linear equation, which 
was formulated via plotting the CHI of a large library of compounds against log DpH 
(Valkó et al. 1997; K. Valkó, 2008 - Personal Communication). 
 
log DpH = 0.0525 x CHI – 1.467  
 
Where, 
CHI = Chromatographic Hydrophobicity Index at a given pH 
0.0525 = The gradient 
-1.467 = The Y-axis intercept 
 
 
The log DpH of the compound has a linear relationship with its CHI at that given 
pH.  The log P, an estimation of partition coefficients for the uncharged molecule, 
and the log POCT, an estimation of the octanol/water bench-top determination of 
partition coefficients for the uncharged molecule, are calculated via the following 
linear equations (Valkó et al. 1997; K. Valkó, 2008 - Personal Communication): 
 
log P = 0.0525 x CHIN – 1.467 
 
Where, 
CHIN = Chromatographic Hydrophobicity Index of the unionised form 
of the molecule (this will be the greatest CHI measured across acidic, 
physiological, and alkali pH conditions) 
0.0525 = The gradient 
-1.467 = The Y-axis intercept 
 
 
 
log POCT = (0.054 x CHIN) + (1.319 x AAP) – 1.877 
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Where, 
CHIN = Chromatographic Hydrophobicity Index of the unionised form 
of the molecule (this will be the greatest CHI measured across acidic, 
physiological, and alkali pH conditions) 
AAP = Abraham Acidity Parameter, calculated by ADAMANTIS 
(GSK‘s proprietary software) 
0.054 = The gradient 
(1.319 x AAP) – 1.877 = the specific Y-axis intercept for that molecule, 
accounting for its AAP 
 
 
2.3.3 Determination of non-specific binding using IAM (phosphoplipid) 
column data 
 
Non-specific binding in vivo can be predicted using HPLC via an immobilized 
artificial membrane (IAM) column composed of phospholipids.  As with the C-18 
column assays, standards with known CHI values were used to convert the 
retention times of test compounds into CHI values.  The log D7.4 (IAM) was 
calculated using the following linear equations (Valkó et al. 2000; Valkó 2004; 
Hollósy et al. 2006), which were derived from a library of compounds by Klara 
Valkó (GSK): 
 
log D7.4 (IAM) = (2.07 x log kIAM) + (1.09 x AAP) + 0.52 
 
Where,  
AAP = Abraham Acidity Parameter, calculated by ADAMANTIS 
(GSK’s proprietary software) 
2.07 = The gradient 
(1.09 x AAP) + 0.52 = The specific Y-axis intercept for that molecule, 
accounting for its AAP 
 
log kIAM = (0.046 x CHIIAM) + 0.42 
 
Where, 
 CHIIAM = Chromatographic Hydrophobicity Index on IAM column 
 0.046 = The gradient 
 0.42 = The Y-axis intercept 
 
 
2.3.4 Determination of blood-brain barrier penetration index using LUNA 
column data 
 
Blood brain barrier penetration can be estimated using a formula incorporating 
data from the alkali LUNA C-18 acetonitrile-eluted column and a physiological pH 
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LUNA C-18 with a methanol elution.  The calculated log BB was determined using 
the equation below (K. Valkó, 2008 - Personal Communication). 
 
c log BB = (0.017 x CHI10.5) + (0.048 x CHI7.4 (MeOH)) – (0.129 x CMR) – 3.11 
 
Where, 
CHI10.5 = Chromatographic Hydrophobicity Index at pH 10.5, acetonitrile elution 
CHI7.4 (MeOH) = Chromatographic Hydrophobicity Index, MeOH elution at pH 7.4 
CMR = calculated molecular refractivity (a measurement of size), determined 
by ADAMANTIS (GSK’s proprietary software) 
 
 
Higher values are interpreted as greater potential for successful brain penetration, 
whilst lower values are interpreted as reduced brain penetration (Garg et al. 2008), 
negative c log BB values are theoretical and interpreted as an inability to penetrate 
the brain. 
 
2.3.5 Determination of plasma protein binding using HSA and AGP column 
data 
 
Compound binding to plasma transport proteins such as human serum albumin 
(HSA) and α-acid glycoprotein (AGP) are used to estimate plasma protein binding 
(c%PPB) by inputting column data into the following equation (Valkó et al. 2011; 
Hollósy et al. 2006), which had been updated via personal communication to 
reflect the ongoing refinement of it: 
 
c%PPB = (0.87 x log kHSA) + (0.17 x log kAGP) + (0.06 x CMR) – 0.27 
 
Where, 
 
CMR = calculated molecular refractivity (a measurement of size), 
calculated by ADAMANTIS (GSK’s molecular predictor software). 
 
 
Log kHSA = log ( %PPBHSA / 101 - %PPBHSA ) 
 
Note:   %PPBHSA = [ ( 101 * 10log kHSA) / ( 1 + 10 log kHSA ) ] 
 
 
Log kAGP = log ( %PPBAGP / 101 - %PPBAGP ) 
 
Note: %PPBAGP = [ ( 101 * 10log kAGP) / ( 1 + 10 log kAGP ) ] 
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Chapter 3 
Imaging Monoamine Transporters in the PCP-induced Rat 
Model of the Metabolic Hypofrontality Observed in 
Schizophrenia 
 
 
 
3.1 Results: 
 
3.1.1 [3H]-nisoxetine binding to the NAT 
 
The distribution of [3H]-nisoxetine binding to the NAT (Table 3-01, Tables 3-02 to 
3-10) is widespread throughout cortical regions (Tables 3-02 to 3-08), and low 
NAT binding was detected in the CA1 (Table 3-06).  Moderate binding densities 
were localized to the RTN (Table 3-05), hippocampal regions CA2, CA3, and DG 
(all Table 3-06), and DRN (Table 3-08) and high NAT binding densities were 
localized in the BNST (Table 3-04) and AVN (Table 3-05).  The highest densities 
for binding to NAT were found in the LC (Table 3-09), from where all noradrenergic 
projections originate.  NAT binding in the LC and CBL appears visually lower 
relative to the other regions due to using half the concentration of [3H]-nisoxetine 
on these sections due to the extremely high density of NAT in the LC.  Binding 
was extremely low in the caudate putamen and nucleus accumbens (both Table 3-
03). 
 
Imaging with [3H]-nisoxetine provided clear delineation of most assayed structures 
with the exception of the caudate putamen and nucleus accumbens (both Table 3-
03). White matter tracts could sometimes be distinguished with [3H]-nisoxetine 
binding and non-specific binding was very low throughout the brain. 
 
There were no statistically significant differences detected in the [3H]-nisoxetine 
binding to the NAT of control and PCP-treated rats (Figure 3-01).  The LC and 
CBL were imaged with 1.5nM [3H]-nisoxetine rather than 3.0nM [3H]-nisoxetine 
due to the intense NAT density in the LC, so these regions have a greater density 
of [3H]-nisoxetine binding sites than is immediately apparent from a cursory glance 
of the data. 
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Table 3-01: The Distribution of the Noradrenaline Transporter (Overview) 
 
Group B Group A 
Structures 
Paxinos and 
Watson 
plate 
Total 
Binding in 
Vehicle-
Treated 
Nonspecific 
Binding in 
Vehicle-
Treated 
Total 
Binding in 
PCP-Treated 
Nonspecific 
Binding in 
PCP-Treated 
Prefrontal Cortex (PrL; 
aka PFC) 
 
 
   
Caudate Putamen 
(CPu), Cingulate 
Anterior (Cg1; aka 
ACg), Nucleus 
Accumbens (AcbC; aka 
N.acc.)      
Bed Nucleus of the 
Striatus Terminalis 
(BSTMV and BSTLV; 
together aka BNST) 
    
Anteroventral Thalamic 
Nucleus (AVDM and 
AVVL; together aka 
AVTN), Reticular 
Thalamic Nucleus (Rt; 
aka RTN)      
Hippocampus CA1 
(CA1), Hippocampus 
CA2 (CA2), 
Hippocampus CA3 
(CA3), Hippocampus 
Dentate Gyrus (DG)      
Ventral Tegmental Area 
(VTA) 
    
Dorsal Raphe Nuclei 
(DRD, DRV, and DRVL; 
together aka DRN) 
 
    
Locus Coeruleus (LC), 
Cerebellum (2; aka 
CBL) 
 
    
Table 3-01: The distribution of 3.0nM [3H]-nisoxetine binding (1.5nM for LC and 
CBL) to the noradrenaline transporter in the vehicle-treated and PCP-treated rat 
brain.  Non-specific binding was defined in the presence of 10.0µM nortriptyline 
hydrochloride.  Structures that were assayed to determine quantitative differences 
are specified for each level and are highlighted on the adapted Paxinos and 
Watson plates.  This overview allows the overall distribution of the NAT throughout 
the brain to be observed.  The caudate putamen appears to be a promising 
reference region to define an absence of binding for in vivo scanning with SPECT 
or PET, rather than the commonly used cerebellum. 
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Table 3-02: The Distribution of the Noradrenaline Transporter 
 Total Binding Nonspecific Binding 
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Prefrontal Cortex (PrL; aka PFC) 
Table 3-02: 3.0nM [3H]-nisoxetine binding to the noradrenaline transporter in 
sections of vehicle-treated and PCP-treated rat brain.  Non-specific binding was 
defined in the presence of 10.0µM nortriptyline hydrochloride.  Structures that 
were assayed to determine quantitative differences are specified for this level and 
are highlighted on the adapted Paxinos and Watson plate. 
 82 
 
Table 3-03: The Distribution of the Noradrenaline Transporter 
 Total Binding Nonspecific Binding 
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Caudate Putamen (CPu), Cingulate Anterior (Cg1; aka ACg), Nucleus Accumbens 
(AcbC; aka N.acc.) 
Table 3-03: 3.0nM [3H]-nisoxetine binding to the noradrenaline transporter in 
sections of vehicle-treated and PCP-treated rat brain.  Non-specific binding was 
defined in the presence of 10.0µM nortriptyline hydrochloride.  Structures that 
were assayed to determine quantitative differences are specified for this level and 
are highlighted on the adapted Paxinos and Watson plate. 
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Table 3-04: The Distribution of the Noradrenaline Transporter 
 Total Binding Nonspecific Binding 
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Bed Nucleus of the Striatus Terminalis (BSTMV and BSTLV; together aka BNST) 
Table 3-04: 3.0nM [3H]-nisoxetine binding to the noradrenaline transporter in 
sections of vehicle-treated and PCP-treated rat brain.  Non-specific binding was 
defined in the presence of 10.0µM nortriptyline hydrochloride.  Structures that 
were assayed to determine quantitative differences are specified for this level and 
are highlighted on the adapted Paxinos and Watson plate. 
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Table 3-05: The Distribution of the Noradrenaline Transporter 
 Total Binding Nonspecific Binding 
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Anteroventral Thalamic Nucleus (AVDM and AVVL; together aka AVTN), Reticular 
Thalamic Nucleus (Rt; aka RTN) 
Table 3-05: 3.0nM [3H]-nisoxetine binding to the noradrenaline transporter in 
sections of vehicle-treated and PCP-treated rat brain.  Non-specific binding was 
defined in the presence of 10.0µM nortriptyline hydrochloride.  Structures that 
were assayed to determine quantitative differences are specified for this level and 
are highlighted on the adapted Paxinos and Watson plate. 
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Table 3-06: The Distribution of the Noradrenaline Transporter 
 Total Binding Nonspecific Binding 
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Hippocampus CA1 (CA1), Hippocampus CA2 (CA2), Hippocampus CA3 (CA3), 
Hippocampus Dentate Gyrus (DG) 
Table 3-06: 3.0nM [3H]-nisoxetine binding to the noradrenaline transporter in 
sections of vehicle-treated and PCP-treated rat brain.  Non-specific binding was 
defined in the presence of 10.0µM nortriptyline hydrochloride.  Structures that 
were assayed to determine quantitative differences are specified for this level and 
are highlighted on the adapted Paxinos and Watson plate. 
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Table 3-07: The Distribution of the Noradrenaline Transporter 
 Total Binding Nonspecific Binding 
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Ventral Tegmental Area (VTA) 
Table 3-07: 3.0nM [3H]-nisoxetine binding to the noradrenaline transporter in 
sections of vehicle-treated and PCP-treated rat brain.  Non-specific binding was 
defined in the presence of 10.0µM nortriptyline hydrochloride.  Structures that 
were assayed to determine quantitative differences are specified for this level and 
are highlighted on the adapted Paxinos and Watson plate. 
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Table 3-08: The Distribution of the Noradrenaline Transporter 
 Total Binding Nonspecific Binding 
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Dorsal Raphe Nuclei (DRD, DRV, and DRVL; together aka DRN) 
Table 3-08: 3.0nM [3H]-nisoxetine binding to the noradrenaline transporter in 
sections of vehicle-treated and PCP-treated rat brain.  Non-specific binding was 
defined in the presence of 10.0µM nortriptyline hydrochloride.  Structures that 
were assayed to determine quantitative differences are specified for this level and 
are highlighted on the adapted Paxinos and Watson plate. 
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Table 3-09: The Distribution of the Noradrenaline Transporter 
 Total Binding Nonspecific Binding 
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Locus Coeruleus (LC), Cerebellum (2; aka CBL) 
Table 3-09: 1.5nM [3H]-nisoxetine binding to the noradrenaline transporter in 
sections of vehicle-treated and PCP-treated rat brain.  This is a lower 
concentration of ligand used in comparison to other regions due to the high 
intensity of binding to NAT in the LC.  Non-specific binding was defined in the 
presence of 10.0µM nortriptyline hydrochloride.  Structures that were assayed to 
determine quantitative differences are specified for this level and are highlighted 
on the adapted Paxinos and Watson plate. 
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[3H]-Nisoxetine Binding to the NAT is Unchanged
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Figure 3-01: Shown as medians of each group for each structure with error bars 
representing interquartile range.  No statistically significant differences, as P > 
0.05 (Mann-Whitney) across all structures.  Structures assayed: prefrontal cortex 
(PFC), anterior cingulate cortex (ACg), caudate putamen (CPu), nucleus 
accumbens (N. acc.), bed nucleus of the striatus terminalis (BNST), anteroventral 
thalamic nucleus (AVTN), reticular thalamic nucleus (RTN), hippocampal regions: 
CA1, CA2, CA3, & dentate gyrus (DG), ventral tegmental area (VTA), dorsal raphe 
nuclei (DRN), locus coeruleus (LC), and cerebellum (CBL).  All structures imaged 
with 3.0nM [3H]-Nisoxetine except LC and CBL, which were imaged with 1.5nM 
[3H]-Nisoxetine due to the high density of noradrenaline transporters in the LC. 
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3.1.2 [3H]-WIN-35,428 binding to the DAT 
 
The distribution of [3H]-WIN-35,428 binding to the DAT (Table 3-10, Tables 3-11 to 
3-18) was high throughout the caudate putamen and the nucleus accumbens (both 
Table 12), and it was in these structures that the highest binding densities were 
found.  The next highest densities were found in the VTA (Table 3-16) and then 
the DRN (Table 3-17), and LC (Table 3-18).  It was interesting to note that, unlike 
the distribution of the NAT, the highest binding density was not found in the cell 
bodies from whence dopaminergic projections originate.  Binding to DAT was 
absent in the hippocampal regions CA1, CA2, CA3, and DG (all Table 3-15), as 
well as in the cerebellum (Table 3-18). 
 
Imaging with [3H]-WIN-35,428 did not offer particularly clear delineation of assayed 
structures with the exception of the caudate putamen, nucleus accumbens (both 
Table 3-12), and VTA (Table 3-16) - the substantia nigra (Table 3-16) was also 
discernable but not assayed. White matter tracts were difficult to distinguish with 
[3H]-WIN-35,428 binding and non-specific binding appeared higher than was 
observed with [3H]-nisoxetine and [3H]-citalopram, but higher nonspecific binding 
was consistent with the use of a relatively higher ligand concentration (10nM) that 
exceeded the KD (5nM) for the binding site on the DAT when compared to the NAT 
or SERT imaging. 
 
There were no statistically significant differences detected between [3H]-WIN-
35,428 biding to the DAT in control and PCP-treated rats (Figure 3-02).  
Hippocampal areas CA1, CA2, CA3, and DG, and the CBL are either devoid of 
[3H]-WIN-35,428 binding sites or are of such low density they are below the 
detection threshold for the assay. 
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Table: 3-10: The Distribution of the Dopamine Transporter (Overview) 
 
Group B Group A 
Structures 
Paxinos and 
Watson 
plate 
Total 
Binding in 
Vehicle-
Treated 
Nonspecific 
Binding in 
Vehicle-
Treated 
Total 
Binding in 
PCP-Treated 
Nonspecific 
Binding in 
PCP-Treated 
Prefrontal Cortex (PrL; 
aka PFC) 
 
    
Caudate Putamen 
(CPu), Cingulate 
Anterior (Cg1; aka 
ACg), Nucleus 
Accumbens (AcbC; aka 
N.acc.)      
Bed Nucleus of the 
Striatus Terminalis 
(BSTMV and BSTLV; 
together aka BNST) 
    
Anteroventral Thalamic 
Nucleus (AVDM and 
AVVL; together aka 
AVTN), Reticular 
Thalamic Nucleus (Rt; 
aka RTN)      
Hippocampus CA1 
(CA1), Hippocampus 
CA2 (CA2), 
Hippocampus CA3 
(CA3), Hippocampus 
Dentate Gyrus (DG)      
Ventral Tegmental Area 
(VTA) 
    
Dorsal Raphe Nuclei 
(DRD, DRV, and DRVL; 
together aka DRN) 
 
    
Locus Coeruleus (LC), 
Cerebellum (2; aka 
CBL) 
 
    
Table 3-10: The distribution of 10.0nM [3H]-WIN-35,428 binding to the dopamine 
transporter in the vehicle-treated and PCP-treated rat brain.  Non-specific binding 
was defined in the presence of 30.0µM nomifensine.  Structures that were 
assayed to determine quantitative differences are specified for each level and are 
highlighted on the adapted Paxinos and Watson plates.  This overview allows the 
overall distribution of the DAT throughout the brain to be observed.   
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Table 3-11: The Distribution of the Dopamine Transporter 
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Prefrontal Cortex (PrL; aka PFC) 
Table 3-11: [3H]-WIN-35,428 binding to the dopamine transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 30.0µM nomifensine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-12: The Distribution of the Dopamine Transporter 
 Total Binding Nonspecific Binding 
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Caudate Putamen (CPu), Cingulate Anterior (Cg1; aka ACg), Nucleus Accumbens 
(AcbC; aka N.acc.) 
Table 3-12: [3H]-WIN-35,428 binding to the dopamine transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 30.0µM nomifensine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-13: The Distribution of the Dopamine Transporter 
 Total Binding Nonspecific Binding 
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Bed Nucleus of the Striatus Terminalis (BSTMV and BSTLV; together aka BNST) 
Table 3-13: [3H]-WIN-35,428 binding to the dopamine transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 30.0µM nomifensine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-14: The Distribution of the Dopamine Transporter 
 Total Binding Nonspecific Binding 
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Anteroventral Thalamic Nucleus (AVDM and AVVL; together aka AVTN), Reticular 
Thalamic Nucleus (Rt; aka RTN) 
Table 3-14: [3H]-WIN-35,428 binding to the dopamine transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 30.0µM nomifensine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-15: The Distribution of the Dopamine Transporter 
 Total Binding Nonspecific Binding 
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Hippocampus CA1 (CA1), Hippocampus CA2 (CA2), Hippocampus CA3 (CA3), 
Hippocampus Dentate Gyrus (DG) 
Table 3-15: [3H]-WIN-35,428 binding to the dopamine transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 30.0µM nomifensine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-16: The Distribution of the Dopamine Transporter 
 Total Binding Nonspecific Binding 
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Ventral Tegmental Area (VTA) 
Table 3-16: [3H]-WIN-35,428 binding to the dopamine transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 30.0µM nomifensine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
 
 98 
 
Table 3-17: The Distribution of the Dopamine Transporter 
 Total Binding Nonspecific Binding 
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Dorsal Raphe Nuclei (DRD, DRV, and DRVL; together aka DRN) 
Table 3-17: [3H]-WIN-35,428 binding to the dopamine transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 30.0µM nomifensine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-18: The Distribution of the Dopamine Transporter 
 Total Binding Nonspecific Binding 
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Locus Coeruleus (LC), Cerebellum (2; aka CBL) 
Table 3-18: [3H]-WIN-35,428 binding to the dopamine transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 30.0µM nomifensine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Figure 3-03: Shown as medians of each group for each structure with error bars 
representing interquartile range.  No statistically significant differences, as P > 
0.05 (Mann-Whitney) across all structures.  Structures assayed: prefrontal cortex 
(PFC), anterior cingulate cortex (ACg), caudate putamen (CPu), nucleus 
accumbens (N. acc.), bed nucleus of the striatus terminalis (BNST), anteroventral 
thalamic nucleus (AVTN), reticular thalamic nucleus (RTN), hippocampal regions: 
CA1, CA2, CA3, & dentate gyrus (DG), ventral tegmental area (VTA), dorsal raphe 
nuclei (DRN), locus coeruleus (LC), and cerebellum (CBL).  All structures imaged 
with 10.0nM [3H]-WIN-35,428.  Structures with no [3H]-WIN-35,428 binding 
reported (CA1, CA2, CA3, DG, and CBL) were either devoid of dopamine 
transporter binding sites or did not contain sufficient density of binding sites to 
meet the detection threshold for the assay. 
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3.1.3. [3H]-citalopram binding to the SERT  
 
The distribution of [3H]-citalopram binding to the SERT (Table 3-19, Tables 3-20 to 
3-27) was widespread throughout the brain, with the exception of the cerebellum 
(Table 3-27) where it was absent.  Higher binding densities were found in 
structures housing the cell bodies from whence monoamingergic projections 
originate, such as the VTA (Table 3-25), DRN (Table 3-26), and LC (Table 3-27), 
with the highest binding density localized to the DRN, from whence serotonergic 
projections originate. 
 
Imaging with [3H]-citalopram provided exceptionally clear delineation of all assayed 
structures with the sole exception of the cerebellum (Table 3-27). White matter 
tracts were easily distinguishable with [3H]-citalopram binding and non-specific 
binding was very low throughout the brain. 
 
Selective statistically significant reductions in [3H]-citalopram binding densities 
were decreased 12% in the anterior cingulate cortex, decreased 11% caudate 
putamen, decreased 15% nucleus accumbens, and decreased 9% and decreased 
15% in hippocampal areas CA2 and CA3, respectively, indicating either a change 
in affinity or a change in number for the [3H]-citalopram binding sites on the 
serotonin transporter in these structures (Figure 3-03).  There were no statistically 
significant differences detected in any remaining structures assayed.  
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Table 3-19: The Distribution of the Serotonin Transporter (Overview) 
 Group B Group A 
Structures 
Paxinos 
and 
Watson 
plate 
Total 
Binding in 
Vehicle-
Treated 
Nonspecifi
c Binding 
in Vehicle-
Treated 
Total 
Binding in 
PCP-
Treated 
Nonspecifi
c Binding 
in PCP-
Treated 
Prefrontal Cortex 
(PrL; aka PFC) 
 
    
Caudate Putamen 
(CPu), Cingulate 
Anterior (Cg1; aka 
ACg), Nucleus 
Accumbens (AcbC; 
aka N.acc.) 
 
    
Bed Nucleus of the 
Striatus Terminalis 
(BSTMV and BSTLV; 
together aka BNST) 
    
Anteroventral 
Thalamic Nucleus 
(AVDM and AVVL; 
together aka AVTN), 
Reticular Thalamic 
Nucleus (Rt; aka 
RTN) 
 
    
Hippocampus CA1 
(CA1), Hippocampus 
CA2 (CA2), 
Hippocampus CA3 
(CA3), Hippocampus 
Dentate Gyrus (DG) 
 
    
Ventral Tegmental 
Area (VTA) 
    
Dorsal Raphe Nuclei 
(DRD, DRV, and 
DRVL; together aka 
DRN) 
 
    
Locus Coeruleus 
(LC), Cerebellum (2; 
aka CBL) 
 
    
Table 3-19: The distribution of 2.0nM [3H]-citalopram binding to the serotonin 
transporter in the vehicle-treated and PCP-treated rat brain.  Non-specific binding 
was defined in the presence of 20.0µM fluoxetine. Structures that were assayed to 
determine quantitative differences are specified for each level and are highlighted 
on the adapted Paxinos and Watson plates. This overview allows the overall 
distribution of the SERT throughout the brain to be observed. 
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Table 3-20: The Distribution of the Serotonin Transporter 
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Prefrontal Cortex (PrL; aka PFC) 
Table 3-20: [3H]-citalopram binding to the serotonin transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 20.0µM fluoxetine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
 104 
 
Table 3-21: The Distribution of the Serotonin Transporter 
 Total Binding Nonspecific Binding 
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Caudate Putamen (CPu), Cingulate Anterior (Cg1; aka ACg), Nucleus Accumbens 
(AcbC; aka N.acc.) 
Table 3-21: [3H]-citalopram binding to the serotonin transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 20.0µM fluoxetine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-22: The Distribution of the Serotonin Transporter 
 Total Binding Nonspecific Binding 
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Bed Nucleus of the Striatus Terminalis (BSTMV and BSTLV; together aka BNST) 
Table 3-22: [3H]-citalopram binding to the serotonin transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 20.0µM fluoxetine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-23: The Distribution of the Serotonin Transporter 
 Total Binding Nonspecific Binding 
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Anteroventral Thalamic Nucleus (AVDM and AVVL; together aka AVTN), Reticular 
Thalamic Nucleus (Rt; aka RTN) 
Table 3-23: [3H]-citalopram binding to the serotonin transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 20.0µM fluoxetine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-24: The Distribution of the Serotonin Transporter 
 Total Binding Nonspecific Binding 
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Hippocampus CA1 (CA1), Hippocampus CA2 (CA2), Hippocampus CA3 (CA3), 
Hippocampus Dentate Gyrus (DG) 
Table 3-24: [3H]-citalopram binding to the serotonin transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 20.0µM fluoxetine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-25: The Distribution of the Serotonin Transporter 
 Total Binding Nonspecific Binding 
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Ventral Tegmental Area (VTA) 
Table 3-25: [3H]-citalopram binding to the serotonin transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 20.0µM fluoxetine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-26: The Distribution of the Serotonin Transporter 
 Total Binding Nonspecific Binding 
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Dorsal Raphe Nuclei (DRD, DRV, and DRVL; together aka DRN) 
Table 3-26: [3H]-citalopram binding to the serotonin transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 20.0µM fluoxetine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Table 3-27: The Distribution of the Serotonin Transporter 
 Total Binding Nonspecific Binding 
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Locus Coeruleus (LC), Cerebellum (2; aka CBL) 
Table 3-27: [3H]-citalopram binding to the serotonin transporter in sections of 
vehicle-treated and PCP-treated rat brain.  Non-specific binding was defined in the 
presence of 20.0µM fluoxetine.  Structures that were assayed to determine 
quantitative differences are specified for this level and are highlighted on the 
adapted Paxinos and Watson plate. 
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Figure 3-04: Shown as medians of each group for each structure with error bars 
representing interquartile range.  Asterisks indicate statistically significant 
differences, where P < 0.05 (Mann-Whitney), with their percentage reductions 
also shown.  Structures assayed: prefrontal cortex (PFC), anterior cingulate 
cortex (ACg), caudate putamen (CPu), nucleus accumbens (N. acc.), bed nucleus 
of the striatus terminalis (BNST), anteroventral thalamic nucleus (AVTN), reticular 
thalamic nucleus (RTN), hippocampal regions: CA1, CA2, CA3, & dentate gyrus 
(DG), ventral tegmental area (VTA), dorsal raphe nuclei (DRN), locus coeruleus 
(LC), and cerebellum (CBL).  All structures imaged with 2.0nM [3H]-Citalopram. 
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3.1.4. In situ hybridisation results 
 
In all instances in situ hybridisation (Table 3-28) revealed highly specific and 
localised binding to the cell bodies of monoaminergic neurones, from whence 
monoaminergic projections originate.  The NAT-specific [35S]-oligonucleotide 
probe binding to mRNA is both highly specific and localised to the locus coeruleus 
in high density (Table 3-31) and NAT-specific mRNA is also apparent in the 
cerebellar lobules, possibly in the granule cell layers.  The DAT-specific [35S]-
oligonucleotide probe binding to mRNA is both highly specific and localised to the 
ventral tegmental area and substantia nigra in high density (Table 3-29).  The 
SERT-specific [35S]-oligonucleotide probe binding to mRNA is both highly specific 
and localised to the dorsal raphe nuclei in high density (Table 3-30). 
 
Qualitative differences between the levels of monoaminergic transporter mRNA in 
control and PCP-treated animals (Figure 3-04) were not statistically significant, 
following a Mann-Whitney non-parametric analysis.  Consequently, the unchanged 
levels of monoamine transporter mRNA mean that the selective reductions of [3H]-
citalopram binding to the SERT is not the result of SERT-specific mRNA 
downregulation.  Furthermore, while NAT-specific mRNA expression in the LC 
appeared to be slightly increased by approximately 5% relative to controls, this 
change was not significant. 
 
The finding that NAT mRNA is present in the cerebellum indicates that the 
noradrenaline transporter is being translated there rather than merely trafficked 
from the locus coeruleus.  Therefore, the mRNA itself may have been trafficked 
there, or there may be cell bodies for non-locus coeruleus origin noradrenergic 
neurons in the cerebellum. 
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Table 3-28: The Distribution of Monoamine Transporter mRNA 
Target 
mRNA 
Paxinos and Watson 
plate with structures 
Total Binding in Vehicle-
Treated 
Nonspecific Binding in 
Vehicle-Treated 
DAT 
 
Ventral Tegmental Area 
(VTA)  
SERT 
 
Dorsal Raphe Nuclei 
(DRD, DRV, and DRVL; 
together aka DRN)  
NAT 
 
Locus Coeruleus (LC) 
 
Table 3-28: The distribution of [35S]-oligonucleotide in situ hybridisation probe 
binding to monoamine transporter mRNA in vehicle-treated rat brain.  Structures 
that were assayed to determine qualitative differences are specified for each level 
and are highlighted on the adapted Paxinos and Watson plates.  There was no 
discernable difference between the sections of vehicle-treated and PCP-treated rat 
brains. 
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Table 3-29: In situ Hybridisation of DAT-specific mRNA 
Paxinos and Watson Rat Brain Atlas 
Anatomical Reference 
(Ventral Tegmental Area) 
Allen Brain Atlas: DAT mRNA 
in situ Hybridisation Specific Binding 
(Ventral Tegmental Area in Mouse Brain) 
DAT mRNA in situ Hybridisation 
Total Binding 
(Ventral Tegmental Area) 
DAT mRNA in situ Hybridisation 
Non-Specific Binding 
(Ventral Tegmental Area) 
Table 3-29: In situ hybridisation imaging of DAT-specific mRNA in the ventral tegmental 
area (VTA) of control rat brains.  The optical density of [35S]-oligonucleotide probe binding 
in the VTA was qualitatively assayed and Mann-Whitney statistical analysis determined 
no statistical differences.  PCP-treated rat brains are also visually indistinguishable from 
controls. 
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Table 3-30: In situ Hybridisation of SERT-specific mRNA 
Paxinos and Watson Rat Brain Atlas 
Anatomical Reference 
(Dorsal Raphe Nuclei) 
Allen Brain Atlas: SERT mRNA 
in situ Hybridisation Specific Binding 
(Dorsal Raphe Nuclei in Mouse Brain) 
 
 
DAT mRNA in situ Hybridisation 
Total Binding 
(Dorsal Raphe Nuclei) 
DAT mRNA in situ Hybridisation 
Non-Specific Binding 
(Dorsal Raphe Nuclei) 
  
Table 3-30: In situ hybridisation imaging of SERT-specific mRNA in the dorsal raphe 
nuclei (DRN) of control rat brains.  The optical density of [35S]-oligonucleotide probe 
binding in the DRN was qualitatively assayed and Mann-Whitney statistical analysis 
determined no statistical differences.  PCP-treated rat brains are also visually 
indistinguishable from controls. 
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Table 3-31: In situ Hybridisation of NAT-specific mRNA 
Paxinos and Watson Rat Brain Atlas 
Anatomical Reference 
(Locus Coeruleus) 
Allan Brain Atlas: NAT mRNA 
in situ Hybridisation Specific Binding 
(Locus Coeruleus in Mouse Brain) 
 
NAT mRNA in situ Hybridisation 
Total Binding 
(Locus Coeruleus) 
NAT mRNA in situ Hybridisation 
Non-Specific Binding 
(Locus Coeruleus) 
  
Table 3-31: in situ hybridisation imaging of NAT-specific mRNA in the locus coeruleus 
(LC) of control rat brains.  The optical density of [35S]-oligonucleotide probe binding in the 
LC was qualitatively assayed and Mann-Whitney statistical analysis determined no 
statistical differences.  PCP-treated rat brains are also visually indistinguishable from 
controls. 
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[35S]-Oligonucleotide Hybridisation to
Transporter-specific mRNA is Unchanged
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Figure 3-04: Shown as medians of the PCP-treated group for the locus coeruleus 
(LC), ventral tegmental area (VTA) and dorsal raphe nuclei (DRN) relative to the 
median of the vehicle-treated group.  Error bars represent interquartile range.  No 
statistically significant differences between the groups, as P > 0.05 (Mann-
Whitney).  Transporter-specific mRNA localisations imaged with [35S]-labelled 
oligonucleotide probes. 
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3.2 Discussion/Conclusions 
 
3.2.1 The noradrenergic system 
 
It was hypothesized that the NAT would have been down-regulated in the 
prefrontal cortex (PFC) because the dopaminergic hypothesis of schizophrenia 
proposes hypoactivity in dopaminergic projections to the PFC (van Rossum 1966; 
Carlsson & Lindqvist 1963; Frankle et al. 2005b; Marek 2007; Laruelle et al. 2005; 
Abi-Dargham 2004), hypometabilism has been demonstrated in the PFC in both 
schizophrenia and in the PCP-induced model, and the NAT is the dominant 
dopamine reuptake mechanism in the PFC (Moron et al. 2002).  Similarly, other 
areas, such as the thalamic regions where a reduction in metabolism has been 
demonstrated (Cochran et al. 2003; Morris et al. 2005) and hippocampal regions 
where tissue atrophy is known to occur (Suddath et al. 1990), have also shown no 
significant difference in NAT binding densities indicating that NAT number and 
affinity remain unperturbed in this model.  If a change in binding densities had 
been detected, it could indicate either a change in affinity between the ligand and 
binding site or a change in binding site number.  A decrease in NAT expression in 
these regions would have indicated that noradrenergic neurones projecting into 
them are less active, thus reducing the modulation exacted upon these regions by 
the noradrenaline system.  It was also apparent that the unchanged qualitative 
measurements of NAT-specific mRNA indicated that there were no upregulations 
of mRNA to compensate for the downregulated NAT concentrations that were 
hypothesized but not found.  It would be interesting to know whether synaptic 
concentrations of noradrenaline are effected in any of these areas or if the 
apparent normality of NAT density is indicative of undisrupted noradrenergic 
neurotransmission to these critical structures.  Noradrenaline has been shown to 
be depleted by the administration of PCP (Tonge & Leonard 1972), so a follow-up 
on noradrenaline concentrations in this particular model could make an interesting 
future study.  If NAT concentrations are unchanged while noradrenaline 
concentrations decrease, then this would reduce the duration of stimulation by 
noradrenaline of the postsynaptic receptors upon quantal release into the 
synapse.  Conversely, if NAT concentrations are unchanged while noradrenaline 
concentrations increase, then the stimulation of postsynaptic receptors by 
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noradrenaline could be prolonged following a slower synaptic clearance if reuptake 
and metabolism mechanisms are overwhelmed.  
 
As the NAT is located on presynaptic neurons, the biological significance of the 
highest binding density for [3H]-nisoxetine detected in the locus coeruleus means 
that this structure is where the majority of noradrenergic modulation occurs – 
noradrenergic interneurons communicating with other nearby neurons within the 
locus coeruleus.  Consequently, there is an argument that the primary brain region 
of interest in the noradrenergic system and the most important one for any 
potential SPECT tracer to image is the locus coeruleus. 
 
It is important to note that despite the sections containing the locus coeruleus and 
the cerebellum receiving a lower concentration of [3H]-Nisoxetine, the lowest 
binding density reported for the NAT was not in the cerebellum but in the caudate 
putamen (CPu).  This is highly relevant to in vivo NAT imaging because in both 
SPECT and PET imaging, a reference region is selected to determine the 
nonspecific binding of the ligand and the cerebellum is a common choice for many 
ligands.  Indeed, where NAT imaging is concerned, the cerebellum clearly 
demonstrates specific binding to the NAT and thus is not suitable for use as a 
reference region.  Given the extremely low specific NAT binding density reported 
in the CPu, this would make a far more acceptable structure to use as a reference 
region. 
 
Interestingly, mRNA for the noradrenaline transporter was detected in the 
cerebellum.  The cerebellum receives noradrenergic innervation from the locus 
coeruleus (Kolasiewicz et al. 2011) and stimulates the firing of globular and Golgi 
cells (Hirono et al. 2012).  Therefore, there is the possibility than in the instance of 
the cerebellum that NAT mRNA is trafficked to the cerebellum from the locus 
coeruleus rather than the NAT protein itself.  The electrophysiology experiments of 
Hirono et al, which showed that noradrenaline stimulates cells in the cerebellum, 
would suggest that noradrenaline transporters in the cerebellum are probably 
functional as there is a need for them to be there – clearance of released 
noradrenaline from synapses would be slow if the sole mechanism for this was 
metabolism by MAO and COMT. 
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3.4.2 The dopaminergic system 
 
It was hypothesized that changes in the binding density for the DAT would have 
been detected in agreement with the dopaminergic hypothesis for schizophrenia 
proposing hyperactivity in mesolimbic and/or mesocortical pathways and the 
mechanism for many traditional neuroleptics is the antagonism of dopaminergic 
neurotransmission.  However, although there was a general trend across many 
limbic structures to indicate an increase in the density of DAT binding in these 
regions, no measurements demonstrated a significant difference, corresponding to 
published data (Laruelle et al. 2000).  Another hypothesis that was not fulfilled was 
the one of areas demonstrating hypometabolism to have expressed changes in 
the binding density of DAT, but no significant differences were detected and 
furthermore no statistically insignificant trends were identified either.  The 
qualitative measurement of DAT-specific mRNA in the VTA indicated no significant 
differences between control and PCP-treated rats, indicating that no upregulation 
took place to compensate for the hypothesized downregulations of DAT.  It would 
be interesting to know whether synaptic concentrations of dopamine are affected 
in any of these areas or if the apparent normality of DAT density is indicative of 
undisrupted noradrenergic neurotransmission to such structures. 
 
It is important to note that DAT was not detected in any hippocampal structures for 
either the control or PCP-treated groups, so although this area appears to play a 
role – either primary or secondary – in the pathology of schizophrenia, it is unlikely 
that the DAT is involved in these structures.  The absence of detectable DAT 
concurs with published autoradiographic studies using [3H]-WIN-35,428 (Andersen 
et al. 2005) and PET studies imaging DAT (Goodman et al. 2000). 
 
The binding densities of [3H]-WIN-35,428 to the DAT were also below that of the 
detection threshold in the cerebellum, indicating that while this structure would not 
be suitable for use as a reference region for NAT, it would be perfectly adequate 
as such for in vivo imaging of the DAT with SPECT or PET scanning technologies. 
 
3.4.3 The serotonergic system 
 
The selective reductions in the hippocampus correlate anatomically to regions 
shown through MRI imaging and post mortem analyses to be compromised in 
 121 
schizophrenia.  Broadly, this correlates with previous studies that have also found 
selective decreases of SERT binding in areas of the forebrain (Joyce et al. 1993; 
Ohuoha et al. 1993; Laruelle et al. 1993).  In areas with unchanged levels of [3H]-
citalopram binding in the forebrain, the binding levels and overall autoradiograph 
appearance correlated well with published literature (Hipolide et al. 2005).  Further 
correlating with published data, there were no statistically significant changes 
detected in the hindbrain structures (Laruelle et al. 2000).  Where there was some 
variation with the literature, Dean et al ( 1995) found an increase in affinity, but no 
change in the density, of SERT binding sites in the hippocampus.  PCP 
administration in rat has been shown to directly deplete noradrenaline and its 
metabolites (Tonge & Leonard 1972), so if a similar effect occurs in the 
serotonergic system then this might explain why fewer SERTs are maintained. 
 
As discussed earlier in this thesis, the serotonin system is the most widely 
innervated of all the monoamine systems and the abundance of SERT labelled 
throughout the brain was not unforeseen.  The assayed region with the lowest 
density of SERT detected was the cerebellum, and would perhaps make a suitable 
reference region for in vivo SERT imaging. 
 
In the corticolimbothalamic circuitry known to be deranged in schizophrenia 
(Morris et al. 2005), the prefrontal cortex stimulates the nucleus accumbens, which 
inhibits the ventral pallidum, which inhibits the thalamus – disinhibition – to enable 
thalamic stimulation of the prefrontal cortex and thus complete a circuit of positive 
feedback.  Meanwhile, the prefrontal cortex and the hippocampus modulate one 
another.  These results, in context, would indicate that a 15.3% reduction in SERT 
affinity or number in the nucleus accumbens might cause some of the disinhibition 
of the thalamus to be removed, thus reducing the positive feedback on the 
prefrontal cortex.  However, binding of all three monoamine transporters seem 
unaffected in thalamic structures.  The binding reductions found in the 
hippocampus, a structure involved in mutual modulation with the prefrontal cortex 
proves interesting.  The dentate gyrus is the ‘gateway’ to the hippocampus and yet 
binding densities here are normal.  Internally, in the CA2 and CA3, selective 
reductions in SERT binding were found but it is difficult to see how this would 
impact the prefrontal cortex unless the dentate gyrus was involved as well. 
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Although these are statistically significant reductions and do affect some key 
regions in the deranged circuitry involved in the pathogenesis of schizophrenia, it 
begs the question as to whether a reduction of up to only 15% of the transporters 
for only one of the monoamine systems has a biological significance.  It is already 
known that monoamine transporters are promiscuous with the monoamines they 
uptake, and with the complexity of monoamine systems and their intermodulation 
in the brain, it seems as though such small reductions may very well be within the 
tolerances provided by natural redundancies in the brain.  It has also been noted 
that SERT binding densities are not significantly correlated with the severity of 
symptoms (Abi-Dargham 2007).  Furthermore, the decreased SERT affinity in the 
hippocampus and decreased density in the frontal cortical regions reported by post 
mortem studies were not confirmed by in vivo studies where no significant 
differences were observed in SERT expression (Frankle et al. 2005a)  – so this 
aspect of the model may very well mimic an artefact of post mortem tissue that is 
not relevant in the living schizophrenic. 
 
Interestingly, there appeared to be no significant differences in the levels of SERT-
specific mRNA in the DRN to attempt to compensate for the reductions in SERT 
found in the PCP model of the metabolic hypofrontality associated with 
schizophrenia.  As with the synaptic concentrations of noradrenaline and 
dopamine, it would be interesting to know what the concentrations of serotonin 
were in the regions where selective reductions were detected and whether the 
selective reductions in SERT have produced a corresponding rise in the 
concentrations of neurotransmitter following neuronal activation, or whether the 
reductions in SERT appear to have occurred following a reduction of serotonin 
release. 
 
3.4.4 Conclusions 
 
The PCP-induced rat model mimics the metabolic hypofrontality observed in 
schizophrenia and is not a complete reproduction of all aspects involved in the 
human disease.  Interestingly, aspects of the model appear to correlate post 
mortem examination of schizophrenic patients, while reductions of serotonin 
transporter expression were not apparent during an in vivo scan of living 
medication-free schizophrenic patients.  However, this may very well be explained 
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by the changes in SERT density being too small and beneath the detection 
threshold for PET imaging. 
 
It had been hypothesised that down-regulation of the NAT would be observed, 
particularly in the pre-frontal cortex, of the PCP-induced rat model of the metabolic 
hypofrontality observed in schizophrenia.  However, the NAT distribution and 
density remained unchanged by chronic low-dose PCP administration, so the 
model does not yield itself as an obvious choice for first demonstration of an 
emerging NAT-specific SPECT brain imaging tracer.  While there were no 
changes detected in NAT levels or NAT-specific mRNA in this model, 
pharmacological intervention exerting influence at the noradrenaline transporter is 
beneficial in modulating monoaminergic neurotransmission in both the model and 
in the human disease, so it is clear that the NAT is important in how schizophrenia 
treatment is approached.  In order to ensure a wider access to in vivo imaging 
techniques in research, a SPECT tracer would be preferable to a PET tracer due 
to the lower costs involved in SPECT imaging associated with using more readily 
available isotopes with longer half-lives.  Currently, there is no SPECT imaging 
tracer for imaging the noradrenaline transporter in vivo so NAT levels in the 
medication-free schizophrenic patient cannot yet be compared to those of the 
model to determine whether the model holds true. 
 
Furthermore, in the development of new antipsychotic drugs to threat 
schizophrenia, it will be important to have a readily available biomarker of in vivo 
NAT occupancy to demonstrate dose-occupancy and therapeutic benefit, as has 
been done at other antipsychotic drug targets in the brain – such as the SERT 
(Takano et al. 2006).  Therefore, compounds structurally related to the clinically-
approved selective noradrenergic reuptake inhibitor reboxetine will be examined 
for their suitability for radiolabelling with SPECT-applicable isotopes and potential 
for use as SPECT brain imaging tracers. 
 
It had been hoped that if changes in NAT expression were present in this model 
then it would have presented itself as a valuable opportunity for validating and 
demonstrating the imaging capabilities of a future NAT-specific SPECT tracer, 
however another model that can demonstrate a clear difference in NAT density will 
have to be sought for that purpose.  Nevertheless, the PCP model of 
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schizophrenic hypofrontality still provides valuable insight into aspects of 
schizophrenia. 
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Chapter 4 
Pharmacological Characterisation of Potential SPECT 
Brain Imaging Tracers for the Noradrenaline Transporter 
 
 
 
 
4.3 Results 
 
4.3.1 Reboxetine affinity for the NAT 
 
The Ki of Reboxetine, a commercial available S,S-/R,R- racemic mixture available 
as a mesylate salt, against [3H]-nisoxetine binding at the NAT was determined as 
6.9 ± 1.6 nM (Figure 1).  This is in the same order of magnitude as, and therefore 
compares favourably to, the published value of 1.1 ± 0.2 nM (Wong et al. 2000).  
Given the highly selectivity (>100-fold) of reboxetine for the NAT, and published 
data in the literature on its monoamine binding profile, it was deemed unnecessary 
to repeat this validation at the SERT or the DAT in this thesis. 
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Reboxetine Displaces [3H]-Nisoxetine at the NAT
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Figure 4-01: Reboxetine competes for [3H]-nisoxetine binding to the noradrenaline 
transporter.   Points are means of 3 independent repetitions and error bars 
represent standard error of the mean.  Ki value is represented as the mean of 3 
independent determinations ± the standard deviation, and was calculated from the 
IC50 using the Cheng-Prusoff equation in GraphPad Prism 4.0. 
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4.1.2 Affinity of novel compounds for the NAT 
 
The iodophenyl ring compounds (Figure 4-02) demonstrated greatest affinity for 
the NAT in the S,S-, R,S-, and R,R-isomers with Ki values of 53.8 ± 2.7 nM, 58.2 ± 
9.4 nM, and 64.0 ± 2.4 nM, respectively.  The S,R-isomer  was an order of 
magnitude greater at 321 ± 9 nM, so this confirmation obviously does not allow the 
molecule to bind effectively to the [3H]-nisoxetine binding site.  While the curve 
clearly shows that these compounds are offering specific displacement of [3H]-
nisoxetine at the NAT, a Ki of ~54nM is not sufficiently high affinity for a SPECT 
brain imaging tracer. 
 
While none of the iodophenyl ring compounds have sufficient affinity for the NAT, 
the differing affinities with structural modification are enlightening.  For the next 
generation of candidate compounds, no further S,R- conformations were 
synthesised, as it was clear this conformation is not suitable for binding to the 
reboxetine binding site on the NAT.  As expected, the S,S- and R,R- 
conformations both showed better affinity and the S,S- conformation molecule is 
what is being taken forward by other groups in the literature as the INER/IPBM 
molecule.  The R,S- conformation molecule has not yet been developed in the 
literature, and perhaps an INER/IPBM-like molecule in this conformation would 
yield a promising candidate for SPECT imaging of the NAT.  For further elucidation 
of important aspects to the molecular structure of potential NAT tracers, several of 
the intermediate compounds in the synthetic process were also evaluated for their 
affinity to the NAT. 
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Iodophenyl Ring Reboxetine Analogues Displace [ 3H]-Nisoxetine at the NAT
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Figure 4-02: Iodophenyl ring iodoreboxetine analogues displacement of [3H]-
nisoxetine binding at the noradrenaline transporter.   Data points are means of 3 
independent repetitions and error bars represent standard error of the mean.  
Total binding (1.2nM [3H]-nisoxetine) plotted as competitor concentration 10-15M 
and non-specific binding (1.2nM [3H]-nisoxetine + 10 µM reboxetine) plotted as 10-
1M.  Ki values are represented as the mean of 3 independent determinations ± the 
standard deviation, and was calculated from the IC50 using the Cheng-Prusoff 
equation in GraphPad Prism 4.0. 
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Benzyl Alcohol Amide Intermediates Displace [3H]-Nisoxetine at the NAT
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Figure 4-03: Benzyl alcohol intermediate compounds displacement of [3H]-
nisoxetine binding at the noradrenaline transporter.   Data points are means of 3 
independent repetitions and error bars represent standard error of the mean.  
Total binding (1.2nM [3H]-nisoxetine) plotted as competitor concentration 10-15M 
and non-specific binding (1.2nM [3H]-nisoxetine + 10 µM reboxetine) plotted as 10-
1M.  Ki values are represented as the mean of 3 independent determinations ± the 
standard deviation, and was calculated from the IC50 using the Cheng-Prusoff 
equation in GraphPad Prism 4.0. 
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The benzyl alcohol amides demonstrated particularly poor affinity (Ki = µM-mM 
range) for the NAT (Figure 4-03) and the loss of the phenoxy ring appears to have 
destroyed the ability of the compound to bind to the NAT, highlighting the 
importance of this ring in reboxetine-like compound pharmacology. 
 
R,S- conformation iodophenoxy compounds (Figure 4-04) demonstrated excellent 
affinity when the iodine was in the ortho position in the NKJ-64 (Ki = 8.4nM), yet 
poor affinity otherwise.  The poor binding exhibited when the phenoxy ring’s iodine 
was in the meta and para positions for NKJ-67 (Ki = 1.1µM) and NKJ-68 (Ki = 
1.7µM), respectively, is further evidence of this ring conferring binding affinity to 
the NAT and that there is an ideal position (ortho) for the iodine in order to 
maintain affinity of the compound for the [3H]-nisoxetine binding site on the NAT.  
 
Of the iodinated compounds synthesised and tested (Table 4-01), NKJ-64 yielded 
the most potent affinity for NAT (Ki = 8.4 ± 1.7 nM), was in the same order of 
magnitude as reboxetine (Ki = 6.9 ± 1.6 nM), and looks to be the most promising 
compound tested here. 
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Iodophenoxy Ring Reboxetine Analogues Displace [ 3H]-Nisoxetine at the NAT
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Figure 4-04: Iodophenoxy ring reboxetine analogues displacement of [3H]-
nisoxetine binding at the noradrenaline transporter.   Data points are means of 3 
independent repetitions and error bars represent standard error of the mean, 
except for NKJ-64 which is derived from 5 independent repetitions.  Total binding 
(1.2nM [3H]-nisoxetine) plotted as competitor concentration 10-15M and non-
specific binding (1.2nM [3H]-nisoxetine + 10 µM reboxetine) plotted as 10-1M.  Ki 
values are represented as the mean of 3 independent determinations ± the 
standard deviation, except for NKJ-64 which is derived from 5 independent 
determinations.  All Ki values were calculated from the IC50 using the Cheng-
Prusoff equation in GraphPad Prism 4.0. 
 
 
 
Table 4-01: Affinity of iodinated reboxetine analogues for the NAT 
Group Compounds NAT Ki 
Iodophenyl ring 
analogues 
(S,R)-iodoreboxetine 
(R,S)-iodoreboxetine 
(S,S)-iodoreboxetine 
(R,R)-iodoreboxetine 
321 ± 9 nM 
58.2 ± 9.4 nM 
53.8 ± 2.7 nM 
64.0 ± 2.4 nM 
Benzyl alcohol amide 
intermediates 
NKJ-38 
NKJ-50 
14,810 ± 810 nM 
> 1,000,000 nM 
Iodophenoxy ring 
analogues 
NKJ-64 
NKJ-67 
NKJ-68 
8.4 ± 1.7 nM 
1,700 ± 500 nM 
1,100 ± 200 nM 
Table 4-01: Summary of affinity of novel iodoreboxetine compounds for the NAT. 
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4.1.3 Serotonin Transporter Pharmacology 
 
The iodophenyl ring compounds (Figure 4-05) demonstrated greatest affinity for 
the SERT in the (R,R)-isomer with a Ki of 646 ± 146 nM and, consequently, the 
(S,S)-isomer shows greater promise as a NAT-specific tracer with a much lower 
affinity for the [3H]-citalopram binding site and a Ki of approximately 2.8 µM.   
 
Unfortunately, depleted stocks for the (S,R)- and (R,S)- isomers of the iodophenyl 
ring compounds resulted in the inability to ascertain their inhibition constants at the 
SERT through a comprehensive displacement protocol, so a pilot experiment was 
conducted to determine if there was any affinity for the SERT (Figure 4-06), 
revealing minimal displacement of [3H]-citalopram binding to the SERT.  
Reboxetine was shown to displace virtually all [3H]-citalopram binding at the SERT 
when applied in both 10µM and 100µM concentrations.  Both of the iodinated 
reboxetine analogues demonstrated less affinity for the SERT than reboxetine. 
The S,R- isomer demonstrated less affinity for the SERT than the R,S- isomer, 
however the precise affinity of these compounds was not able to be determined 
with the solution stocks remaining following assays at other monoamine 
transporter sites.  Additional compound could be synthesised for a comprehensive 
characterisation, but the poor NAT affinity of the S,R- isomer precludes further 
development as a NAT tracer and makes a comprehensive characterisation of 
these particular compounds inconsequential. 
 
The benzyl alcohol amides are intermediate compounds in the production of the 
iodophenoxy reboxetine analogues and their characterisation aids in determining 
which aspects of reboxetine-like compounds are contributing to the 
pharmacological properties of the molecule.  The benzyl alcohol amide 
intermediates demonstrated particularly poor affinity for the SERT and both Ki 
values were greater than 100µM (Figure 4-07).  The loss of the phenoxy ring 
appears to have destroyed the ability of the compound to bind to the SERT as well 
as the NAT, once again confirming the importance of this aspect of reboxetine-like 
compounds to monoamine transporter pharmacology. 
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Iodophenyl Ring Reboxetine Analogues Displace [ 3H]-Citalopram at the SERT
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Figure 4-05: Iodophenyl ring reboxetine analogues displacement of [3H]-
citalopram binding at the serotonin transporter.   Data points are means of 2 
independent repetitions and error bars represent standard error of the mean. Total 
binding (2.0nM [3H]-citalopram) plotted as competitor concentration 10-15M and 
non-specific binding (2.0nM [3H]-citalopram + 20 µM fluoxetine) plotted as 10-1M.  
Ki values are represented as the mean of 2 independent determinations ± the 
standard deviation, and are calculated from the IC50 using the Cheng-Prusoff 
equation in GraphPad Prism 4.0. 
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Figure 4-06: (S,R)- and (R,S)- iodophenyl ring reboxetine analogues displacement 
of [3H]-citalopram binding at the serotonin transporter.  Bars representative one 
determination and error bars represent standard error of samples in triplicate for 
that single assay only.  Total binding was defined with 2.0nM [3H]-citalopram and 
non-specific binding was defined with 2.0nM [3H]-citalopram in the presence of 20 
µM fluoxetine.  Ki values cannot be accurately determined from this data set. 
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Figure 4-08: Benzyl alcohol intermediate compounds displacement of [3H]-
citalopram binding at the serotonin transporter.   Data points are means of 3 
independent repetitions and error bars represent standard error of the mean.  
Total binding (2.0nM [3H]-citalopram) plotted as competitor concentration 10-15M 
and non-specific binding (2.0nM [3H]-citalopram + 20 µM fluoxetine) plotted as 10-
1M.  Ki values are represented as the mean of 3 independent determinations ± the 
standard deviation, and was calculated from the IC50 using the Cheng-Prusoff 
equation in GraphPad Prism 4.0.  For these compounds, the bottom of the graph 
(i.e. 0% binding) was ill-defined, so IC50 and Ki could not be accurately calculated.  
Greater concentrations of competitor were not available and the Ki values are 
approximately stated as > 100,000 nM. 
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The iodophenoxy ring reboxetine analogues as a group actually show greater 
overall affinity for the SERT than they do the NAT.  The highest SERT affinity of 
these compounds was displayed by the NKJ-68 with a Ki of 34.5 ± 1.7 nM, 
following by the NKJ-64 with a Ki of 51.5 ± 8.4 nM, and finally the NKJ-67 has the 
lowest affinity with a Ki of 154 ± 12 nM (Figure 4-08). 
 
Elucidation of the SERT-binding properties for the (R,S)-conformation 
iodophenoxy compounds demonstrated that although the ortho-position 
compound, NKJ-64, demonstrated notable affinity for the SERT, it was 
approximately 6-fold more selective for the NAT and therefore may yet make an 
acceptable NAT brain imaging tracer.   The meta-position compound, NKJ-67 
demonstrated poor affinity for SERT as well as for NAT.  Interestingly, the para-
position molecule, NKJ-68, which demonstrated poor affinity at the NAT, showed 
some affinity for SERT.  Should this prove highly selective for the SERT, it may 
have had potential as a SERT brain imaging tracer if not for superior affinity, pre-
existing compounds already in use for both clinical and research contexts. 
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Figure 4-08: Iodophenoxy ring reboxetine analogues displacement of [3H]-
citalopram binding at the serotonin transporter.  Data points are means of 3 
independent repetitions and error bars represent standard error of the mean.  
Total binding (2.0nM [3H]-citalopram) plotted as competitor concentration 10-15M 
and non-specific binding (2.0nM [3H]-citalopram + 20 µM fluoxetine) plotted as 10-
1M.  Ki values are represented as the mean of 3 independent determinations ± the 
standard deviation, and was calculated from the IC50 using the Cheng-Prusoff 
equation in GraphPad Prism 4.0.   
 
 
Table 4-02: Affinity of iodinated reboxetine analogues for the SERT 
Group Compounds SERT Ki 
Iodophenyl ring 
analogues 
(S,R)-iodoreboxetine 
(R,S)-iodoreboxetine 
(S,S)-iodoreboxetine 
(R,R)-iodoreboxetine 
- 
- 
2,793 ± 480 nM 
646 ± 142 nM 
Benzyl alcohol amide 
intermediates 
NKJ-38 
NKJ-50 
> 100,000 nM 
> 100,000 nM 
Iodophenoxy ring 
analogues 
NKJ-64 
NKJ-67 
NKJ-68 
51.5 ± 8.4 nM 
154 ± 12 nM 
34.5 ± 1.7 nM 
Table 4-02: Summary of affinity of novel iodoreboxetine compounds for the SERT.  
Broadly, the iodophenoxy ring analogues had the highest SERT affinity, the 
iodophenyl ring analogues were either untested or had poor affinity, and the 
benzyl alcohol amide intermediates had no noteworthy SERT affinity at all. 
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The affinity of the iodophenyl ring reboxetine analogues were reasonably low for 
the SERT (Table 4-02) and thus were highly specific for the NAT – however their 
inadequate affinity for the NAT is still problematic.  The benzyl alcohol amide 
intermediates have no notable affinity for the SERT.  Although the iodophenoxy 
ring analogues as a group demonstrated notable affinity for the SERT, the 6-fold 
selectivity of NKJ-64 for the NAT means it still has potential as a SPECT brain 
imaging tracer for the noradrenaline transporter. 
 
4.1.4 Dopamine Transporter Pharmacology: 
 
To complete the pharmacological binding profile for monoamine transporters and 
elucidate the specificity for each compound, the dissociation constants of the 
produced compounds for which there were stocks remaining were determined at 
the DAT. 
 
The iodophenyl ring compounds demonstrated encouragingly low affinity for the 
DAT (Figure 4-09), although displayed the greatest affinity in the (R,R)-isomer with 
a Ki value of 716 ± 20 nM.  The (S,S)-isomer yielded a Ki of approximately 1.4 µM 
and so is the more favourable molecule in the group from the perspective of a NAT 
brain imaging tracer.   
 
Unfortunately, depleted stocks for the (S,R)- and (R,S)- isomers of the iodophenyl 
ring compounds resulted in the inability to ascertain their inhibition constants at the 
DAT, although a pilot experiment was conducted and demonstrated low affinity for 
the [3H]-WIN-35,428 binding site on the DAT (Figure 4-10).   
 
Reboxetine was shown to displace virtually all [3H]-WIN-35,428 binding at the DAT 
when applied in both 10µM and 100µM concentrations.  Relative to reboxetine, 
(R,S)-iodoreboxetine demonstrated less affinity for the DAT and there was no 
significant displacement in the nanomolar range.  Unfortunately, from this data set, 
it is difficult to draw comparative observations against reboxetine with (S,R)-
iodoreboxetine, but there was no significant displacement in the nanomolar range.
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Iodophenyl Ring Reboxetine Analogues Displace [ 3H]-WIN-35,428 at the DAT
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Figure 4-09: Iodophenyl ring reboxetine analogues displacement of [3H]-WIN-
35,428 binding at the dopamine transporter.   Data points are means of 2 
independent repetitions and error bars represent standard error of the mean. Ki 
values are represented as the mean of 2 independent determinations ± the 
standard deviation, and are calculated from the IC50 using the Cheng-Prusoff 
equation in GraphPad Prism 4.0.   
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Figure 4-10: (S,R)- and (R,S)- iodophenyl ring reboxetine analogues displacement 
of [3H]-WIN-35,428 binding at the dopamine transporter.   Bars representative one 
determination and error bars represent standard error of samples in triplicate for 
that single assay only. Ki values cannot be accurately determined from this data 
set. 
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Benzyl alcohol amides stocks had precipitated out of solution and their inhibition 
constants at the DAT were not ascertained, and nor was any sort of affinity 
established via pilot experiment.  The distinct lack of any notable affinity for either 
the NAT or the SERT meant that preparing more of these compounds for analysis 
at the DAT was not a worthwhile endeavour.  For monoamine pharmacology of 
reboxetine-like molecules, the trends seem to indicate that the phenoxy ring is the 
critical aspect conferring monoamine transporter affinity and it is predicted that the 
loss of this would have similarly destroyed affinity at the DAT. 
 
Elucidation of the DAT-binding properties for the (R,S)-conformation iodophenoxy 
analogues revealed poor affinity for the DAT from all three compounds (Figure 4-
12).   
 
For [3H]-WIN-35,428 binding, there is a high affinity and low affinity binding site on 
the DAT.  The curves for the iodophenoxy ring reboxetine analogues seem less 
traditionally shaped for a one-site competition than the curves on the iodophenyl 
ring reboxetine analogue competition assays.  It is possible that this form of the 
molecule has a greater affinity for the low-affinity binding site, thus affecting the 
shape of the curve.  Regardless, the compounds’ affinity for the DAT in the range 
of 0.5 – 2.1 µM should mean that images of the NAT will not be disturbed by the 
influence of DAT binding. 
 
None of the compounds showed any problematic affinity for the [3H]-WIN-35,428 
binding site on the DAT (Table 4-03) and it appears that the minimal binding at this 
monoaminergic target will not detract from the selectivity of the compounds for the 
NAT. 
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 Figure 4-11: Iodophenoxy ring reboxetine analogues displacement of [3H]-WIN-
35,428 binding at the dopamine transporter (A).  NKJ-68 appears to have affinity 
for more than one binding site on the DAT and this has been reanalysed and re-
presented with the other iodophenoxy compounds to demonstrate both Ki values 
(B).  Data points for both graphs are means of 3 independent repetitions and error 
bars represent standard error of the mean. Ki values are represented as the mean 
of 3 independent determinations ± the standard deviation, and are calculated from 
the IC50 using the Cheng-Prusoff equation in GraphPad Prism 4.0.   
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Table 4-03: Affinity of iodinated reboxetine analogues for the DAT 
Group Compounds DAT Ki 
Iodophenyl ring 
analogues 
(S,R)-iodoreboxetine 
(R,S)-iodoreboxetine 
(S,S)-iodoreboxetine 
(R,R)-iodoreboxetine 
- 
- 
1,457 ± 150 nM 
716 ± 20 nM 
Benzyl alcohol 
amide 
intermediates 
NKJ-38 
NKJ-50 
- 
- 
Iodophenoxy 
ring analogues 
NKJ-64 
NKJ-67 
NKJ-68 
526 ± 126 nM 
1,900 ± 600 nM 
5.81 ± 5.19 nM  &  4,100 ± 1,300 nM 
Table 4-03: Summary of affinity of novel iodoreboxetine compounds for the DAT. 
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4.1.5 Monoamine Transporter Pharmacology (Summary) 
 
The data set for the pharmacological characterisation of the Glasgow-produced 
reboxetine-like compounds at monoamine transporters is summarised in Tables 4-
04 and 4-05. 
 
The iodophenyl ring reboxetine analogues were very selective for NAT but the 
affinity was not sufficient for use as SPECT tracers for imaging the NAT.  The 
benzyl alcohol analogues had poor affinity for all monoamine sites tested and it 
would seem that the phenyl ring is critical for conferring monoamine transporter 
binding.  The iodophenoxy ring reboxetine analogues as a group were more 
selective for the SERT than they were for the NAT, however when the iodine was 
in the ortho position it conferred both affinity and selectivity for the NAT.  The 
iodophenoxy ring compounds with the iodine in the para- and meta- positions had 
greatly diminished affinity to the NAT in comparison to the ortho-position 
compound.  Therefore, based on pharmacological binding profiles, the placement 
of the iodine on the phenoxy ring is of critical importance to the affinity of the 
compound for the NAT.  This indicates that placing the iodine in the para- and 
meta- positions on the phenoxy ring interferrs with the ability of reboxetine to bind 
to the NAT and that these portions of the molecule are therefore important in 
confirring NAT affinity and selectivity.  Based on these pharmacological binding 
profiles, the ortho-positioned compound, (2R,3S)-2-[(2-
Iodophenoxy)phenylmethyl]morpholine, also known as NKJ-64, is therefore the 
most promising candidate for further development as a SPECT brain imaging 
tracer to be used for studying the NAT. 
 
Interestingly, the para-position iodophenoxy molecule, also known as NKJ-68 or 
(2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine, proved to have noteable 
affinity for the SERT with an inhibition constant of 34.5nM.  Furthermore, this 
compound demonstrated multiple affinities for the DAT, indicating that there were 
two distinct conformations or sites for NKJ-68 binding to the DAT. 
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Table 4-04: Novel Iodoreboxetine Compound Affinities 
Compound Pharmacology (Ki in nM) 
Type Structure * Names NAT SERT DAT 
Re
fe
re
n
ce
 
 
Reboxetine, prepared as  
racemic mix: (S,S)/(R,R) 
 
(2S,3S)/(2R,3R) -2-[(2-
Ethoxyphenoxy)phenylmethyl] 
morpholine 
6.9 ± 1.6 not tested not tested 
 
(S,R)-iodoreboxetine 
 
(2S,3R)-2-[(4-Iodophenyl)-(2-
ethoxyphenoxy)methyl] 
morpholine 
321 ± 9 
Pilot only: 
80% 
inhibition @ 
200µM; no 
inhibition @ 
2nM 
Pilot only: 
100% 
inhibition @ 
200µM; 
inhibits <5% 
@ 2nM 
 
(R,S)-iodoreboxetine 
 
(2R,3S)-2-[(4-Iodophenyl)-(2-
ethoxyphenoxy)methyl] 
morpholine 
58.2 ± 9.4 
Pilot only: 
100% 
inhibition @ 
200µM; 
inhibits <5% 
@ 2nM 
Pilot only: 
>95% 
inhibition @ 
200µM; 
inhibits <5% 
@ 2nM 
 
(S,S)-iodoreboxetine 
 
(2S,3S)-2-[(4-Iodophenyl)-(2-
ethoxyphenoxy)methyl] 
morpholine 
53.8 ± 2.7 
 
2,793 
± 480 
(2) 
 
1,457 
± 150 
(2) 
Io
do
-
ph
en
yl 
rin
g 
re
bo
xe
tin
e
 
a
n
al
o
gu
e
s 
 
(R,R)-iodoreboxetine 
 
(2R,3R)-2-[(4-Iodophenyl)-(2-
ethoxyphenoxy)methyl] 
morpholine 
64.0 ± 2.4 
 
 
646 ± 142 
 
(2) 
 
 
716 ± 20 
 
(2) 
I
HO O
N
H
O
1
2
3
6
 
NKJ-38 
 
(2S,3S)-2-[α-Hydroxy-(4-
iodophenyl)methyl]morpholine-5-
one 
14,810 
± 810 
 
 
>100,000 
 
(2) 
not tested 
Be
n
zy
l a
lc
o
ho
l 
io
do
-
a
m
id
e
 
in
te
rm
e
di
a
te
s 
I
HO O
N
H
O
2
3
6
 
NKJ-50 
 
(2R,3R)-2-[α-Hydroxy-(4-
iodophenyl)methyl]morpholine-5-
one 
> 
1,000,000 
 
 
>100,000 
 
(2) 
not tested 
 
NKJ-64 
 
(2R,3S)-2-[(2-
Iodophenoxy)phenylmethyl] 
morpholine 
 
 
8.4 ± 1.7 
 
(5) 
51.5 ± 8.4 526 ± 126 
 
NKJ-67 
 
(2R,3S)-2-[(3-
Iodophenoxy)phenylmethyl] 
morpholine 
1,700 
± 500 154 ± 12 
1,900 
± 600 
Io
do
-
ph
e
n
o
xy
 
rin
g 
re
bo
xe
tin
e
 
a
n
a
lo
gu
es
 
 
NKJ-68 
 
(2R,3S)-2-[(4-
Iodophenoxy)phenylmethyl] 
morpholine 
1,100 
± 200 34.5 ± 1.7 
5.81 
± 5.19 
& 
4,100 
± 1,300 
Table 4-04: Pharmacological binding profile summary for iodoreboxetine analogues at 
monoamine transporters in the CNS.  Ki determined at the NAT, SERT, and DAT with 
[3H]-nisoxetine, [3H]-citalopram, and [3H]-WIN-35,428, respectively.  Data are means of 3 
determinations ± SEM unless otherwise specified (bottom right corner).  NKJ-68 appears 
to have affinity for two binding sites on the DAT and so two Ki determinations are listed. 
* Note: Structures from Jobson, NK (Ph.D. Thesis 2008). 
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Table 4-05: Novel Iodoreboxetine Compound Selectivity 
Compound Selectivity 
Type Structure * Names NAT:SERT NAT:DAT 
R
ef
e
re
n
ce
 
 
Reboxetine, prepared as  
racemic mix: (S,S)/(R,R) 
 
(2S,3S)/(2R,3R) -2-[(2-
Ethoxyphenoxy)phenylmethyl] 
morpholine 
- - 
 
(S,R)-iodoreboxetine 
 
(2S,3R)-2-[(4-Iodophenyl)-(2-
ethoxyphenoxy)methyl] 
morpholine 
- - 
 
(R,S)-iodoreboxetine 
 
(2R,3S)-2-[(4-Iodophenyl)-(2-
ethoxyphenoxy)methyl] 
morpholine 
- - 
 
(S,S)-iodoreboxetine 
 
(2S,3S)-2-[(4-Iodophenyl)-(2-
ethoxyphenoxy)methyl] 
morpholine 
52 : 1 27 : 1 
Io
do
-
ph
e
n
yl 
rin
g 
re
bo
xe
tin
e
 
a
n
a
lo
gu
es
 
 
(R,R)-iodoreboxetine 
 
(2R,3R)-2-[(4-Iodophenyl)-(2-
ethoxyphenoxy)methyl] 
morpholine 
10 : 1 11 : 1 
I
HO O
N
H
O
1
2
3
6
 
NKJ-38 
 
(2S,3S)-2-[α-Hydroxy-(4-
iodophenyl)methyl]morpholine-5-
one 
7 : 1 - 
Be
n
zy
l a
lc
o
ho
l 
io
do
-
a
m
id
e
 
in
te
rm
e
di
a
te
s 
I
HO O
N
H
O
2
3
6
 
NKJ-50 
 
(2R,3R)-2-[α-Hydroxy-(4-
iodophenyl)methyl]morpholine-5-
one 
1: 10 - 
 
NKJ-64 
 
(2R,3S)-2-[(2-
Iodophenoxy)phenylmethyl] 
morpholine 
6 : 1 63 : 1 
 
NKJ-67 
 
(2R,3S)-2-[(3-
Iodophenoxy)phenylmethyl] 
morpholine 
1 : 11 1 : 1 
Io
do
-
ph
e
n
ox
y 
rin
g 
re
bo
xe
tin
e 
a
n
a
lo
gu
e
s 
 
NKJ-68 
 
(2R,3S)-2-[(4-
Iodophenoxy)phenylmethyl] 
morpholine 
1 : 32 - 
Table 4-05: Pharmacological selectivity summary for iodoreboxetine analogues at 
monoamine transporters in the CNS.  Data calculated via Ki data at the NAT, SERT, and 
DAT with [3H]-nisoxetine, [3H]-citalopram, and [3H]-WIN-35,428, respectively.  Where data 
is insufficient for calculation is denoted with a dash.  Ratios accurate to nearest integer.  
NAT:DAT selectivity for NKJ-68 is not listed, as this compound appears to have affinity for 
two binding sites at the DAT.   * Note: Structures from Jobson, NK (Ph.D. Thesis 2008). 
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4.2 Discussion 
 
4.2.1 Summary of findings 
 
The main findings of this chapter are that the addition of the iodine atom to a 
reboxetine-like molecule lowered the binding affinity in every compound 
synthesised and the position of the iodine greatly affects the binding properties of 
the various analogues of iodoreboxetine.   When the iodine atom is positioned on 
the phenyl ring, this enabled a NAT affinity of approximately 54nM in the most 
potent of these analogues, (S,S)-iodoreboxetine, and demonstrated excellent 
selectivity for NAT over DAT and SERT.  However, the affinity of this iodophenyl 
ring reboxetine analogue was not high enough for SPECT imaging, as it would 
give a simple binding estimation of approximately 1.3, compared to the required 
value of approximately 12 (Schou et al. 2007).  The benzyl alcohol iodo-amide 
intermediates are reboxetine-like molecules lacking the phenoxy ring and their 
extremely low affinity for NAT demonstrated how important this ring is for the 
binding properties of reboxetine and any future iodoreboxetine molecules.  When 
the iodine is positioned on the phenoxy ring, this yielded the greatest affinity for 
NAT of all the compounds produced, NKJ-64 (8.4 nM), and acceptable selectivity 
– but the orientation of the iodine atom in the ortho-position on the ring is critical to 
maintaining the capability for binding to the NAT and other phenoxy ring 
analogues were not suitable.   
 
NKJ-64’s Ki at the NAT of 8.4nM compares favourably with the similarly-structured 
SPECT candidate compound INER/IPBM, which has Ki determinations of 0.84nM 
(Kanegawa et al. 2006) and 4.22nM (Tamagnan et al. 2007), and while the Ki 
measurement was higher it is in the same order of magnitude.  A Ki of 8.4nM also 
compares favourably against the Ki determinations in the literature for 
methylreboxetine/MRB/MeNER, 3-Cl-methylreboxetine, and oxaprotiline, at 
4.63nM, 6.11nM, and 9.07nM, respectively (Logan et al. 2007; Ding et al. 2005).  
Once again, NKJ-64 is within the same order of magnitude. 
 
It was interesting to note that the Ki determined in this thesis for reboxetine was 
6.9nM, compared to 1.1nM (Wong et al. 2000) in the literature.  While this is 
approximately 6-fold higher, it is in the same order of magnitude and I haven no 
cause to doubt my determination.  Pilot experiments showed that reboxetine itself 
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displayed affinity for the SERT and DAT.  As aforementioned, the inhibition 
constant for reboxetine at the SERT was determined as 129±13nM (Wong et al. 
2000) and the pilot assay at the SERT merely confirmed that reboxetine is 
exhibiting displacement at this site, although the precise determination was not 
repeated.  The inhibition constant for reboxetine at the DAT was not precisely 
determined but has previously been recorded as exhibiting no significant 
displacement at 10µM (Wong et al. 2000; Millan et al. 2001), so finding a 
significant blockade of [3H]-WIN-35,428 binding when this concentration was 
applied is interesting.  Had the leading compound demonstrated significant affinity 
for the DAT then it may have been worthwhile performing a full displacement 
experiment with reboxetine against [3H]-WIN-35,428 at the DAT to determine to 
what extent the structural changes to the compound had affected the DAT affinity 
– positively or negatively.  However, without problematic DAT binding in the lead 
compound, this curiosity was not attributed great importance and was not 
investigated further. 
 
4.4.2 What alternative molecules are emerging? 
 
Although several reboxetine analogues have since shown promise in vitro and 
been applied to PET imaging (Table 4-06), compounds such as (S,S)-[11C]-
MeNER and (S,S)-[18F]-MeNER-D2 exhibited similar in vivo problems to [11C]-
nisoxetine, resulting in slow uptake, rapid radioisotope decay, and noisy images 
with poor contrast (Zeng et al. 2008). 
 
Although the 2β,3α-(substituted phenyl) nortropane compound selected and 
developed by Zeng et al ( 2007) exhibited great affinity and selectivity in vitro, high 
uptake in the caudate meant that this compound did not present an acceptable 
reference region for in vivo imaging and thus was not suitable for further use.  
Similarly, (S,S)-MRB/MeNER/Methylreboxetine proved to have good affinity, 
specificity, displaceable binding, stability, metabolism, and suitable in vivo blood-
brain barrier penetration, but unfortunately a low specific-to-nonspecific ratio due 
to high uptake in reference regions and an intrinsic PET-associated difficulty in 
accurately defining the specific binding meant that there was a low signal-to-noise 
ratio and  the assessment of many low NAT concentration structures was difficult.   
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Turning to efforts on SPECT compounds, the nisoxetine analogues PYINXT and 
INXT / MIPP displayed high affinity and selectivity in vitro using cloned cell lines, 
however the non-specific binding and in vivo kinetics for [125I]-INXT were 
unacceptable (Lakshmi et al. 2008).  Through modification of the molecule, [125I]-
PYINXT demonstrated 67% specific binding in vivo and more favourable kinetics – 
placing the nonspecific binding of this molecule equivalent to that of [11C]MeNER 
(Lakshmi et al. 2008; Ding et al. 2005). 
 
[125I]-INER/IPBM has been demonstrated as having favourable in vivo 
characteristics with maximal brain radioactivity achieved after 10 minutes following 
bolus injection and a slow washout over 2 hours with specifically displaceable 
regional distributions consistent with those known of the NAT (Tamagnan et al. 
2007; Kanegawa et al. 2006).  Nonspecific binding was approximately 40% and 
the compound therefore has potential as a SPECT brain imaging tracer for 
evaluating the NAT – however the aforementioned [125I]PYINXT, although slightly 
lower in NAT affinity, demonstrated superior specific binding and may therefore 
make a more valuable tracer once the in vivo stability of the molecule is 
determined. 
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Table 4-06: NAT affinity of emerging brain imaging tracer compounds 
Compound Ki (nM) * Isotope Technique References 
2β,3α-(substituted 
phenyl) nortropane 1.78 [
11C] PET Zeng 2007 
Methylreboxetine / 
MeNER / MRB 0.95 – 5.0 
[11C], 
[18F] PET 
Zeng 2009 
Schou 2009; 
Zeng 2008; 
Logan 2007; 
MENET / FENET / 
FPNET  1.02 – 3.68 
[11C], 
[18F] PET Zeng 2009 
(S,S)-S-
methylreboxetine / 
MESNET 
0.30 – 1.35 [
11C], 
[18F] PET 
Zeng 2009; 
Zeng 2008 
PYINXT 5.3 * [125I] SPECT Lakshmi 2008 
Table 4-06: Recently emerging compounds characterised and suggested for in 
vivo imaging of the NAT. 
* Note: Ki values determined against [3H]-nisoxetine, except for PYINXT, which 
was determined against [125I]-nisoxetine.  
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4.2.3 Identifying what the lead compound will be capable of imaging 
 
Whilst the affinity of NKJ-64 is not as high as some compounds reviewed in the 
literature, the good selectivity combined with the reasonable affinity and novel 
routes of synthesis warrants further evaluation of this compound as a potential 
SPECT imaging tracer for the NAT.   Reapplication of the simple Bmax/Kd 
calculation to approximate binding potential (Schou et al. 2007) to the quantitative 
autoradiographic post mortem data set of Donnan et al ( 1991) gives a rough 
guide (Table 4-07) to the in vivo imaging potential of NKJ-64 (Ki = 8.4 ± 1.7 nM).  
When the Ki for a competitive compound is defined at the Kd for the ligand it is 
competing against, the Ki of the competitor may be considered an approximation 
for its Kd to the same site.  The Ki determinations for competitor compounds 
undertaken in this thesis have all occurred at or very near the Kd for each relevant 
ligand, and therefore BMAX/Ki for those compounds can be taken as an 
approximation of BMAX/Kd and appear in Table 4-07.  This allows a rough 
approximation of binding potential for the lead candidate compound to be 
compared with other similar compounds such as INER/IPBM. 
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Table 4-07: Binding Potential Estimations for NAT-specific SPECT Brain 
Imaging Tracer Candidates 
Structure 
Regional Bmax of 
NAT in Human 
Brain (pmol/g wet 
weight, ~nM) 
NKJ-64 
Bmax/Kd 
INER/IPBM 
Bmax/Kd * 
Globus Pallidus 8.7 1.04 3.44 
Ventral Pallidum 2.0 0.24 0.79 
Bed Nucleus of the 
Striatus Terminalis 8.0 0.95 3.16 
Thalamus 10.5 1.25 4.15 
Hypothalamus 36.7 4.37 14.51 
Red Nucleus 7.6 0.90 3.00 
Substantia Nigra 
pars compacta 
pars reticulata 
 
  - 
5.4 
 
- 
0.64 
 
 - 
2.13 
Edinger-Westphal 
Nucleus 18.4 2.19 7.27 
Rostral Linear Nucleus 7.2 0.86 2.85 
Caudal Linear Nucleus 50.5 6.01 19.96 
Parabrachial Pigmented 
Nucleus 1.0 0.12 0.40 
Paranigral Nucleus 4.6 0.55 1.82 
Central Grey 18.0 2.14 7.11 
Dorsal Raphe Nucleus 60.8 7.24 24.03 
Medial Raphe Nucleus 47.3 5.63 18.70 
Raphe Magnus Nucleus 7.1 0.84 2.81 
Raphe Obscurus Nucleus 21.0 2.50 8.30 
Raphe Pallidus Nucleus 10.2 1.21 4.03 
Paramedian Raphe 68.6 8.17 27.11 
Locus Coeruleus 70.8 8.33 27.98 
Cerebellum 6.6 0.79 2.61 
Dorsal Tegmental 
Nucleus 27.5 3.27 10.86 
Subpenduncular 
Pigmented Nucleus 20.3 2.42 8.02 
Table 4-07: Distribution of the NAT in human brain and simple estimations of 
binding potentials for NAT-specific prospective SPECT brain imaging tracers.  
Green boxes indicate a simple binding potential estimation ≥12, and therefore 
indicative of a structure likely to be imaged by the prospective tracer according to 
Schou et al (2007). 
* Note: INER/IPBM Kd applied as an average of the literature-reported values, 
2.53nM. 
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The NKJ-64 did not meet the binding potential calculation criteria, as suggested by 
Schou et al (2007), while INER/IPBM – the (S,S)-isomer of an ortho-position 
iodophenoxy reboxetine analogue – did so across 6 structures: the hypothalamus, 
the caudal linear nucleus, the dorsal raphe nucleus, the raphe magnus nucleus, 
the paramedian raphe, and of course the locus coeruleus.  It should be noted that 
the ratio defined by Schou et al was on the basis of PET, not SPECT, radioligands 
and that this simple calculation does not account for the levels of non-specific 
binding – resulting in a lower binding potential measured in vivo than those 
estimated here.  As SPECT ligand isotopes have a longer half-life compared to 
PET ligand isotopes, more time is afforded for achieving maximal specific binding 
for image acquisition and it is possible that the ratio required for a successful 
SPECT tracer is less than that of a useful PET tracer.    In that context, the simple 
binding potential ratios calculated for NKJ-64 across the raphe nuclei and the 
locus coeruleus are not so disheartening and combined with favourable levels of 
non-specific binding could indicate the utility of this molecule as a SPECT tracer. 
 
4.2.4 Next steps for NKJ-64 development 
 
The in vitro evaluation of the NKJ-64 indicates that it possesses sufficient affinity 
and specificity for the NAT to warrant characterisation of its potential in vivo.  
Although the INER/IPBM molecule characterised in the literature by Tamagnan et 
al (2007) and Kanegawa et al (2006) has greater affinity for the NAT, it is not a 
foregone conclusion that the in vivo characteristics of this compound will also be 
more favourable and thus further study of NKJ-64 developed in this thesis is 
required to determine its in vivo potential.   As previously discussed, it is not 
always the ligand with the greatest affinity that is the most viable and valuable as a 
SPECT brain imaging tracer.  Should it be found that NKJ-64 possesses superior 
blood-brain barrier penetrability, lower non-specific binding, and/or reduced 
plasma protein association combined with stability in circulation, then it may yet 
prove a more valuable SPECT brain imaging tracer for the NAT than those 
described thus far in the literature. 
 
The next phase of ligand development is to predict the in vivo characteristics of the 
lead molecules using high performance liquid chromatography (HPLC) techniques 
to provide justification for conducting in vitro assays with radiolabelled compound.  
Encouraging results at that phase, the development programme would progress to 
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in vivo assays in an animal model, and continue towards the ultimate goals of use 
in drug occupancy studies and clinical application. 
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Chapter 5 
Using High-Performance Liquid Chromatography (HPLC) 
to Predict in vivo Characteristics of Tracer Candidates 
 
 
5.1 Results: 
 
5.1.1 Reboxetine Compounds 
 
5.1.1.1 Lipophilicity (log POCT) 
 
Reboxetine-like compounds (Figure 5-01) that fall inside the ideal log POCT range 
of 1-3.5 (Waterhouse 2003) are: commercially available reboxetine mesylate (log 
POCT 2.81), the iodinated amide compounds NKJ-38 (log POCT 1.88) and NKJ-50 
(log POCT 1.87), and the iodoreboxetine compound NKJ-64 (log POCT 3.40). 
 
Reboxetine-like compounds (Figure 5-01) that were measured as outwith of the 
ideal log POCT range of 1-3.5 are the iodoreboxetine compounds (S,S)-
iodoreboxetine (log POCT 3.54), (R,R)-iodoreboxetine (log POCT 3.57), NKJ-67  (log 
POCT 3.68), and NKJ-68 (log POCT 3.62), which all demonstrated greater 
lipophilicity than the ideal range’s upper threshold of log POCT 3.5. 
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Lipophilicity of Iodoreboxetine Compounds
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
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NKJ-38
Reboxetine mesylate (S,S/R,R)
NKJ-64
(S,S)-iodoreboxetine
(R,R)-iodoreboxetine
NKJ-68
NKJ-67
log POCT
Figure 5-01:  Measured lipophilicity of reboxetine analogues.  The best blood-
brain penetration without problematic non-specific binding is anticipated to be 
exhibited by compounds with log POCT values between 1.0 (dotted blue line) and 
3.5 (dotted red line).  Retention times used in CHI calculations, which were used in 
log POCT calculations, were highly reproducible and variance between 
determinations was not within the sensitivity of the assay. 
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5.2.1.1 Phospholipophilicity (log D7.4 IAM) 
 
The phospholipophilicity of reboxetine (Figure 5-02) was determined as log D7.4 IAM 
5.90.  Relative to reboxetine, the iodinated reboxetine compounds (S,S)-
iodoreboxetine (log D7.4 IAM 7.08), (R,R)-iodoreboxetine (log D7.4 IAM 7.08), NKJ-64 
(log D7.4 IAM 6.87), NKJ-67 (log D7.4 IAM 7.38), and NKJ-68 (log D7.4 IAM 7.17) were all 
more phospholipophilic.  The iodinated amide compounds NKJ-38 (log D7.4 IAM 
4.14) and NKJ-50 (log D7.4 IAM 4,.14) were relatively less phospholipophilic, 
however do not have any notable affinity for the NAT (Chapter 4). 
 
5.2.1.2 Blood-Brain Barrier Penetration (clog BB) 
 
Blood brain barrier penetration of iodoreboxetine molecules (Figure 5-03) suggests 
that all iodoreboxetine compounds (clog BB 1.29-1.53) should penetrate the blood 
brain barrier more successfully than reboxetine (clog BB 0.88), with the exception 
of the iodoamide compounds (clog BB 0.23 each), which do not have any 
noteworthy affinity for the NAT (Chapter 4). 
 
 
5.2.1.3 Plasma Protein Binding (c%PPB) 
 
The plasma protein binding predictor for reboxetine (c%PPB 82.75) was 
determined to be below the threshold of 95%, above which it is thought the degree 
of plasma protein binding could be problematic (Figure 5-04).  The iodination of 
reboxetine resulted in greater than a predicted plasma protein binding greater than 
95% in all cases (c%PPB 97.49-98.60) with NKJ-64 exhibiting the lowest and most 
favourable measurement amongst them (c%PPB 97.49).  The iodinated amides 
NKJ-38 (c%PPB 46.09) and NKJ-50 (c%PPB 44.15) had very low plasma protein 
binding predictors, however poor affinity for the NAT (Chapter 4) means they 
would not make suitable brain imaging tracers. 
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Phospholipophilicity of Iodoreboxetine Compounds
0 1 2 3 4 5 6 7 8
(S,S)-iodoamide
(R,R)-iodoamide
Reboxetine mesylate (S,S/R,R)
NKJ-64
NKJ-50
NKJ-38
NKJ-68
NKJ-67
log D7.4 IAM
Figure 5-02: Measured phospholipophilicity (log D7.4 IAM) of reboxetine analogues.  
Phospholipophilicity is used as predictor of nonspecific binding and very high 
values may indicate problematic nonspecific binding.  Retention times used in CHI 
calculations, which were used in log D7.4 IAM calculations, were highly reproducible 
and variance between determinations was not within the sensitivity of the assay. 
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Blood Brain Barrier Penetration of Iodoreboxetine Compounds
-3 -2 -1 0 1 2 3
NKJ-50
NKJ-38
Reboxetine mesylate (S,S/R,R)
NKJ-64
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NKJ-67
c log BB
Figure 5-03: Measured blood-brain barrier penetration predictors (clog BB) for 
reboxetine analogues.  Higher and lower values indicate greater and lesser brain 
penetration, respectively.  Retention times used in CHI calculations, which were 
used in log clog BB calculations, were highly reproducible and variance between 
determinations was not within the sensitivity of the assay. 
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Plasma Protein Binding of Iodoreboxetine Compounds
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Figure 5-04:  Plasma protein binding derived from a combination of HSA and 
AGP affinity determinations for reboxetine analogues.  Plasma protein binding is 
considered inversely proportional to availability of a compound in plasma, 
although some compounds can use plasma proteins as carrier molecules to more 
successfully penetrate the brain.  Retention times used in CHI calculations, which 
were used in log c%PPB calculations, were highly reproducible and variance 
between determinations was not within the sensitivity of the assay. 
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5.2.2 Reference Compounds 
 
5.2.2.1 Lipophilicity (log POCT) 
 
Reference compounds (Figure 5-05) that fall inside the ideal log POCT range of 1-
3.5 (Waterhouse 2003) are MIBG (log POCT 2.96), MK-801 (log POCT 2.68) 5-I-A-
85380 (log POCT 2.68) FIAU (log POCT 1.24) and α-3-iodo-2-methyltyrosine (log 
POCT 1.17).  Reference compounds that fell outside the ideal log POCT range of 1-
3.5 are: I-QNB (log POCT 3.55), CNS-1261 (log POCT 3.86), PK-11195 (log POCT 
3.85), β-CIT (log POCT 3.84), and 5-iodo-2’-deoxyuridine (log POCT 0.97).   
 
5.2.2.2 Phospholipophilicity (log D7.4 IAM) 
 
The reference compounds that returned relatively moderate values for 
phospholipophilicity (Figure 5-06) are β-CIT (log D7.4 IAM 5.55), MK-801 (log D7.4 IAM 
5.45), PK-11195 (log D7.4 IAM 5.35), 5-I-A-85380 (log D7.4 IAM 5.01), and α-3-iodo-2-
methyltyrosine (log D7.4 IAM 2.75).  The higher reported reference compound values 
came from CNS-1261 (log D7.4 IAM 6.38), MIBG (log D7.4 IAM 6.75), and I-QNB (log 
D7.4 IAM 6.97).  
 
5.2.2.3 Blood-Brain Barrier Penetration (clog BB) 
 
A high clog BB measurement is indicative of likely success for blood-brain barrier 
penetration and low clog BB measurements suggest that blood-brain barrier 
penetration would be poor (Figure 5-07).  Compounds FIAU (clog BB -1.56), α-3-
iodo-2-methyltyrosine (clog BB -2.81), and 5-iodo-2’-deoxyuridine (clog BB -2.98) 
are all indicated to have unfavourable blood-brain barrier penetration 
characteristics.  Compounds PK11195 (clog BB 1.62), I-QNB (clog BB 1.31), CNS-
1261 (clog BB 1.03), β-CIT (clog BB 0.99), MK-801 (clog BB 0.87), and MIBG 
(clog BB 0.56) are all indicated to have favourable blood-brain barrier penetration 
characteristics by this predictor.  The predictor for 5-I-A-85380 (clog BB -0.01) is 
borderline unfavourable. 
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Lipophilicity of Reference Compounds
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Figure 5-05:  Measured lipophilicity of the successful and failed imaging tracers 
comprising the reference compounds.  The best blood-brain penetration without 
problematic non-specific binding is anticipated to be exhibited by compounds with 
log POCT values between 1.0 (dotted blue line) and 3.5 (dotted red line).  Retention 
times used in CHI calculations, which were used in log POCT calculations, were 
highly reproducible and variance between determinations was not within the 
sensitivity of the assay. 
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Phospholipophilicity of Reference Compounds
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Figure 5-06: Measured phospholipophilicity (log D7.4 IAM) of the successful and 
failed imaging tracers comprising the reference compounds.  Phospholipophilicity 
is used as a predictor of nonspecific binding and high values indicate higher 
nonspecific binding.  Retention times used in CHI calculations, which were used in 
log D7.4 IAM calculations, were highly reproducible and variance between 
determinations was not within the sensitivity of the assay. 
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Blood Brain Barrier Penetration of Reference Compounds
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Figure 5-07: Measured blood-brain barrier penetration predictors (clog BB) for the 
successful and failed tracers comprising the reference compounds.  Higher and 
lower values indicate greater and lesser brain penetration, respectively.  The 
negative numbers are theoretical and are interpreted as an inability to penetrate 
the blood-brain barrier.  Retention times used in CHI calculations, which were 
used in clog BB calculations, were highly reproducible and variance between 
determinations was not within the sensitivity of the assay. 
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5.2.2.4 Plasma Protein Binding (c%PPB) 
 
I-QNB (c%PPB 97.72), PK-11195 (c%PPB 97.66), posted very similar predictors 
to the iodinated reboxetine compounds for plasma protein binding, although it is 
over the defined 95% threshold for desirable levels of plasma protein binding.  
CNS-1261 (c%PPB 95.84) was also determined to be above the 95% threshold for 
plasma protein binding (Figure 5-08).  MIBG (c%PPB 71.44), α-3-iodo-2-
methyltyrosine (c%PPB 68.97), β-CIT (c%PPB 67.62), MK-801 (c%PPB 48.59), 5-
I-A-85380 (c%PPB 27.91), FIAU (c%PPB 19.16), 5-iodo-2’-deoxyuridine (c%PPB 
4.31) were well within limits with low predictors for plasma protein binding. 
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Plasma Protein Binding of Reference Compounds
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Figure 5-08:  Plasma protein binding derived from a combination of HSA and 
AGP affinity determinations for the successful and failed tracers comprising the 
reference compounds.  Plasma protein binding is considered inversely 
proportional to availability of a compound in plasma, although some compounds 
can use plasma proteins as carrier molecules to more successfully penetrate the 
brain.  Retention times used in CHI calculations, which were used in c%PPB 
calculations, were highly reproducible and variance between determinations was 
not within the sensitivity of the assay. 
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5.2.3 Combined Data Sets 
 
5.2.3.1 Lipophilicity (log POCT) 
 
Relative to reboxetine, the addition of the iodine increased the lipophilicity of the 
iodoreboxetine compounds (Table 5-01). Out of these, NKJ-64 is the only 
iodinated reboxetine analogue with favourable pharmacological characteristics 
(high selectivity and Ki <10nM, see Chapter 4) and is expected to penetrate the 
brain with moderate/high nonspecific binding.  Overall, there is good correlation 
between the log POCT predictor and brain penetration as well as nonspecific 
binding, although there are discrepancies where compounds such as MIBG, FIAU, 
and α-3-iodo-2-methyltyrosine do not conform to that trend. 
 
Comparison of the log POCT data for reboxetine-like compounds with that of the 
reference compounds indicates that all iodinated reboxetine and iodoamide 
compounds should cross the blood-brain barrier.  The iodinated reboxetine 
analogues on the whole can be expected to exhibit high nonspecific binding, while 
the iodoamide compounds are predicted to have low nonspecific binding.  
Individually, NKJ-64 is the most favourable compound. 
 
5.2.3.2 Phospholipophilicity (log D7.4 IAM) 
 
The iodinated reboxetine compounds have all demonstrated high value log D7.4 IAM 
predictors and therefore can be expected to exhibit high nonspecific binding (Table 
5-02).  Out of the compounds with acceptable NAT affinity (Chapter 4), NKJ-64 
has the lowest predictor for nonspecific binding and is similar in determination to 
that of I-QNB, which exhibits moderate nonspecific binding.  However, NKJ-64 
also returned higher predictors for nonspecific binding than CNS-1261 and 
PK11195, both of which are known to have high nonspecific binding when used for 
imaging. 
 
On the whole, the log D7.4 IAM predictor was generally well correlated with 
nonspecific binding demonstrated in vivo, however there are no clear-cut 
thresholds. 
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Table 5-01: Combined Lipophilicity Results 
Log POCT Compound 
Blood-Brain 
Barrier 
Penetration? 
Nonspecific 
Binding 
3.83 CNS-1261 Yes High 
3.68 NKJ-67   
3.62 NKJ-68   
3.60 PK11195 Yes High 
3.57 (R,R)-iodoreboxetine   
3.56 β-CIT Yes Low 
3.55 I-QNB Yes Moderate 
3.54 (S,S)-iodoreboxetine   
3.40 NKJ-64   
2.96 MIBG No Not a brain imaging tracer 
2.81 Reboxetine Yes Not a brain imaging tracer 
2.68 MK-801 Yes  
2.68 5-I-A-85380 Yes Low 
1.88 NKJ-38   
1.87 NKJ-50   
1.24 FIAU No Not a brain imaging tracer 
1.17 α-3-iodo-2-
methyltyrosine 
Yes 
(Active Transport)  
0.97 5-iodo-2’-deoxyuridine No  
Table 5-01: Lipophilicity (log POCT) of reboxetine-like tracer candidate compounds 
and lipophilicity (log POCT), blood brain barrier penetration (where known), and 
nonspecific binding (where known) for the reference compounds that are 
comprised of both successful and failed tracers.  Compounds with measured 
lipophilicity values that fall within the ideal log POCT range of 1-3.5 are highlighted 
in green shading.   
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Table 5-02: Combined Phospholipophilicity Results 
Log D7.4 IAM Compound Nonspecific Binding 
7.38 NKJ-67  
7.17 NKJ-68  
7.08 (R,R)-iodoreboxetine  
7.08 (S,S)-iodoreboxetine  
6.97 I-QNB Moderate 
6.87 NKJ-64  
6.75 MIBG Not a brain imaging tracer 
6.38 CNS-1261 High 
5.90 Reboxetine Not a brain imaging tracer 
5.55 β-CIT Low 
5.45 MK-801  
5.35 PK11195 High 
5.01 5-I-A-85380 Low 
4.14 NKJ-38  
4.14 NKJ-50  
2.75 α-3-iodo-2-methyltyrosine Low 
2.09 FIAU Not a brain imaging tracer 
1.80 5-iodo-2’-deoxyuridine  
Table 5-02: Phospholipophilicity (log D7.4 IAM) of reboxetine-like compounds and 
reference compounds comprised of both successful and failed tracers.  Higher 
determined values indicate higher nonspecific binding.  Reference compounds 
have nonspecific binding characteristics listed where known. 
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5.2.3.3 Blood-Brain Barrier Penetration (clog BB) 
 
The clog BB predictor indicates that all of the reboxetine-like compounds tested 
will cross the blood-brain barrier (5-03).  NKJ-64 returned a very similar predictor 
to I-QNB, which has been used successfully as a brain imaging tracer.  The 
iodinated reboxetine analogues indicated greater blood-brain barrier penetrability 
than reboxetine and the iodoamides were determined to have lesser blood-brain 
barrier penetrability in comparison to reboxetine.  Overall, there is good correlation 
between the clog BB predictor and the known blood-brain barrier penetration of 
the reference compounds, although there are anomalies such as MIBG which are 
known not to successfully penetrate the brain. 
 
5.2.3.4 Plasma Protein Binding (c%PPB) 
 
All the predictors for the iodinated reboxetine compounds exceeded the 95% 
threshold for plasma protein binding (Table 5-04).  However the c%PPB value for 
NKJ-64 is not too dissimilar to I-QNB or PK11195, which have both been used 
successfully for imaging, so it is not clear whether this will be problematic or not.  
Reboxetine and the iodoamides were determined to have predictor values well 
below the 95% however the iodoamides have no notable affinity for the NAT. 
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Table 5-03: Combined Blood-Brain Barrier Penetration Results 
clog BB Compound Blood-Brain Barrier Penetration? 
1.62 PK11195 Yes 
1.53 NKJ-67  
1.48 NKJ-68  
1.39 (R,R)-iodoreboxetine  
1.38 (S,S)-iodoreboxetine  
1.31 I-QNB Yes 
1.29 NKJ-64  
1.03 CNS-1261 Yes 
0.99 β-CIT Yes 
0.87 MK-801  
0.88 Reboxetine Yes 
0.56 MIBG No 
0.23 NKJ-38  
0.23 NKJ-50  
-0.01 5-I-A-85380 Yes 
-1.56 FIAU No 
-2.81 α-3-iodo-2-methyltyrosine Yes (Active Transport) 
-2.98 5-iodo-2’-deoxyuridine No 
Table 5-03: Blood-brain barrier penetration (clog BB) of reboxetine-like 
compounds and reference compounds comprised of both successful and failed 
tracers.  Higher determined values indicate greater brain penetration and green 
shading denotes likelihood to cross the blood brain barrier based upon the clog BB 
value. 
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Table 5-04: Combined Plasma Protein Binding Results 
c%PPB Compound Plasma Protein Binding Below 95%? 
98.60% NKJ-67   
98.37% NKJ-68   
97.91% (S,S)-iodoreboxetine   
97.87% (R,R)-iodoreboxetine  
97.72% I-QNB  
97.66% PK11195 Yes 
97.49% NKJ-64  
95.84% CNS-1261 Yes 
82.75% Reboxetine  
71.44% MIBG  
68.97% α-3-iodo-2-methyltyrosine  
67.62% β-CIT Yes 
48.59% MK-801 Yes 
46.09% NKJ-38  
44.15% NKJ-50  
29.91% 5-I-A-85380 Yes 
19.16% FIAU  
4.31% 5-iodo-2’-deoxyuridine Too unstable to measure. 
Table 5-04: Plasma protein binding (c%PPB) of reboxetine-like compounds and 
reference compounds comprised of both successful and failed tracers.  
Determined values above 95% indicate the potential for problematic plasma 
protein binding, while green shading indicates sufficiently low plasma protein 
binding to increase likelihood of plasma availability. 
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5.2.3.5 Summary 
 
NKJ-64 displayed good lipophilicity, high phospholipophilicity, high blood-brain 
barrier penetration, and high plasma protein binding (Tables 5-05 and 5-06).  With 
regard to potentially unfavourable phospholipophilicity and plasma protein binding, 
examples of successful tracers had similar determinations so the thresholds for 
these criteria are not absolute.   
 
The predictors of the iodinated reboxetine compounds as a group were generally 
of good brain penetration, high nonspecific binding, and high plasma protein 
binding.  As tracers, neuroimaging may be difficult if nonspecific binding is too high 
and availability of the tracer in serum may be reduced if the plasma protein binding 
proves excessive.  The iodoamides generally demonstrated good brain 
penetration, good nonspecific binding, and low plasma protein binding and thus 
have demonstrated many of the qualities consistent with the successful tracer.  
However, the iodoamides have previously been shown to have insufficient affinity 
at monoamine transporters to be considered as tracers at these sites (Chapter 4). 
 
On the whole, the determined predictor values correlated well with known trends 
for reference compounds, although there were anomalies (Tables 5-05 and 5-06).  
Many compounds that have been determined to have a high lipophilicity (log POCT) 
also returned high predictors for phospholipophilicity (log D7.4 IAM), calculated 
blood-brain barrier penetration (clog BB), and calculated plasma protein binding 
(c%PPB). 
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Table: 5-05: HPLC Summary – Predictors of in vivo molecular behaviour 
Categories and Compounds log POCT log D7.4 IAM clog BB c%PPB 
Ideal Range or Preferable Trend 1 – 3.5 Low High <95% 
Reboxetine mesylate (S,S/R,R) 2.81 5.90 0.88 82.75 
(S,R)-iodoreboxetine 
(R,S)-iodoreboxetine not tested 
(S,S)-iodoreboxetine 3.54 7.08 1.38 97.91 
(R,R)-iodoreboxetine 3.57 7.08 1.39 97.87 
NKJ-38 1.88 4.14 0.23 46.09 
NKJ-50 1.87 4.14 0.23 44.15 
NKJ-64 3.40 6.87 1.29 97.49 
NKJ-67 3.68 7.38 1.53 98.60 
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NKJ-68 3.62 7.17 1.48 98.37 
PK11195 3.60 5.35 1.62 97.66 
MIBG 2.96 6.75 0.56 91.44 
β-CIT 3.56 5.55 0.99 67.62 
CNS-1261 3.83 6.38 1.03 95.84 
5-I-A-85380 2.68 5.01 -0.01 27.91 
I-QNB 3.55 6.97 1.31 97.72 
α-3-iodo-2-methyltyrosine 1.17 2.75 -2.81 68.97 
5-iodo-2’-deoxyuridine 0.97 1.80 -2.98 4.31 
FIAU 1.24 2.09 -1.56 19.16 
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MK-801 2.68 5.45 0.87 48.59 
Table 5-05: HPLC-measured predictors for in vivo molecular behaviour of 
reboxetine analogues and the successful and failed brain imaging tracers 
comprising the reference compounds. 
 
 
Table 5-06: HPLC Summary – Predictors of in vivo molecular behaviour 
Categories and Compounds log POCT log D7.4 IAM clog BB c%PPB 
Ideal Range or Preferable Trend Moderate Low High <95%? 
Reboxetine mesylate (S,S/R,R) Moderate Moderate Moderate Yes 
(S,R)-iodoreboxetine 
(R,S)-iodoreboxetine not tested 
(S,S)-iodoreboxetine High High High No 
(R,R)-iodoreboxetine High High High No 
NKJ-38 Moderate Low Moderate Yes 
NKJ-50 Moderate Low Moderate Yes 
NKJ-64 Moderate High High No 
NKJ-67 High High High No 
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NKJ-68 High High High No 
PK11195 High Moderate High No 
MIBG Moderate High Moderate Yes 
β-CIT High Moderate Moderate Yes 
CNS-1261 High Moderate Moderate No 
5-I-A-85380 Moderate Moderate Low Yes 
I-QNB High High High No 
α-3-iodo-2-methyltyrosine Moderate Low Very Low Yes 
5-iodo-2’-deoxyuridine Low Low Very Low Yes 
FIAU Moderate Low Very Low Yes 
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MK-801 Moderate Moderate Moderate Yes 
Table 5-06: HPLC-derived predictors for in vivo molecular behaviour of reboxetine 
analogues and the successful and failed brain imaging tracers comprising the 
reference compounds.  Determined values have been converted into general 
descriptors. 
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5.2 Discussion 
 
5.2.1 Iodinated reboxetine compounds 
 
NKJ-64 has displayed many of the HPLC-determined properties that are 
consistent with successful tracers and has previously been shown to have 
favourable NAT-specific pharmacology (Chapter 4).  Predictors for lipophilicity (log 
POCT) indicated good blood-brain penetration, calculated blood-brain barrier 
penetration predictors (clog BB) were similarly favourable, and calculated plasma 
protein binding (c%PPB) that was high but not dissimilar to successful reference 
compounds. 
 
The position of the iodine on the iodoreboxetine compounds did not greatly affect 
lipophilicity, although the only compound within range was NKJ-64 with the iodine 
in the ortho position. Predictors for phospholipophilicity (log D7.4 IAM) indicated that 
nonspecific binding would be high in all iodinated reboxetine compounds, but the 
predictor for NKJ-64 was similar to the value returned by reference compound I-
QNB, which has moderate nonspecific binding in vivo.  The iodinated reboxetine 
analogues (log D7.4 IAM 6.87-7.38) all had higher phospholipophilicity than 
reboxetine (log D7.4 IAM 5.90).  Given the limited library of reference compounds 
with which to compare, it is difficult to ascertain with certainty whether nonspecific 
binding will be problematic until an iodinated reboxetine compound is radiolabelled 
and examined further. 
 
The iodination of reboxetine increased the blood-brain barrier penetrability as 
determined by the clog BB measurement and it was not greatly affected by the 
position of the iodine.  While there is of yet no firmly defined threshold for blood-
brain barrier penetrability, a greater library of reference compounds in future 
studies may yield sufficient data to establish one.  One of the reasons the 
methanol elution may be tried is to improve the peak shape or reproducibility for 
compounds being eluted from the column when a compound demonstrates low 
solubility in acetonitrile (Kalendarev et al. 2001) and is a worthwhile technique.   
 
The plasma protein binding measured for the iodinated reboxetine analogues was 
very high, and plasma protein binding can deplete tracer availability in serum.  The 
lead compound, NKJ-64, had the lowest plasma protein binding predictor of any of 
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the pharmacologically favourable compounds, although this was still greater than 
95%.  The location of the iodine, whether on the phenoxy or phenyl ring, seemed 
to make little difference to the degree of increase in plasma protein binding relative 
to reboxetine.  If indeed plasma protein binding greater than 95% results in a 
problematic decrease in tracer availability in the serum, then these results could 
indicate unsuitability from these compounds.  However, that is not to say that all 
compounds with high serum protein binding properties are disadvantaged from 
entering the brain; the clinical drugs diazepam and fluoxetine exhibit 93.2% and 
97.1% binding to HSA, respectively (Hollósy et al. 2006).  One such hypothesis to 
explain this is that plasma proteins can mediate transport of tracers across the 
blood-brain barrier, as was found with AGP (Lin et al. 1987), and it could be that 
the plasma protein binding of highly lipophilic compounds prevent their 
sequestering into peripheral interstitium, muscle, and adipose tissue – thus 
maintaining compound concentrations in the plasma for brain penetration. 
 
The iodinated amides NKJ-38 and NKJ-50, lacking the phenoxy ring from their 
molecular structure, had far reduced plasma protein binding predictors of c%PPB 
46.09 and c%PPB 44.15, respectively.  However, the monoamine transporter 
pharmacology of the amide compounds is extremely poor (Chapter 4) and they 
would not make suitable brain imaging tracers. 
 
 
5.2.2 Reference compounds (successful and failed tracers) 
 
The HPLC methodology applied here returns on average a higher log P value than 
is recorded in the literature for similar molecules.  However, as Waterhouse (2003) 
took several different types of determination into account for setting out the ideal 
log P range of 1-3.5, it is still a reasonable range to apply here to give useful 
feedback on the suitability of a compound – although perhaps allowing some 
flexibility in the upper ranges and particular stringency in the lower ranges of 
returned values would be appropriate for the selection process.  Generally, these 
compounds followed the same trends relative to one another as they do in the 
literature, with MIBG the most notable of a few exceptions.  
 
MIBG and FIAU are unable to cross the blood-brain barrier (Gourand et al. 2010; 
Jacobs et al. 2001; respectively) and lipophilicity values for MIBG in the literature 
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report log POCT -0.51 (DeGrado & Wang 1998) and log P 0.15 (Raffel & Wieland 
2001b) – with a great discrepancy between those values and my predictor of log 
POCT 2.96 for MIBG and a smaller discrepancy for FIAU, for which my predictor 
was POCT 1.24.  These outlying values from the ideal range suggested by 
Waterhouse (2003) better reflect what is known about the in vivo behaviour of 
MIBG and FIAU.  Perhaps the molecular modelling I used was not accounting for 
certain characteristics of these molecules, such as strongly electronegative double 
oxygen bonds in FIAU or polar amine groups in MIBG.  Gourand et al (2010) 
demonstrated a liphophilic dihydroquinoline/quinolinium salt could be used as a 
chemical delivery system to carry MIBG across the blood-brain barrier, perhaps by 
improving the overall lipophilicity of the temporarily combined molecule.  
Unfortunately, standardisation is very poor in calculations of log P and even log 
POCT, so perhaps the molecular modelling used by DeGrado & Wang and Raffel & 
Wieland were better suited to MIBG and FIAU.  If it is a case that no model yet 
exists to encompass all types of compound, then future investigations could 
examine a larger library of compounds that exhibit similar in vivo behaviour to 
determine if there is a common structural arrangement or feature that means one 
molecular model should be chosen over another for predicting the behaviour of a 
particular class of compound. 
 
MK-801 was determined by HPLC measurement to have good lipophilicity and 
phospholipophilicity, although the iodinated SPECT tracer compound has 
excessive nonspecific binding manifested through accumulation in white matter 
(Owens et al. 1997).  The compound measured in this thesis is structurally that of 
the therapeutic drug and not the iodinated SPECT imaging tracer, so this disparity 
between the predictor for the uniodinated compound and the known binding of the 
iodinated SPECT tracer is interesting.  Assuming that the predictors are a fair 
reflection of MK-801’s in vivo behaviour, when combined with the increases in log 
POCT and log D7.4 IAM that iodination causes to the reboxetine molecule, it supports 
the hypothesis that iodination will typically increase both lipophilicity and 
phospholipophilicity.  CNS-1261 (log POCT 3.86), PK-11195 (log POCT 3.85) and β-
CIT (log POCT 3.84) were all outliers from the ideal range and yet all have been 
used successfully as imaging tracers (Bressan et al. 2005; Chauveau et al. 2008; 
Laruelle et al. 2000; respectively).  However, these outliers were not outwith of the 
ideal range by a large degree and so the method’s general trend for predicting 
compound behaviour was maintained. 
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α-3-iodo-2-methyltyrosine was measured to be favourably lipophilic (log POCT 1.17) 
and although it does get into the brain it has been shown to cross the blood-brain 
barrier via specific transport (Langen et al. 1991).  Consequently, it is unclear to 
what extent its lipophilicity contributes, if at all, to its brain penetration.  Quite 
clearly in the Waterhouse review (2003), the ideal log P range does not apply to 
compounds that have an alternative route across the blood-brain barrier such as 
active transport.  Given the time and resources, it would be better to build up a 
database of tested compounds in order to determine new limits and perhaps 
improving upon the Waterhouse criteria is something for future investigations to 
undertake.  
 
For a compound to be successful, an ideal log POCT value appears to be a 
guideline rather than a rule, so falling within this range does not guarantee 
successful brain penetration and, conversely, falling outside of this range does not 
certify blood brain barrier impenetrability – so it is clear that measured lipophilicity 
is not the quintessential property that exclusively determines tracer success and 
therefore the other properties of a compound are also important.  Lipophilicity is, 
however, one of the key behavioural properties that may not necessarily be 
compensated for in the other characteristics of a candidate compound, so those 
molecules that fall within the ideal range appear to have a greater likelihood of 
penetrating the blood-brain barrier successfully, while keeping within acceptable 
limits for nonspecific binding. 
 
High predictors for nonspecific binding in terms of phospholipophilicity were 
derived for iodinated reboxetine compounds.  If indeed these translate into high 
nonspecific binding in vivo, one comparison compound could be CNS-1261, which 
yielded a not too dissimilar phospholipophilicity of log D7.4 IAM 6.38.  CNS-1261 has 
been used successfully as a tracer even though in vivo nonspecific binding was 
estimated in white matter to be 60-80% (Erlandsson et al. 2003).  5-I-A-85380 
exhibits virtually no nonspecific binding in vitro (Pimlott et al. 2004) and has been 
used successfully for in vivo brain imaging (Ogawa et al. 2009) with demonstrated 
nonspecific binding of 28-30% as ascertained by displacement studies (Fujita et al. 
2000).  β-CIT has similarly been successfully applied as a brain imaging tracer 
(Laruelle et al. 2000; Scanley et al. 2000) and demonstrated nonspecific binding of 
8% (Al-Tikriti et al. 1995).  PK11195 has been used as a successful brain imaging 
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tracer despite a fairly high demonstrated nonspecific binding of 60% (Petit-Taboue 
et al. 1991), although this value did include the free fraction during the in vivo 
scans and the nonspecific binding alone was not determined.  MK-801 posted a 
reasonable phospholipophilicity (log D7.4 IAM 5.45) in comparison to many other 
reference compounds used here, but is known to have difficulties with nonspecific 
binding (Erlandsson et al. 2003). 
 
For clinical imaging purposes, MIBG is predominantly used in the periphery, 
because it does not cross the blood brain barrier in humans (Guilloteau et al. 
1983a; - French language, cited by Baulieu et al. 1990) unless the blood brain 
barrier is compromised, and the high phospholipophilicity reported here (log D7.4 
IAM 6.75) is a potential explanation for its inability to penetrate into the brain in light 
of the acceptable lipophilicity discussed earlier.  As a substrate compound, MIBG 
has found use in treating NAT- and SERT-expressing neuroblastomas and is also 
taken up by platelets via the SERT (Tytgat et al. 2002), causing thrombocytopenia.  
Throughout this use, nonspecific binding in the periphery is difficult to quantify 
given the widespread locations of NAT and SERT.   However, quantification 
seems unnecessary given the immensely amplified level to which tumours over-
express monoamine transporters and accumulate MIBG.  I-QNB demonstrates the 
highest  phospholipophilicity recorded by any of my chosen reference compounds 
(log D7.4 IAM 6.97) and in practice has shown in vivo nonspecific binding of 42-55% 
in relation to the cerebellum, which was taken as a reference region (Varastet et 
al. 1992).   
 
FIAU was measured to have a low phospholipophilicity (log D7.4 IAM 2.09) and this, 
in combination with a low lipophilicity (albeit still within the Waterhouse-proposed 
range) may very well contribute to its inability to effectively cross the blood-brain 
barrier.  However, low phospholipophilicity appears not to always be a 
disadvantage as α-3-iodo-2-methyltyrosine (log D7.4 IAM 2.75) exhibits, alongside 
active transport into the brain, a passive blood-brain barrier penetration 
representing 10% of α-3-iodo-2-methyltyrosine brain uptake (Riemann et al. 2001). 
 
5-iodo-2’-deoxyuridine (log D7.4 IAM 1.80) cannot be assessed for nonspecific 
binding in the same sense as a ligand because it is a gene marker that becomes 
incorporated into rapidly proliferating cells where upon a specific signal is 
measured, while in contact with free serum it succumbs to rapid dehalogenation, 
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making nonspecific binding in vivo extremely difficult to quantify for the parent 
compound (Khalili et al. 2003).  While it was shown to exhibit 40% nonspecific 
binding in cells, it is unknown how this might relate to the HPLC-derived 
phospholipophilicity measurement.  With such a low aforementioned lipophilicity 
and phospholipophilicity, it would not be surprising if it was unable to penetrate the 
brain without the active transport processes that it relies upon for crossing the 
blood-brain barrier. 
 
So although a high phospholipophilicity is associated with the potential for high 
nonspecific binding, it is not a characteristic that is unequivocally associated with 
all failed tracers and lacked by all successful ones.  A precise range or threshold is 
not defined, but generally it would be preferable to observe low 
phospholipophilicity as it would be a predictor of low nonspecific binding in vivo. 
 
The clog BB measurement was generally in good agreement with what is known 
about the ability of each reference compound to cross the blood-brain barrier, 
however there are no defined thresholds and the library of compounds here was 
too small to identify one.  MIBG and 5-I-A-85380 were exceptions to the trend, with 
MIBG reporting a clog BB of 0.56 while being unable to cross the blood-brain 
barrier and 5-I-A-85380 measured as -0.01 while penetrating the blood-brain 
barrier successfully.  A value of -2.81 was returned for α-3-iodo-2-methyltyrosine, 
however this molecule is actively transported into the brain and thus cannot be 
said to be an anomaly in a predictor that only applies to passive diffusion across 
the blood-brain barrier.  Furthermore, the process of active transport via amino 
acid carriers by compounds such as α-3-iodo-2-methyltyrosine undoubtedly 
involves some association between blood-brain barrier proteins and plasma 
proteins to penetrate the brain.   
 
Successful SPECT brain imaging tracers 5-I-A-85380, CNS-1261, and PK-11195 
have exhibited greater than 95% plasma protein binding measured via HPLC, 
despite studies showing that availability in plasma for compounds such as CNS-
1261 are below this threshold (Bressan et al. 2004) and PK11195 can be defined 
as simply >80% (Lockhart et al. 2003).  While MIBG is another anomaly that falls 
beneath the plasma protein binding threshold and fails to penetrate the brain, 
there may be other reasons for this that are unrelated to the availability of MIBG in 
the serum.  These discrepancies between the plasma protein binding predictions 
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and the known behaviour of reference compounds in the serum suggest that 
perhaps the threshold for acceptable plasma protein binding as determined via 
HPLC requires further optimisation.  
 
It has been previously reported that immobilized AGP, used to derive the c%PPB 
figure, is not suitable as a chromatographic method due to carboxylic groups 
which are occupied by bonding with the silica support and thus are not available 
for interaction with positively-charged compounds (Schill et al. 1986).  According to 
C-18 lipophilicity determinations at neutral (near-physiological) pH levels which 
demonstrated reboxetine-like compound species as being more closely related to 
the alkali than acidic conditions, at physiological pH levels the reboxetine-like 
tracer candidate compounds are more likely to assume the negatively charged 
species than the positively charged species when using these elutions.  However, 
the potential for variability in retention time for compounds that might assume a 
positively charged species with this column and elution combination means that 
this data cannot be taken as a guarantee of serum availability for compounds 
predicted to have <95% plasma protein binding and nor does it certify poor 
availability for blood brain barrier penetration for compounds with >95% plasma 
protein binding predicted. 
 
Across all four measurements, lipophilicity (log POCT), phospholipophilicity (log D7.4 
IAM), calculated blood-brain barrier penetration (clog BB), and calculated plasma 
protein binding (c%PPB), the general trend of the reference compounds was 
indicated correctly.  However, there were anomalies in every instance and thus 
underlines the importance of having a sufficiently large library of reference 
compounds so as to diminish the impact that individual anomalies have upon the 
analysis. 
 
5.2.3 Conclusions 
 
NKJ-64 displayed predictors for good lipophilicity, high phospholipophilicity, high 
blood-brain barrier penetration, and high plasma protein binding.  With regard to 
the potentially unfavourable phospholipophilicity and plasma protein binding, 
examples of successful tracers had similar determinations so the thresholds for 
these criteria are not absolute.  The overall trend was that the addition of the 
iodine atom to reboxetine increased the values of every HPLC-derived predictor, 
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which was desirable in the cases of the lipophilicity and blood-brain barrier 
penetration predictors, but unfavourable in some cases of the phospholipophilicity 
and plasma protein binding predictors.  It was NKJ-64 that most closely 
demonstrated HPLC-derived properties that were consistent with successful 
tracers to date, while also possessing favourable monoamine transporter 
pharmacology (Chapter 4).  It is therefore the best candidate from the tested 
library of iodinated reboxetine compounds for further development as a SPECT 
tracer. 
 
For this and future studies, when considering all the investigated criteria together 
they have more value than when examined individually and this overcomes some 
of the shortcomings of vague thresholds.  The reference compounds give meaning 
to the values in each of the HPLC determinations and so, to define these 
thresholds more specifically, a greater library of reference compounds with known 
behaviour in vivo is required to further validate the method and increase its 
usefulness.   
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Chapter 6 
General Conclusions 
 
6.1 The NAT is not down-regulated in the PCP model of schizophrenic 
hypofrontality. 
 
Monoamine transporters were probed with radioligands and their distributions 
were found to be consistent with those in the published literature (Chapter 3).   
 
In a model of a disease state, I had hypothesised that the probing of monoamine 
transports in a PCP model of schizophrenic hypofrontality would reveal a down-
regulation of the NAT in the prefrontal cortex (Chapter 3).  However, no changes 
were found in the distributions or binding densities of the NAT or the DAT.  
Selective down-regulation of binding densities to the SERT was observed, 
although it is unclear whether the very small changes detected would be 
biologically significant, as biological systems can compensate for small 
disturbances.  For example, in Parkinson’s Disease, the onset of motor symptoms 
does not occur until 70% of nigrostriatal neurons are lost (Przuntek et al. 2004) 
and until the neurodegeneration reaches that point at which compensation fails, 
diagnosis is difficult in the absence of motor control symptoms or a neuroimaging 
scan.  There were no significant differences to measured levels of mRNA for any 
of the monoamine transporters, so the small selective changes observed in SERT 
density were either not driven by a regulation of gene expression or the ligand 
binding has greater sensitivity to detect the changes than in situ hybridisation. It is 
possible that PCP was interacting directly with the SERT causing a conformational 
change to reduce its affinity for autoradiographic ligand binding, or causing it to be 
internalised into the neuron. 
 
It had been hoped that the PCP model of schizophrenic hypofrontality would 
provide a model in which to demonstrate the capabilities of a SPECT tracer for the 
NAT, but the PCP model has no utility in that area.  However, since modulation of 
noradrenergic neurotransmission via the blockade of the NAT has been shown to 
ease the negative symptoms associated with schizophrenia, the need to be able to 
image the NAT in both clinical and research scenarios remains.  The elucidation of 
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how the noradrenergic system is able to be used to modulate the brain regions 
receiving its innervations to mitigate the negative symptoms associated with 
schizophrenia, and also how the brain reacts to long-term atypical neuroleptic 
administration, would be aided by a clinical tracer able to image noradrenaline 
transporter distribution.  The competition for receptor occupany in single scans 
may reveal mechanisms for successful neuroleptics that are partly mediated by 
the noradrenergic system.  Long-term monitoring may reveal on follow-up scans 
that long-term stability or long-term deterioration for patients on antipsychotic 
medication may be acheived by a compensatory up- or down-regulation of sites in 
the noradrenergic system.  Imaging the NAT would provide valuable information 
on which areas of the brain the noradrenergic system is most strongly innervated 
over time.  Correlating that information with clinical reports would enable any NAT-
targeted medications to be adjusted accordingly and provide feedback for future 
drug development needs. 
  
6.2   The best pharmacology was demonstrated by NKJ-64, the ortho-
position iodophenoxy ring compound. 
 
The evaluation of the in vitro pharmacology of the various candidate compounds 
has enabled me to select NKJ-64 as the best available compound to take forward 
and evaluate for predictors of in vivo molecular behaviour. 
 
The greatest affinity for the NAT was demonstrated by NKJ-64 (Chapter 4); this 
compound compares favourably to the (S,S)-isomer in the published literature and 
affinity was in the same order of magnitude as INER/IPBM (Tamagnan et al. 2007; 
Kanegawa et al. 2006).   
 
The greatest selectivity for the NAT over other monoamine transporters was 
demonstrated amongst the iodophenyl ring compounds, however this group of 
compounds did not have sufficient affinity for the NAT to be used as SPECT 
imaging tracers.  The placement of the iodine on the phenyl ring disturbed the 
ability of the compounds to fit into the binding site on the noradrenaline 
transporter.  However, the placement of the iodine in the ortho position on the 
phenoxy ring yielded NKJ-64 and its demonstrated favourable selectivity for the 
NAT over the DAT and the SERT.  
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6.3  The best HPLC-derived predictors of in vivo behaviour were 
demonstrated by NKJ-64, the ortho-position iodophenoxy ring 
compound. 
 
Using HPLC-derived predictors of in vivo molecular behaviour, NKJ-64 has been 
selected as the most probable candidate to yield success as a SPECT brain 
imaging tracer from the array of synthesised compounds (Chapter 5). 
 
The HPLC-derived predictors indicated that the (S,S)- and NKJ-50s would have 
made the best brain imaging tracers, however, these molecules lacked the 
phenoxy ring and demonstrated no noteworthy affinity for the NAT and therefore 
were not suitable as NAT brain imaging tracers. 
 
NKJ-64 was determined to have good lipophilicity and predictors of blood-brain 
barrier penetration, however phospholipophilicity was high and indicates that non-
specific binding may be high.  Plasma protein binding was also high, although it is 
uncertain whether this will be an advantage or disadvantage – it remains to be 
seen whether a strong plasma protein binding association in this case will deplete 
available tracer for crossing the blood-brain barrier or act as a carrier molecule to 
slow metabolism in the plasma. 
 
6.4   Conclusions:  NKJ-64, the ortho-position iodophenoxy ring 
compound, has been identified as the lead candidate for further 
development. 
 
This aim of this thesis was to develop a novel SPECT brain tracer for the 
noradrenaline transporter, and so satisfy the need for an in vivo imaging probe for 
this important monoamine system.  The future academic research into the 
implication of NAT in neurological disease, clinical diagnoses and monitoring, and 
drug occupancy studies in pharmaceutical development would all greatly benefit 
from the availability of such a tool.  The result is that, from a selection of 
compounds, a lead candidate has been identified to be taken forward for further 
development.  
 
NKJ-64, the ortho-position iodo-phenoxy ring compound was identified as having 
the most favourable pharmacology (Chapter 4) and in vivo predictors (Chapter 5) 
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for imaging the noradrenaline transporter.  The data suggests that this compound 
has suitable affinity for the NAT, selectivity for the NAT over other monoamine 
transporters, and should be capable of crossing the blood-brain barrier, however 
data indicates that non-specific binding may be high. 
 
6.5   Subsequent Work: radiolabelled compound 
 
The next step for determining this compound’s suitability is radiolabelling with a 
SPECT isotope such as 123I or 125I followed by a direct saturation assay on rat 
brain homogenates to establish a precise KD and levels of nonspecific binding.  
The binding distribution should then be defined with in vitro autoradiography and 
compared to the distribution obtained by [3H]-nisoxetine, using reboxetine as a 
displacer to ascertain nonspecific binding throughout the brain.  If nonspecific 
binding for the radiolabelled compound is favourable in vitro and acceptable 
images are achieved with autoradiography, then development could move forward 
to ex vivo autoradiography to determine whether, following intravenous 
administration, plasma protein binding conditions have allowed for sufficient tracer 
availability, that blood-brain barrier penetration actually occurs, and that 
nonspecific binding in vivo is not problematic.  The ex vivo autoradiography could 
be combined with an attempt at a pilot SPECT scan in the rat model using a micro-
SPECT scanner to monitor brain uptake and distribution prior to the schedule 1 kill 
for brain harvesting, sectioning, and exposure to radiosensitive film. 
 
Recently, these next stages in the development of NKJ-64 were undertaken by 
Tavares et al. ( 2011), referring to the compound as [125I]-NKJ64 in the literature, 
and it was determined that in vitro KD was established as 4.82 ± 0.87 nM in rat 
brain homogenates, and nonspecific binding defined in the presence of 10µM 
reboxetine displacer was 77% at a concentration of 6.25nM [125I]-NKJ-64.  This 
high nonspecific binding correlates with the in vivo predictors ascertained by HPLC 
analysis (Chapter 5), giving validation and confidence to the HPLC technique for 
use in future tracer development studies.  Distribution of [125I]-NKJ-64 throughout 
coronal rat brain sections matched the known distribution of the noradrenaline 
transporter (Tavares et al. 2011). 
 
In vivo experimentation with intravenously administered [125I]-NKJ-64 yielded good 
brain uptake and ex vivo autoradiography demonstrated a good target:non-target 
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ratio of 2.8, indicating that nonspecific binding was reasonable, although the low 
density of the NAT in cortical and limbic regions meant that this radiotracer did not 
have sufficient sensitivity to detect displacement by pre-treatment with reboxetine 
in cortical or limbic regions.  Displacement was demonstrable in the locus 
coeruleus only and, given the dimensions of the locus coeruleus, a high-resolution 
modern SPECT scanner will be required to ascertain worthwhile readings of 
pharmacological displacement or regulatory changes in this brain region should 
this compound be applied to future imaging studies.  Given this data, any 
neuroimaging study using [125I]-NKJ-64 would need to rely on imaging of the locus 
coeruleus to make a broad observation of the noradrenaline system and more 
detailed imaging of noradrenaline transporters throughout the brain may not be 
possible with this tracer. 
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Appendix I 
 
A1.1 Do the groups have equal variances? 
 
The summary of statistically significant differences for the means and variances of 
the monoamine transporter autoradiograms demonstrates that a parametric 
analysis of this data set was not appropriate (Table A1-01).    The spreads of the 
data sets for [3H]-nisoxetine binding to the NAT, [3H]-WIN-35,428 binding to the 
DAT, and [3H]-citalopram binding to the SERT are provided in Tables A1-02, A1-
03, and A1-04, respectively.   
 
It had been assumed that the varying expression of monoamine transporters and 
monoamine transporter-specific mRNA within each group would follow that of a 
normal distribution.  With a P threshold of 0.05 and continuous repetition of the 
tests, two statistically different means and two statistically different variances could 
have been expected on pure chance alone. Five statistically different variances 
indicated that it could not be presumed that each PCP-treated animal is 
responding to the same degree to the treatment regime, with some rats being 
affected more than others resulting in the differences in the variances for several 
important regions.  This was particularly evident for the measurement of SERT 
binding, where most of the differences between the group means were detected.  
Consequently, a non-parametric technique was deemed necessary and a Mann-
Whitney analysis was applied to all data sets to compare the sum of rank order.  
Assuming the two groups have similar distributions, even if unequal variances, 
then this comparison of the sum of ranks can be interpreted as a comparison of 
medians.  Analysed data from which interpretations were drawn is therefore 
expressed graphically as the median ± the interquartile range in Chapter 3.  As 
aforementioned, Table A1-01 displays the T-test and F-tests that were used to 
determine that a parametric analysis would not be appropriate for this data set. 
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Table: A1-01: Parametric analysis of autoradiographic imaging of 
monoamine transporters is not appropriate 
[3H]-nisoxetine data [3H]-WIN-35,428 data [3H]-citalopram data 
Structure Means 
(T-test) 
Variances 
(F-test) 
Means 
(T-test) 
Variances 
(F-test) 
Means 
(T-test) 
Variances 
(F-test) 
PFC ≈ ≈ ≈ ≈ ≈ ≈ 
ACg ≈ ≈ ≈ ≈ ≠ ≈ 
CPu ≈ ≈ ≈ ≠ ≠ ≈ 
N.Acc. ≈ ≠ ≠ ≈ ≠ ≈ 
BNST ≈ ≈ ≈ ≈ ≈ ≠ 
AVTN ≈ ≈ ≈ ≈ ≈ ≈ 
RTN ≈ ≈ ≈ ≈ ≈ ≠ 
CA1 ≈ ≈ No Binding No Binding ≠ ≈ 
CA2 ≈ ≈ No Binding No Binding ≠ ≈ 
CA3 ≈ ≈ No Binding No Binding ≠ ≈ 
DG ≈ ≈ No Binding No Binding ≈ ≈ 
VTN ≈ ≈ ≈ ≈ ≈ ≈ 
DRN ≈ ≈ ≈ ≈ ≈ ≈ 
LC ≈ ≈ ≈ ≈ ≈ ≠ 
CBL ≈ ≈ No Binding No Binding ≈ ≈ 
Table A1-01: Summary of T-test and F-test to determine statistical differences 
between means and variances for [3H]-ligand binding to monoamine transporters 
in control and PCP-treated rat brain.  The means and variances are designated as 
either statistically equivalent (≈) or statistically different (≠).  Significance was set 
at a P value of 0.05 for both tests.   
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Table A1-02: T-test and F-test of [3H]-Nisoxetine Binding Data 
NAT in Prefrontal Cortex
Control PCP
0.0
0.5
1.0
1.5
2.0
2.5
Treatment  Regime
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g 
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T-test: P = 0.1411 (equivalent means) 
F-test: P = 0.3181 (equivalent variances) 
NAT in Anterior Cingulate Cortex
Control PCP
0
5
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20
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Treatment  Regime
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n
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n
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T-test: P = 0.5052 (equivalent means) 
F-test: P = 0.5108 (equivalent variances) 
NAT in Caudate Putamen
Control PCP
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
Treatment Regimes
Sp
ec
ifi
c 
[3 H
] N
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o
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e 
B
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n
g 
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o
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g-
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T-test: P = 0.1782 (equivalent means) 
F-test: P = 0.1054 (equivalent variances) 
NAT in Nucleus Accumbens
Control PCP
0
1
2
3
4
5
6
7
8
9
10
Treatment Regime
Sp
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c 
[3 H
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o
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e 
B
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n
g 
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o
l.m
g
-
1 )
 
T-test: P = 0.6134 (equivalent means) 
F-test: P = 0.0382 (statistically different variances) 
NAT in Bed Nucleus of the Striatus Terminalis
Control PCP
0
20
40
60
80
100
120
Treatment Regime
Sp
ec
ifi
c 
[3 H
] N
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x
et
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e 
Bi
n
di
n
g 
(fm
o
l.m
g
-
1 )
 
T-test: P = 0.9827 (equivalent means) 
F-test: P = 0.1769 (equivalent variances) 
NAT in Anterovental Thalamic Nucleus
Vehicle PCP
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100
120
140
160
180
200
Treatment Regime
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c 
[3 H
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n
g 
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g
-
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T-test: P = 0.1641 (equivalent means) 
F-test: P = 0.5802 (equivalent variances) 
Table A1-02: T-test and F-test of [3H]-nisoxetine binding data. Control (n=10) and 
PCP-treated (n=10) data points plotted with mean indicated by bars.  Significance 
threshold set at P < 0.05.  Group variances were statistically different in the 
nucleus accumbens. 
 191 
 
Table A1-02: T-test and F-test of [3H]-Nisoxetine Binding Data (continued) 
NAT in Reticular Thalamic Nuclei
Control PCP
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T-test: P = 0.7655 (equivalent means) 
F-test: P = 0.5321 (equivalent variances) 
NAT in Hippocampus CA1
Control PCP
0
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n
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T-test: P = 0.8989 (equivalent means) 
F-test: P = 0.2750 (equivalent variances) 
NAT in Hippocampus CA2
Control PCP
0
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ec
ifi
c 
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n
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n
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T-test: P = 0.1714 (equivalent means) 
F-test: P = 0.3084 (equivalent variances) 
NAT in Hippocampus CA3
Control PCP
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Treatment Regime
Sp
ec
ifi
c 
[3 H
] N
is
o
x
et
in
e 
Bi
n
di
n
g 
(fm
o
l.m
g
-
1 )
 
T-test: P = 0.2802 (equivalent means) 
F-test: P = 0.0587 (equivalent variances) 
NAT in Hippocampus (Dentate Gyrus)
Control PCP
0
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T-test: P = 0.0643 (equivalent means) 
F-test: P = 0.4057 (equivalent variances) 
NAT in Ventral Tegmental Area
Control PCP
0
2
4
6
8
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16
Treatment Regime
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n
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n
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T-test: P = 0.3368 (equivalent means) 
F-test: P = 0.6196 (equivalent variances) 
Table A1-02 (continued): T-test and F-test of [3H]-nisoxetine binding data. 
Control (n=10) and PCP-treated (n=10) data points plotted with mean indicated by 
bars.  Significance threshold set at P < 0.05.   
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Table A1-02: T-test and F-test of [3H]-Nisoxetine Binding Data (continued) 
NAT in Dorsal Raphe Nuclei
Control PCP
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T-test: P = 0.1493 (equivalent means) 
F-test: P = 0.6749 (equivalent variances) 
NAT in Locus Coeruleus
Control PCP
0
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Treatment Regime
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n
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T-test: P = 0.4521 (equivalent means) 
F-test: P = 0.9853 (equivalent variances) 
NAT in Cerebellum
Control PCP
0
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T-test: P = 0.2034 (equivalent means) 
F-test: P = 0.4839 (equivalent variances) 
Table A1-02 (continued): T-test and F-test of [3H]-nisoxetine binding data. 
Control (n=10) and PCP-treated (n=10) data points plotted with mean indicated by 
bars.  Significance threshold set at P < 0.05.   
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Table A1-03: T-test and F-test of [3H]-WIN-35,428 Binding Data 
DAT in Prefrontal Cortex
Control PCP
0
1
2
3
4
5
6
7
8
Treatment  Regime
Sp
ec
ifi
c 
[3 H
] W
IN
-
35
,4
28
 
B
in
di
n
g 
(fm
o
l.m
g
-
1 )
 
T-test: P = 0.5841 (equivalent means) 
F-test: P = 0.6886 (equivalent variances) 
DAT in Cingulate Anterior
Control PCP
0
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T-test: P = 0.3039 (equivalent means) 
F-test: P = 0.2747 (equivalent variances) 
DAT in Caudate Putamen
Control PCP
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T-test: P = 0.0781 (equivalent means) 
F-test: P = 0.0073 (statistically different variances) 
DAT in Nucleus Accumbens
Control PCP
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T-test: P = 0.0365 (statistically different means) 
F-test: P = 0.3839 (equivalent variances) 
DAT in Bed Nucleus of the Striatus Terminalis
Control PCP
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T-test: P = 0.1620 (equivalent means) 
F-test: P = 0.0740 (equivalent variances) 
DAT in Anteroventral Thalamic Nucleus
Control PCP
0
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T-test: P = 0.5625 (equivalent means) 
F-test: P = 0.7139 (equivalent variances) 
Table A1-03: T-test and F-test of [3H]-WIN-35,428 binding data. Control (n=10) and PCP-
treated (n=10) data points plotted with mean indicated by bars.  Significance threshold set 
at P < 0.05.  Group variances were statistically different in the caudate putamen.  Group 
means were statistically different in the nucleus accumbens. 
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Table A1-03: T-test and F-test of [3H]-WIN-35,428 Binding Data (continued) 
DAT in Reticular Thalamic Nuclei
Control PCP
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T-test: P = 0.3967 (equivalent means) 
F-test: P = 0.8361 (equivalent variances) 
DAT in Ventral Tegmental Area
Control PCP
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T-test: P = 0.6973 (equivalent means) 
F-test: P = 0.7218 (equivalent variances) 
DAT in Dorsal Raphe Nuclei
Control PCP
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T-test: P = 0.1949 (equivalent means) 
F-test: P = 0.9758 (equivalent variances) 
DAT in Locus Coeruleus
Control PCP
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T-test: P = 0.1681 (equivalent means) 
F-test: P = 0.1106 (equivalent variances) 
Table A1-03 (continued): T-test and F-test of [3H]-WIN-35,428 binding data. 
Control (n=10) and PCP-treated (n=10) data points plotted with mean indicated by 
bars.  Significance threshold set at P < 0.05.  
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Table A1-04: T-test and F-test of [3H]-Citalopram Binding Data 
SERT in Prefrontal Cortex
Control PCP
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T-test: P = 0.7370 (equivalent means) 
F-test: P = 0.9611 (equivalent variances) 
SERT in Cingulate Anterior
Control PCP
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T-test: P = 0.0294 (statistically different means) 
F-test: P = 0.2767 (equivalent variances) 
SERT in Caudate Putamen
Control PCP
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T-test: P = 0.0157 (statistically different means) 
F-test: P = 0.4652 (equivalent variances) 
SERT in Nucleus Accumbens
Control PCP
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T-test: P = 0.0255 (statistically different means) 
F-test: P = 0.1332 (equivalent variances) 
SERT in Bed Nucleus of the Striatus Terminalis
Control PCP
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
Treatment Regime
Sp
ec
ifi
c 
[3 H
] C
ita
lo
pr
am
 
Bi
n
di
n
g 
(fm
o
l.m
g
-
1 )
 
T-test: P = 0.4846 (equivalent means) 
F-test: P = 0.0063 (statistically different variances) 
SERT in Anterovental Thalamic Nucleus
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T-test: P = 0.9094 (equivalent means) 
F-test: P = 0.4872 (equivalent variances) 
Table A1-04: T-test and F-test of [3H]-citalopram binding data.  
Control (n=10) and PCP-treated (n=10) data points plotted with mean indicated by bars.  
Significance threshold set at P < 0.05.  Group means were statistically different in the 
cingulate anterior, caudate putamen, and nucleus accumbens.  Group variances were 
statistically different in the bed nucleus of the striatus terminalis. 
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Table A1-04: T-test and F-test of [3H]-Citalopram Binding Data (continued) 
SERT in Reticular Thalamic Nuclei
Control PCP
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T-test: P = 0.0604 (equivalent means) 
F-test: P = 0.0365 (statistically different variances) 
SERT in Hippocampus CA1
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T-test: P = 0.0390 (statistically different means) 
F-test: P = 0.3195 (equivalent variances) 
SERT in Hippocampus CA2
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T-test: P = 0.0109 (statistically different means) 
F-test: P = 0.2501 (equivalent variances) 
SERT in Hippocampus CA3
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T-test: P = 0.0086 (statistically different means) 
F-test: P = 0.1271 (equivalent variances) 
SERT in Hippocampus (Dentate Gyrus)
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T-test: P = 0.9617 (equivalent means) 
F-test: P = 0.1209 (equivalent variances) 
SERT in Ventral Tegmental Area
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T-test: P = 0.0751 (equivalent means) 
F-test: P = 0.7901 (equivalent variances) 
Table A1-04 (continued): T-test and F-test of [3H]-citalopram binding data. Control 
(n=10) and PCP-treated (n=10) data points plotted with mean indicated by bars.  
Significance threshold set at P < 0.05.  Group variances were statistically different in the 
reticular thalamic nuclei.  Group means were statistically different in the CA1, CA2, and 
CA3 regions of the hippocampus. 
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Table A1-04: T-test and F-test of [3H]-Citalopram Binding Data (continued) 
SERT in Dorsal Raphe Nuclei
Control PCP
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T-test: P = 0.3386 (equivalent means) 
F-test: P = 0.9731 (equivalent 
variances) 
SERT in Locus Coeruleus
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T-test: P = 0.3361 (equivalent means) 
F-test: P = 0.0183 (statistically different 
variances) 
SERT in Cerebellum
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T-test: P = 0.1170 (equivalent means) 
F-test: P = 0.4767 (equivalent variances) 
Table A1-04 (continued): T-test and F-test of [3H]-citalopram binding data. 
Control (n=10) and PCP-treated (n=10) data points plotted with mean indicated by 
bars.  Significance threshold set at P < 0.05.  Group variances were statistically 
different in the locus coeruleus. 
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Appendix II 
 
 
A1.1 HPLC system calibrations 
 
 
Figures A2-01 to A2-07 are the calibration curves for the in vitro HPLC methods to 
predict the in vivo characteristics of potential SPECT imaging compounds.  Full 
methodology is described in Chapter 2, Section 2.3. 
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Luna (pH 2.5) Calibration
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Figure A2-01: Calibration curve for the Luna (C-18) lipid column at pH 2.5.  The 
known CHI of standards was used to calibrate retention times to determine the 
CHI values of samples run on the column. 
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Luna (pH 10.5) Calibration
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Figure A2-02: Calibration curve for the Luna (C-18) lipid column at pH 10.5.  The 
known CHI of standards was used to calibrate retention times to determine the 
CHI values of samples run on the column. 
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Luna (pH 7.4) Calibration
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Figure A2-03: Calibration curve for the Luna (C-18) lipid column at pH 7.4.  The 
known CHI of standards was used to calibrate retention times to determine the 
CHI values of samples run on the column. 
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Immobilized Artificial Membrane (IAM) Calibration
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Figure A2-04: Calibration curve for the immobilized artificial membrane (IAM) 
phospholipid column at pH 7.4.  The known CHI of standards was used to 
calibrate retention times to determine the CHI values of samples run on the 
column. 
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Luna (MeOH Elution) Calibration
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Figure A2-05: Calibration curve for the Luna (C-18) column at pH 7.4 with a 
methanol elution.  The known CHI of standards was used to calibrate retention 
times to determine the CHI values of samples run on the column. 
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α-Acid Glycoprotein (AGP) Calibration
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Figure A2-06: Calibration curve for the immobilized α-acid glycoprotein (AGP) 
column at pH 7.4.  The known linearised log k (measure of protein binding) of 
standards was used to calibrate retention times to determine the linearised log k 
values of samples run on the column. 
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Human Serum Albumin (HSA) Calibration
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Figure A2-07: Calibration curve for the immobilized human serum albumin (HSA) 
column at pH 7.4.  The known linearised log k (measure of protein binding) of 
standards was used to calibrate retention times to determine the linearised log k 
values of samples run on the column. 
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